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The tetraspanins are a large superfamily of membrane proteins that contribute to the 
organisation of other cell surface proteins through homo- and heterogeneous lateral 
interactions. In platelets four of the 33 mammalian tetraspanins have been found to 
participate in mechanisms that regulate platelet sensitivity and activation. Tspan9 
was recently discovered as a new platelet tetraspanin using an antibody and is highly 
expressed on platelets when compared to other tissues. Tspan33 was another new 
platelet tetraspanin identified by membrane proteomic approach. Neither tetraspanin 
had yet been functionally characterised on platelets and so their contribution to 
platelet biology was unknown. The aims of this thesis were to investigate the function 
of Tspan9 and Tspan33 in platelets using their respective knockout mice. The 
conclusion of this thesis was twofold. Firstly that Tspan33 is a member of the 
TspanC8 subfamily of tetraspanins that regulate the metalloprotease ADAM10, but is 
likely not expressed on mouse platelets. Secondly, Tspan9 promotes platelet 
activation through the collagen receptor GPVI by regulating its membrane dynamics. 
These novel regulatory mechanisms for ADAM10 and GPVI offer new avenues of 
research into therapy for diseases such as Alzheimer's disease and atherosclerosis 
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CHAPTER I: INTRODUCTION 
1.1 Tetraspanins 
1.1.1 Tetraspanins overview 
Tspan9 and Tspan33 (also called Penumbra) are members of the tetraspanin 
superfamily of transmembrane proteins of which there are 33 found in humans 
(Yáñez-Mó et al., 2009, Charrin et al., 2009). Only discovered around 20 years ago, 
tetraspanins have now been identified in organisms that represent nearly all of the 
major eukaryotic groups and are increasingly gaining more attention. Lacking 
obvious signalling machinery, catalytic domains and ligand binding sites, the 
tetraspanins are an enigmatic group of proteins. They have an intriguing ability to 
form heterogeneous clusters in cell membranes that coordinate other 
transmembrane proteins and have roles in processes as diverse as cell migration, 
cell adhesion and cell-cell fusion (Charrin et al., 2009, Yáñez-Mó et al., 2009, 
Hemler, 2005). Important tools such as antibodies are not available to most 
tetraspanins and consequently many known tetraspanins remain unstudied. 
However, as research in this field gathers momentum, mounting evidence highlights 











1.1.2 Tetraspanin structure 
As the name suggests tetraspanin proteins have four transmembrane (TM) domains 
that span the cell membranes in which they are found. They are set apart from other 
four TM proteins by the following general structure and several conserved 
‘tetraspanin signature’ motifs. A diagram of this basic tetraspanin structure can be 
seen in Figure 1. Tetraspanins generally start with a short (less than 10 amino acids) 
intracellular N-terminal tail followed by the first TM domain called TM1. This TM 
region is connected to the next (TM2) by the first of two extracellular loop regions. 
This small extracellular loop (EC1) is overshadowed by the large extracellular loop 
(EC2) which is situated between the third and fourth TM domains (TM3 and TM4). 
Ending TM4 is the usually short (generally less than 20 amino acids) intracellular C-
terminal tail. The entire extracellular portion of most tetraspanins extends only around 
5 nm from the lipid membrane making tetraspanins dwarves of the cell surface in 
comparison to most other membrane proteins (Conley et al., 2012). Although there is 
currently only one crystal structure of a tetraspanin available, that of the EC2 of 
human CD81 (Kitadokoro et al., 2001b), other studies using techniques such as cryo-
electron microscopy (Min et al., 2006), nuclear magnetic resonance spectroscopy 
(Rajesh et al., 2012), computational modelling (Seigneuret et al., 2001) and 
tetraspanin sequence analysis (Kovalenko et al., 2005) have allowed insight into the 
detail of tetraspanin structure. Figure 2 shows the most detailed structure of a full 
tetraspanin in the field which was derived from modelling studies by Seignueret 





















Figure 1. The basic structure of Tetraspanin superfamily proteins. 
Tetraspanins are four transmembrane proteins that only extend 5 nm from the cell 
membrane. The four transmembrane proteins named 1 - 4 are delimited by two 
extracellular loops, one small termed EC1 and one large termed EC2. TM2 and TM3 
are linked by a very short inter connecting or IC loop and the N and C-terminal tails 
are generally less than 10 and 20 amino acids respectively. Conserved cysteines that 
contribute to disulphide bridges in the variable region in the EC2 are shown in red 























Figure 2. Model of tetraspanin CD81 by Seigneuret (2006).  
This structure of computer modelled CD81 is currently the most detailed structure of 
a full tetraspanin in the field. Transmembrane domains are in blue, EC1 is in red, 
EC2 conserved domain is in green and the variable domain in purple. The disulphide 
bridges in the EC2 are in yellow. Sites that are probably palmitoylated are marked 








1.1.2.1 Tetraspanin transmembrane domains are tightly compact. 
Tetraspanins appear to form very compact rod-like structures that do not extend far 
above or below the lipid bilayer. This compact structure is mainly created by the tight 
packing of the tetraspanin transmembrane domains into a left-handed coiled coil as 
seen in both computational modelling and cryo-electron microscopy (Seigneuret et 
al., 2001, Min et al., 2006). This left-handed coiled structure, which interestingly is 
more closely packed than a right-handed version, is created by conserved motifs and 
residues in each of the tetraspanin transmembrane domains. TM1, 2 and 3 all 
contain a heptad repeat pattern (abcdefg)n that is apparent in all coiled coil structures 
(Kovalenko et al., 2005, Seigneuret et al., 2001). Positions a and d are hydrophobic 
residues that face the inside of the coil and positions e and g are exposed external 
residues. These important heptad positions (a, d, e and g) all correspond to 
conserved residues in the tetraspanin superfamily (Seigneuret et al., 2001). Further 
supporting the close packing of the coiled coil is the size conservation of particular 
amino acid side chains in TM2 and TM3 that allow the transmembrane regions to fit 
closely together by 'knob into hole' packing and the very short connecting loop 
between TM2 and TM3 (Seigneuret et al., 2001, Kovalenko et al., 2005). The whole 
cylinder created by the transmembrane domain is further stabilised by van der Waals 
interactions and inter-coil hydrogen bonding, again maintained throughout the 
tetraspanin superfamily by conservation of key residues. It is predicted that residues 
involved in inter-helical contacts would be more conserved than those that face lipids 
as mutations in the former are more likely to cause destabilisation of protein 
structure. This indeed appears to be the case for the tetraspanin superfamily proteins 
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(Min et al., 2006, Kovalenko et al., 2005, Tachibana et al., 1997, Seigneuret et al., 
2001).  
Interestingly the transmembrane cylinder of tetraspanins does not appear to be a 
symmetrical structure. An accumulation of aromatic residues is seen in many 
tetraspanins around the TM1/2 side of the transmembrane region. These aromatic 
residues are hypothesised to be potential binding sites for cholesterol, as cholesterol 
binding sites in other proteins are aromatic residues (Kovalenko et al., 2005, 
Seigneuret et al., 2001). Whilst it is yet to be experimentally confirmed that the 
aromatic residues are cholesterol binding sites on tetraspanins, it is intriguing that 
some tetraspanins have such lateral asymmetry in a highly conserved part of their 
structure, especially when one considers the different types of interactions that a 
single tetraspanin is thought to be able to simultaneously coordinate. Additionally the 
overall hydrophobic nature of the transmembrane region may promote interactions 
with the particular membrane lipids with which they are known to associate 
(Seigneuret, 2006).  
 
1.1.2.2 Tetraspanin extracellular domains 
The extracellular regions of tetraspanins continue the compact nature of the 
transmembrane regions. The first of the extracellular loops, the EC1, is situated 
between TM1 and TM2 and is generally less than 30 amino acids in length 
(Seigneuret, 2006). The main feature known of this lesser studied extracellular loop 
is a generally conserved secondary structure of a -strand at its centre. This central 
-strand is enriched in hydrophobic residues (sequence ELLYLQ in CD81) and is 
predicted to come into close contact with a hydrophobic patch on the EC2 
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(Seigneuret, 2006). It has been suggested that this interaction may contribute to the 
stability of the large extracellular loop, however the folded EC2 has been produced in 
isolation, without EC1, and so this may not be the case (Rajesh et al., 2012, 
Kitadokoro et al., 2001a).  
The large extracellular loop is a structurally and functionally interesting part of a 
tetraspanin containing both some of the most conserved and most variable parts of 
the protein, consequently it is the most studied aspect of tetraspanin structure. 
Different studies of this region, including the only tetraspanin crystal structure, all 
indicate that the EC2 is helical in nature and can be divided into two domains, one 
conserved and one variable (Kitadokoro et al., 2001b). The conserved region of the 
EC2 is made up of three -helices termed A, B and E. These helices form a 
membrane proximal, structurally conserved, fold that, as previously discussed, may 
interact with the EC1 -strand. The variable domain was thought to be comprised of a 
further two -helices, namely C and D which were observed in the CD81 crystal 
structure (Kitadokoro et al., 2001b). However a more recent NMR study has 
suggested that actually it is more likely that the 'D helix' is a highly dynamic single 
turn helical loop and not an -helix (Rajesh et al., 2012). In either case the 'D helix' is 
the most exposed part of the EC2 and it contains a hypervariable region that 
undergoes considerable insertions and deletions of sequence from tetraspanin to 
tetraspanin (Seigneuret, 2006). Interestingly this region in the CD81 crystal structure 
contains an exposed hydrophobic patch of amino acids that are conserved between 
different CD81 species, despite it being an energetically unfavourable formation due 
to its solvent exposed position (Kitadokoro et al., 2001b). It is suggested that regions 
of this type are important in protein-protein recognition and mutagenesis studies of 
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this region in several different tetraspanins support a protein interaction role for this 
area of tetraspanin EC2s (Kazarov et al., 2002).  The structural integrity of the EC2 is 
in part maintained by disulphide bonds formed by conserved cysteine residues. All 
tetraspanins have at least 4 cysteine residues, which are contributed by tetraspanin 
signature motifs, the absolutely conserved CCG with another cysteine proximal to 
TM4 and a mostly conserved PXXC motif (Stipp et al., 2003). Many tetraspanins 
have an additional pair of cysteines to give 6 in total and the TspanC8 subgroup have 
8 (Charrin et al., 2009, Stipp et al., 2003). These cysteine residues have been used 
to trace the evolutionary history of the tetraspanin superfamily (DeSalle et al., 2010).  
 
1.1.2.3 Tetraspanin intracellular tails 
The intracellular tails of tetraspanins are generally less than 20 amino acids long 
excluding those of Tspan10, Tspan12, Tspan15, Tspan32, RDS and ROM1. The C-
terminus does not contain any conserved tetraspanin features but does contain other 
protein motifs. Some contain short PDZ binding motifs (such as CD63) and/or 
internalisation sequences such as the YXXwhere represents an amino acid with 
a bulky side chain) found in CD151 (Liu et al., 2007a), and some carry an overall 
basic charge which is also shown to mediate protein-protein interactions. Both termini 
are thought to lie close to the intracellular membrane and are generally thought to be 
non-ordered. Interestingly tetraspanins have membrane proximal cysteine residues 
that are palmitoylated. This post-translational modification is thought to have an 
effect on the N-terminal tail, causing it to form an amphipathic helix along the 
underside of the plasma membrane (Seigneuret, 2006, Granseth et al., 2005). This is 
a common feature of transmembrane proteins and in tetraspanins that do not have a 
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membrane proximal cysteine available for palmitoylation in the N-terminal (such as 
CD53), there is instead a hydrophobic residue so that the amphipathic nature is 
retained (Seigneuret, 2006, Stipp et al., 2003). Whilst the C-terminal tail structure is 
thought to be mainly randomly ordered, the amino acid side chains are thought to 
also align along the membrane (Seigneuret et al., 2001).   
As well as palmitoylation most tetraspanins also undergo N-linked glycosylation as a 
post-translational modification. The position and number of glycosylation sites are not 
conserved in the tetraspanin superfamily and so the function of this modification is a 
poorly understood aspect of tetraspanin structure (Stipp et al., 2003, Seigneuret, 
2006). One recent study investigated the glycosylation of Tspan1 and found that this 
modification is important for the correct folding and progression of Tspan1 through 
the endoplasmic reticulum (ER) (Scholz et al., 2009b).  
 
1.1.3 Tetraspanin microdomains 
A major functional characteristic of tetraspanin proteins is that once in the cell 
membrane they self-associate, forming clusters called microdomains. As all cell types 
are thought to express many tetraspanins (for example more than 20 in endothelial 
cells (Bailey et al., 2011)) these microdomains contain several different tetraspanins 
and consequently several other surface membrane proteins. The current thought is 
that each protein found in a tetraspanin microdomain is there because of a specific 
association with a specific tetraspanin (Charrin et al., 2009). Studies of tetraspanin 
microdomains show that these structures are distinct from other lipid enriched 
microdomains such as lipid rafts. The current view of these microdomains is that they 
form from a series of interactions between different tetraspanins building a network 
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termed the tetraspanin web (Charrin et al., 2009). The mobile nature of tetraspanins 
and their multiple interactions suggests that the tetraspanin web is highly dynamic 
and this allows it to contribute to the regulation of specific proteins by influencing their 
position and movement in the cell membrane (Espenel et al., 2008).  
 
1.1.3.1 Tetraspanin microdomains are formed by interactions between 
tetraspanins 
Investigation into the different interactions within tetraspanin microdomains using 
detergents of differing properties has found that there are different strengths of 
protein-protein interactions found within the microdomain (Claas et al., 2001). The 
main building blocks of tetraspanin microdomains, the homo- and hetero- interactions 
between the tetraspanins, can only be maintained after cell lysis by using detergents 
such as Brij97. Lysis buffers containing Brij97 or other low stringency non-ionic 
surfactants appear unable to disrupt the interactions between tetraspanins and thus, 
though solubilised, tetraspanin microdomains are preserved after lysis. Interestingly 
this ability is augmented when the lysis buffer contains the divalent cations CaCl2 and 
MgCl2. This property has allowed the discovery and investigation of tetraspanin 
associated proteins which co-immunoprecipitate with tetraspanins in these lysis 
buffers. Cell lysis by more stringent detergents such as Triton X-100 does not 
preserve the interactions between tetraspanins thus disrupting tetraspanin 
microdomains. In these detergents however, tetraspanin-partner protein complexes 
are often maintained. This indicates a stronger interaction than that between 
tetraspanins themselves, which can be maintained where a more complete disruption 
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of the cell membrane occurs (Charrin et al., 2003b, Charrin et al., 2002, Hemler, 
2001, Claas et al., 2001).  
The difference between the interactions captured by these two different detergents 
can be clearly seen in Figure 3 (taken from Protty et al. (2009) where, in Brij97 lysis 
conditions, the 'barcode' of tetraspanin associated proteins can be seen in addition to 
the immunoprecipitated tetraspanin. This barcode pattern is similar no matter which 
tetraspanin is immunoprecipitated (from the same cell type) and is also seen when a 
tetraspanin partner protein is immunoprecipitated (6). This barcode pattern is 
however not evident when a non tetraspanin-associated protein is 
immunoprecipitated (2). When the same cells are lysed in Triton X-100, no barcode 
pattern is seen when microdomain resident proteins are immunoprecipitated and 
instead only the tetraspanin and, in some cases, its partner protein band can be 
























Figure 3. Tetraspanin-tetraspanin interactions are maintained in the weak 
detergent Brij97. 
 
Surface biotinylated human platelets were lysed and immunoprecipitated with 
indicated detergents and antibodies. Western blotting with streptavidin identifies 
biotinylated proteins. The tetraspanin-tetraspanin interactions are only maintained in 
the less stringent lysis condition (1% Brij97) and are only seen when tetraspanin 
microdomain associated proteins are immunoprecipitated (CD9, CD151, Tspan9 and 
α6). These interactions are lost in more stringent detergents (1 % Triton X-100) 




















1.1.3.2 Tetraspanin microdomains are associated with certain lipids but are 
distinct from lipid rafts 
As well as being enriched in tetraspanins and their partner proteins, tetraspanin 
microdomains are also enriched with specific lipids, in particular gangliosides and 
cholesterol. Cell line studies have demonstrated an interaction between CD9 and the 
ganglioside GM3 (Kawakami et al., 2002, Mitsuzuka et al., 2005). Other evidence for 
ganglioside involvement in tetraspanin microdomains include the reduction of 
tetraspanin-tetraspanin associations in cells where the glycosphingolipid biosynthetic 
pathway is inhibited or in which there is ectopic expression of a sialidase (Odintsova 
et al., 2006). As with tetraspanin partner protein interactions this association of 
tetraspanins and gangliosides is restricted to specific gangliosides, the two best 
characterised being GM3 and GMD1 (Hemler, 2005). Cholesterol is also enriched in 
tetraspanin microdomains as evidenced by the precipitation of tetraspanin 
microdomains by the saponin Digitonin (Charrin et al., 2003c), the fractionation of 
tetraspanin microdomains into low density fractions of sucrose gradients (Charrin et 
al., 2003b, Berditchevski et al., 2002, Claas et al., 2001, Delaguillaumie et al., 2004) 
and the interaction of tetraspanins with cholesterol analogues (Charrin et al., 2003c). 
How these lipids interact with tetraspanins and their functional consequence for 
tetraspanin microdomains is currently unknown. Current evidence from other multi-
transmembrane proteins points to cholesterol binding by the palmitates attached to 
juxtamembrane cysteine residues found in all tetraspanins. Interestingly, whilst not 
required for initiating tetraspanin-tetraspanin interactions, palmitoylation is required to 
stabilise tetraspanin microdomains which, if they are responsible for tetraspanin 
cholesterol binding, could indicate a similar function for cholesterol (Charrin et al., 
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2002). This hypothesis is however juxtaposed with the results of experiments using 
methyl--cyclodextrin (MCD). Cholesterol depletion from cell membranes using 
MCD, whilst attenuating tetraspanin mediated cell functions, does not disrupt 
tetraspanin microdomains (Claas et al., 2001, Charrin et al., 2003c). Another 
potential cholesterol binding site is the band of exposed aromatic residues found in 
many tetraspanins around transmembrane domains 1 and 2. These residues serve 
as binding sites in other transmembrane proteins too, however whilst present in 
many, they are not found in all tetraspanins (Seigneuret, 2006, Stipp et al., 2003).  
The enrichment of tetraspanin microdomains with particular lipids and their 
separation into low density sucrose gradient fractions leads to their comparison with 
other membrane microdomains, in particular lipid rafts (Simons and Gerl, 2010). 
Whilst sharing these general similarities there are key differences between them 
which demonstrate that tetraspanin microdomains are clearly distinct from lipid rafts. 
As shown in Table 1, these differences are at the level of the biochemical 
characteristics that characterise many membrane microdomains and also in the 
repertoire of proteins found in each (Hemler, 2005). In addition to the experimental 
evidence provided in Table 1, lipid rafts and tetraspanin microdomains differ 
fundamentally in that tetraspanin microdomains are formed on the basis of protein-
protein interactions whereas lipid rafts are formed through the interaction of lipid and 









 Tetraspanin microdomain Lipid raft 
Temperature Maintained at 37 C Disrupted at 37 C 
Cholesterol 
Resistant to cholesterol 
depletion 




Mostly soluble in non-ionic 
detergents 





Enriched in tetraspanins 
Do not contain GPI-linked 
proteins, caveolin and Src-
family kinases 
Do not contain tetraspanins 
Contain GPI-linked proteins, 
caveolin and Src-family 
kinases  
 
Table 1. Comparison of tetraspanin microdomains and lipid rafts. 
Despite being enriched in particular lipids and sometimes partitioning into low density 
membrane fractions, tetraspanin microdomains are distinct from the classical lipid raft 
microdomains. Some of the main differences are listed in this table. Abbreviations - 















1.1.3.3 Tetraspanin microdomains are dynamic structures 
Discussion so far as focussed on the biochemical analysis of tetraspanin 
microdomains which, whilst highly informative of their composition and of the 
interactions that form them, gives little insight into how these microdomains may 
behave in the plasma membrane. Tetraspanins and their microdomains have also 
been studied using microscopy techniques that allow their analyses in live and fixed 
cell membranes. Initial studies used confocal microscopy to look at the distribution 
and size of tetraspanin microdomains by labelling CD9, CD81, CD82 and CD63 in 
HeLa cells. This study found them numerous and scattered across the cell surface 
with a size of ~200 nm (Nydegger et al., 2006). As this size is at the diffraction limit of 
light, more sophisticated techniques that overcome this limitation of light microscopy 
were used to look at these structures in more detail and at the movement of 
individual tetraspanins in the cell membrane. Förster resonance energy transfer 
(FRET) analysis showed that in addition to their microdomain forming interactions, 
tetraspanins also appeared to interact outside of tetraspanin microdomains (Barreiro 
et al., 2008). Single particle tracking microscopy (SPTM) allowed closer analysis of 
this and demonstrated that tetraspanins are highly mobile and undergo successive 
transient interactions (Espenel et al., 2008). These studies suggest that tetraspanins 
(and so the associated partner proteins), by their nature, are highly mobile and thus 
many microdomains may be highly dynamic, being formed transiently and 
successively many times. For tetraspanin microdomains that are longer lived (also 
seen in FRET and SPTM studies), it is predicted that a tetraspanin partner protein 
would be anchored to one position with many interactions becoming centred around 
this initial microdomain (Charrin et al., 2009).  
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1.1.3.4 Tetraspanin microdomains interact with cytosolic proteins 
In addition to co-ordinating other transmembrane proteins there is evidence to 
suggest that proteins resident in the cytosol can also associate with tetraspanin 
microdomains. This promotes the idea that the tetraspanin microdomain and the 
tetraspanin web exists not only as a structure above the membrane, despite the short 
intracellular tails of tetraspanins. Several cytoplasmic effector proteins have been 
shown to associate with tetraspanin microdomains generally through interactions with 
tetraspanin C-terminal tails. These include PDZ domain containing proteins that act 
as molecular scaffolds (Pan et al., 2007, Bassani et al., 2012, Latysheva et al., 
2006), actin-binding ezrin-radixin-moesin (ERM) family proteins (Sala-Valdés et al., 
2006) and the signalling proteins phosphatidylinositol 4-kinases (PI4Ks) (Yauch and 
Hemler, 2000) and Rac GTPase (Tejera et al., 2013) and the classical PKC kinases 
PKCα and PKCβ (Zhang et al., 2001). It is thought that tetraspanins may act as linker 
molecules between these cellular effectors and the other transmembrane proteins 












1.1.4 Tetraspanin regulation of partner proteins 
Tetraspanins have been found to play roles in very diverse cellular functions, which is 
probably due to the diverse array of membrane proteins that interact with 
tetraspanins and the ubiquitous nature if tetraspanins throughout the body. The 
current view of tetraspanin microdomains as a tetraspanin web suggests that these 
structures influence the organisation of particular proteins in the plasma membrane 
and this regulates and facilitates efficiency of cell function (Charrin et al., 2009). 
Unfortunately, the detailed study of the function of tetraspanin microdomains as 
whole units has not yet been achieved. Instead studies have focussed on 
understanding the function of individual tetraspanins and the identification of their 
partner proteins.  
There have been four main approaches to studying tetraspanins. Historically the 
effects of monoclonal antibodies against some tetraspanins on different cell types 
were the starting points of research into tetraspanin function (Levy et al., 1998, 
Higginbottom et al., 2000, Wu et al., 2001). The field is now dominated by silencing, 
mutagenesis and overexpression studies, whole organism knockout models including 
plants (Olmos et al., 2003), worms (Dunn et al., 2010), flies (Kopczynski et al., 1996) 
and mice (Maecker et al., 1998) and more recently discoveries of tetraspanin 
mutations in human diseases. In many of these approaches it can be difficult to 
ensure the observed effects of tetraspanin manipulation are specific to the targeted 
tetraspanin. This is due to the extensive interactions between tetraspanins and the 
influence of tetraspanin microdomain disruption on the many different proteins 
thought to be regulated by tetraspanins and the tetraspanin web (Charrin et al., 
2003b, Charrin et al., 2009). An additional problem that is faced by knockdown 
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studies or knockout models is that cells express many tetraspanins, some of which 
may share partner proteins or similar functions. As such the loss of one tetraspanin 
may be compensated by another which can diminish or abrogate the effects caused 
by the loss of the targeted tetraspanin (Dornier et al., 2012, Haining et al., 2012). 
Despite this, and the wide ranging nature of tetraspanin partner proteins, three main 
areas of tetraspanin influence on their partner proteins have be identified: (a) 
regulation of biosynthetic transport and maturation, (b) regulation of trafficking, 
localisation and surface expression and (c) regulation of lateral mobility and 
clustering.     
 
1.1.4.1 Tetraspanins regulate partner protein biosynthetic transport and 
maturation 
Several tetraspanins have been shown to interact with their partner proteins in the 
ER. Furthermore, for a more select group of tetraspanins, this interaction early in 
protein synthesis is necessary for the progression of the partner proteins from the ER 
to the golgi and then forward to later cellular compartments (Charrin et al., 2009). 
Three key examples of this function of tetraspanins can be seen in studies of CD19 
and CD81 (Tsitsikov et al., 1997, Shoham et al., 2003, van Zelm et al., 2010), the 
uroplakins and their partner proteins (Hu et al., 2005, Tu et al., 2006) and ADAM and 
the TspanC8 tetraspanins (Dornier et al., 2012, Haining et al., 2012, Prox et al., 
2012). In each case the tetraspanin must be co-expressed for the partner protein to 
egress from the ER. This is clearly demonstrated by a patient that carried an insertion 
gene mutation in human CD81 which prevented CD81 expression. This patient had a 
severe immunodeficiency caused by the loss of CD19 (a subunit of the B cell antigen 
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receptor complex) from the surface of B cells (van Zelm et al., 2010). The mechanism 
by which these tetraspanins regulate the egress of their partner proteins from the ER 
is currently unknown, however masking of an ER retention motif or facilitation of 
partner protein glycosylation have both been suggested hypotheses (Haining et al., 
2012, Scholz et al., 2009a).  
 
1.1.4.2 Tetraspanins regulate partner protein cell surface expression 
Other tetraspanins have been shown to regulate the cellular localisation and/or 
turnover of their partner proteins. CD63 is an interesting tetraspanin in this regard as 
it is found predominantly on intracellular compartments (Kobayashi et al., 2000). As 
such it is unsurprising that there are several examples of this tetraspanin regulating 
the targeting and/or retention of its partner proteins in intracellular compartments. 
Two partner proteins retained in intracellular compartments by CD63 expression are 
the chemokine receptor CXCR4 in MT-4 cells and the H+/K+ATPase in HEK 293T 
cells. In both cases, knockdown or mutation of CD63 caused an increased surface 
expression of these proteins as they were no longer trafficked to intracellular 
compartments (Yoshida et al., 2008, Duffield et al., 2003, Codina et al., 2005). The 
mechanism by which CD63 exerts this function is incompletely understood, however 
evidence suggests that association of these proteins with CD63 allows the cell to 
have a stimulus-regulated surface expression of these proteins. CD151 is also known 
to regulate the cellular localisation of some of its partner proteins, not by targeting 
them to a particular part of the cell but by influencing their turnover from the plasma 
membrane. Mutagenesis studies in a breast cancer cell line demonstrated that the 
internalisation motif (YXXfound in the C-terminal tail of CD151 not only regulated 
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the turnover of CD151 from the plasma membrane but also that of integrins 
31and61, with which it associates(Liu et al., 2007b) Another example of this 
type of regulation was more recently discovered as a function of the tetraspanin 
Tspan1 in human intestinal cells. Expression of this tetraspanin in this cell type was 
shown to cause a doubling of the half life of the thiamine transporter with which it was 
found to associate (Nabokina et al., 2011).  
 
1.1.4.3 Tetraspanins regulate partner protein membrane organisation 
The final general theme of tetraspanin regulation of partner proteins is the regulation 
of how partner proteins are organised in the plasma membrane. Several tetraspanins 
have been shown to facilitate the clustering of their partner proteins into nano-
platforms to facilitate efficient cell function. Key examples of this are the formation of 
adhesion platforms on endothelial cells by tetraspanins CD9 and CD151 (Barreiro et 
al., 2008) and the clustering of P-selectin and MHC class II molecules by CD63 and 
CD9 respectively (Doyle et al., 2011, Khandelwal and Roche, 2010). The formation of 
these clusters is thought to rely on the ability of tetraspanins to interact with one 
another as they move through the tetraspanin web. This is thought to contribute to 
efficient and rapid formation of homo- and heterogeneous clusters in response to 
stimuli. Linked to this function is the ability of tetraspanins to regulate the lateral 
mobility of their partner proteins in the plasma membrane. The modulation of the 
movement of integrin by CD151 is one example of this aspect of tetraspanin 
function. In breast cancer epithelial cells integrin was observed by single particle 
tracking microscopy to diffuse in a mostly confined manner in the cell membrane. 
After CD151 knockdown, however, this changed to a mostly directed diffusion (Yang 
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et al., 2012b). This discovery explained why CD151 knockdown in breast cancer 
lines affected integrin clustering and functions without effecting integrin expression 
or activation (Lammerding et al., 2003, Yang et al., 2008). The diffusion of integrin 
is also influenced by its tetraspanin partner. It was shown to be less mobile and in 
smaller clusters in CD37-deficient B cells when compared to wildtype as 
demonstrated by confocal, electron and fluorescence recovery after photobleaching 
(FRAP) microscopy (van Spriel et al., 2012). Other tetraspanins are predicted to 
influence their partner proteins lateral mobility but are yet to be studied in this way. 
Despite the mechanism of how tetraspanins regulate partner protein clustering and 
lateral mobility being incompletely understood, this final aspect of tetraspanin 
function provides the most clues as to the function of tetraspanin microdomains and 















1.1.5 Tetraspanin mutations cause human disease 
Tetraspanins are reported to regulate a hugely diverse array of cellular functions. 
This diversity may be due to their likely expression in all mammalian cell types, the 
wide range of tetraspanin partner protein functions and, as just discussed, the 
different ways in which tetraspanins can regulate these proteins. The partner proteins 
for many tetraspanins are yet to be identified and so the mechanisms through which 
they exert their observed regulation of cell functions are unknown. Despite this, the 
importance of tetraspanins is clearly evidenced by the human diseases linked to 
mutations in tetraspanin genes. The following describes the known tetraspanin 
mutations linked to human diseases and, where known, how these mutations cause 
disruption of cellular processes.   
Tspan7 was originally described due to its mutation in non-specific forms of X-linked 
mental retardation (Zemni et al., 2000). Subsequent research into its function 
resulted in a recently published study that demonstrated a role for this tetraspanin in 
the trafficking of the AMPA receptor (α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid receptor) in hippocampal neurones (Bassani et al., 2012). 
Tspan7 appeared to regulate the turnover from the membrane of the GluA2 subunit 
of the AMPA receptor, not by direct association, but by competing for a mutually 
binding intracellular protein, PICK1. Through this regulation of AMPA levels the 
strength of synaptic signalling and synapse maturity in hippocampal neurones is 
regulated by Tspan7. This function in synapse maturity has been suggested as the 




Mutations in the tetraspanin Tspan12 are one of the causes of the progressive retinal 
vascular disease familial exudative vitreoretinopathy (FEVR) (Yang et al., 2011). In 
this disease the vasculature of the retina is not maintained and its degeneration leads 
to blindness (Yang et al., 2011). Investigations of the Tspan12 knockout mouse 
revealed that Tspan12 is involved in the regulation of Norrin-induced Frizzed 4 
signalling in retinal angiogenesis. Tspan12 appears to promote multimerisation of the 
Frizzed 4 receptor in newly forming blood vessels in the retina, which is important for 
Norrin-induced signalling and the development and maintenance of the retinal 
vasculature. Consequently Tspan12 knockout mice phenocopy defects seen in 
retinas from Norrin knockout mice and the human disease FEVR (Junge et al., 2009).  
Mutations in two other tetraspanins, ROM-1 and Peripherin/retinal degeneration slow 
(RDS), are also known to cause progressive degeneration in the eye. 
Peripherin/RDS is a tetraspanin found specifically in the membranes of the retinal 
cone and rod cell outer segments. It is essential for the correct organisation and 
maintenance of the outer segment discs required for the initiation of 
phototransduction in the retina (Goldberg et al., 2007). There have been 70 different 
mutations identified in the Peripherin/RDS gene, each contributing to one of several 
diseases collectively known as macular dystrophies (Goldberg, 2006). Retinitis 
pigmentosa, a subset of this group of diseases, has been found to involve another 
synergistic mutation in tetraspanin ROM1 (Loewen et al., 2003). This tetraspanin is 
also found in the outer membranes of the rod and cone cells and its loss or mutation 
also leads to disorganisation of the rod and cone cells disc stacks (Boesze-Battaglia 
et al., 2007). 
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Moving on from the eye, mutations in the tetraspanin CD151, that results in a 
truncated protein lacking its integrin binding region, causes end stage hereditary 
nephritis and a skin blistering disease known as pretibial epidermolysis bullosa 
(Karamatic Crew et al., 2004). These diseases are thought to be due to disruption in 
the organisation of basement membranes in which the laminin binding integrins, 
which are partner proteins for CD151, are found. Finally, a patient presenting with 
severe immunodeficiency was subsequently found to carry a mutation in CD81 that 
prevented its expression. As previously discussed this deletion of CD81 from B cells 
prevented the surface expression of CD19, a partner protein for CD81, essential for 
the function of the B cell antigen receptor thus resulting in immunodeficiency (van 
















1.1.6 Tetraspanins and cancer 
As well as having diverse roles in the normal functioning of many cells and 
processes, as detailed in the previous section, tetraspanins also appear to play a role 
in cancer. Many tetraspanins have been linked to various aspects of cancer initiation, 
progression and metastasis as they are often found up or down regulated in many 
different cancers from a variety of tissues. Two tetraspanins in particular, CD151 and 
CD82, have been shown to play roles specifically in cancer metastasis. CD82 has 
been termed a metastasis suppressor gene as it is frequently down regulated in 
many late stage epithelial cancers (Odintsova et al., 2000). Unlike other metastasis 
suppressor genes CD82 appears to suppress metastasis through several different 
mechanisms that ultimately lead to the inhibition of migration and invasiveness and 
the promotion of responses to external stimuli (Tsai and Weissman, 2011). 
Conversely CD151 is found to be upregulated in end stage cancers and is thought to 
be a metastasis promoter, promoting cell motility through its laminin binding integrin 
partner proteins (Haeuw et al., 2011). For other tetraspanins the exact consequences 
of the change in their expression for the cancer is poorly understood. Some 
tetraspanins are, however, advocated as biomarkers and prognostic markers of 
particular cancers which could impact cancer diagnosis and treatment (Hirano et al., 
2009, Wang et al., 2013, Kwon et al., 2012). There is currently one tetraspanin 
targeted approach to cancer treatment in clinical trials. Antibodies against CD37 are 
currently in phase I clinical trials for use in the treatment of non-Hodgkin's lymphoma 
and chronic lymphocytic leukaemia, demonstrating the potential of targeting 




1.1.7 Tetraspanins and infectious disease 
Aside from the numerous reports of tetraspanin involvement in cancers there are 
more specific functions of tetraspanins known in human disease, in particular in the 
use of tetraspanins by infectious agents, especially by viruses. The most well studied 
and understood role of tetraspanins in infectious disease is the function of CD81 in 
the entry of hepatitis C virus into hepatocytes. CD81 is a co-receptor for the virus 
thought, with another protein called scavenger receptor class B member 1 (SRB-1), 
to be responsible for the initial attachment of the virus to the cells (Pileri et al., 1998, 
Reynolds et al., 2008). After attachment via CD81 the evidence suggests that the 
virus then utilises the particular movement of CD81 in the plasma membrane to 
promote its interaction with its other entry co-factors (claudin-1 and occludin) and its 
endocytosis into the target cell (Harris et al., 2013). As it plays such a key role in the 
infection of hepatocytes by hepatitis C virus, CD81 is the focus of much research as 
a potential drug target for this important human disease.    
Another well documented example of viral targeting of tetraspanins is the molecular 
mimicry of Tspan4 by cytomegalovirus. Antibodies produced by many infected 
individuals against the cytomegalovirus protein UL94 cross-react with Tspan4 and 
due to the expression of Tspan4 on blood vessel endothelial cells and fibroblasts the 
anti-UL94 antibodies bind to these cells (Lunardi et al., 2000). The effects of anti-
UL94 antibody binding are thought to be causative of the disease systemic 
scleroderma, that can occur after cytomegalovirus infection, and as such Tspan4 
(also known as NAG-2) is also a potential drug target to prevent the development 
and progression of this disease (Traggiai et al., 2010). Other viruses, including 
human immunodeficiency virus 1 (Gordón-Alonso et al., 2006), influenza virus (Thali, 
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2011), human papillomavirus 16 (Scheffer et al., 2013) and herpes simplex virus 1 
(Wang et al., 2010), are also known to require tetraspanins for their uptake into target 
cells, for replication and intracellular trafficking and/or for budding from host cells. 
However, the role of tetraspanins in the life cycle of these viruses is much less 
understood than the examples of hepatitis C and cytomegalovirus.  
Other infectious agents also utilise tetraspanin expression on target cells, for 
example uropathogenic E. coli bacteria require the uroplakin tetraspanins to adhere 
to and invade the kidney urothelium (Zhou et al., 2001), and the protozoan 
Plasmodium (which is responsible for malaria) requires CD81 to invade hepatocytes 
in its sporozoite form, a step necessary for prolonged malaria infection (Silvie et al., 
2003). The use of tetraspanins by infectious agents is the focus of research that aims 
to neutralise infections by targeting the tetraspanin-organism interaction using 
antibodies and recombinant proteins. Interestingly, as tetraspanins are discovered in 
more organisms, research has now also begun to target tetraspanin homologues 
expressed on some parasites to develop vaccines against important diseases such 











1.1.8 Tetraspanins in lower eukaryotes 
In addition to their clear roles in mammals, tetraspanins are also found in lower 
eukaryotes including flies, worms, fungi and plants. Knockout studies in these 
organisms, as in mice and humans, revealed diverse functions for tetraspanins. The 
following describes some of the key studies of tetraspanins in these lower 
eukaryotes. In C. elegans RNAi knockdown of tetraspanin Tsp-15 caused an 
abnormal morphology (Moribe et al., 2004). Consequent investigation demonstrated 
that Tsp-15 was required for the functioning of the dual oxidase pathway in the worm. 
This pathway, conserved through to mammals, generates reactive oxygen species 
required to crosslink the collagens that form the C. elegans exoskeleton (Moribe et 
al., 2012). Interestingly work in C. elegans has also discovered a role for the 
mammalian TspanC8 tetraspanin homologues Tsp-12 and Tsp-14 in the cleavage of 
the ADAM10 target protein Notch (Dunn et al., 2010). The conclusion of this work 
was that Tsp-12 and Tsp-14 may regulate -secretase activity, however in the light of 
three subsequent papers demonstrating the regulation of ADAM10 by the TspanC8 
tetraspanin subfamily, it is possible that these C. elegans tetraspanins instead 
regulate Notch via ADAM10 (Haining et al., 2012, Prox et al., 2012, Dornier et al., 
2012).  
There are 37 tetraspanin proteins found in the fruit fly D. melanogaster. Three of 
these tetraspanin genes (late bloomer, Tsp42Ee and Tsp42Ej) are required for 
correct motor neurone synapse formation (Kopczynski et al., 1996, Fradkin et al., 
2002). Tetraspanin Tsp42Ej is also called sunglasses due to the degeneration of 
photoreceptors in its null mutant fly. This fly tetraspanin is most closely related to 
CD63 and, like this mammalian tetraspanin, is predominantly found on intracellular 
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organelles, in this case lysosomes (Xu et al., 2004). Finally the tetraspanin Tsp68C 
has an as yet undetermined role in regulating the proliferation of fly hemocytes 
(Sinenko and Mathey-Prevot, 2004).  
As previously mentioned, tetraspanins genes are also conserved in plants and have 
been found in rice, maize, wheat and moss. In the model organism Arabidopsis 
thaliana there are 17 different tetraspanins termed TET1 to TET17. Only TET1 has 
been studied by mutation. In two separate approaches mutations in this gene caused 
aberrant pattern formation and contortion of the plant organs. Whilst the mechanisms 
behind these phenotypes are incompletely understood, these mutants clearly 
demonstrate an important role for at least TET1 in plant development (Olmos et al., 
2003, Cnops et al., 2006, Chiu et al., 2007).  
Additional to these studies, tetraspanins have also been studied in fungi and in the 
parasitic worms that cause schistosomiasis and filariasis. In all three cases 
tetraspanin proteins are the focus of study to either reduce pathogenicity and 
infectivity, or are the targets of vaccines against disease (Gnanasekar et al., 2008, 
Tran et al., 2006, Lambou et al., 2008). In the case of schistosomiasis, vaccines 
against its surface expressed tetraspanin Tsp2 are currently being developed (Curti 
et al., 2013). This tetraspanin is known through knockout studies to be essential for 
the development and maintenance of the teguments that form the outer body of the 







1.1.9 Tetraspanins are enriched in exosomes 
One final aspect of tetraspanin function not yet discussed is their enrichment and 
function in the formation and targeting of exosomes. Exosomes are lipid vesicles that 
are released from the surface of multi vesicular bodies and are thought to target 
specific cells to deliver their contents, usually proteins or RNAs of varying sorts 
(Raposo and Stoorvogel, 2013). Tetraspanins are unusually enriched in exosomes 
and there is evidence to suggest that specific tetraspanins are recruited to particular 
exosomes destined for different target cells or containing differing cargo (Rana and 
Zöller, 2011). The mechanisms governing exosome formation and cell targeting are 
still incompletely understood, however tetraspanins are the focus of intense research 
in this area as they show potential in advancing current drug delivery strategies and 























1.1.10 Platelet tetraspanins 
Five tetraspanins have been identified on the platelet cell surface using antibodies, 
namely CD9, CD63, CD151, Tspan32 and Tspan9. CD9 is the most highly expressed 
tetraspanin in platelets and also is the second most highly expressed protein on the 
human platelet cell surface (roughly 50,000 copies per platelet), behind the very 
highly expressed αIIbβ3 integrin. The function of these tetraspanins on platelets, 
apart from Tspan9, has been investigated by generating the knockout mouse for 
each protein. A summary of the findings from these knockout mice can be seen in 
Table 2. Despite its high expression on platelets CD9-deficient platelets only 
displayed a mild defect in responses. This manifested in a mild hyper-responsive 
phenotype with increased activation of the αIIbβ3 integrin (Mangin et al., 2009). The 
CD63 knockout also shared a similar phenotype with mildly increased responses to a 
range of agonists (Schröder et al., 2009). Both of these phenotypes were attributed 
to augmented inside-out signalling leading to increased integrin activation, however 
no mechanism has been investigated to prove this hypothesis. 
Conversely the CD151 and Tspan32 deficient platelets showed evidence of 
decreased activity of the integrin αIIbβ3. Additionally the phenotypes of both these 
knockout mice were more pronounced than the mild defects seen in the CD9 and 
CD63 knockouts. The CD151 knockout showed impairment of platelet responses in 
several assays including increased bleeding times and instances of re-bleeding 
(Wright et al., 2004), impaired spreading and clot retraction (Lau et al., 2004) and in 
vivo thrombus formation (Orlowski et al., 2009). These defects were shown to be 
platelet mediated as reconstitution experiments eliminated endothelial cell 
involvement (CD151 is also expressed in these cells). The Tspan32 (also known as 
TSSC6) knockout mice also had a similar phenotype with impaired spreading, clot 
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retraction and thrombus formation in in vivo experiments (Goschnick et al., 2006). 
Impaired signalling of the integrin into the platelets (outside-in signalling) was 
hypothesised as the cause of the defects in both these knockout mice as inside-out 
signalling as measured by integrin activation appeared normal. As for the CD9 and 
CD63 knockout mice, no clear mechanism was described to explain the effects of 
CD151 or Tspan32 knockout on αIIbβ3 integrin function.  
Tspan9 was recently identified as the fifth platelet tetraspanin using an antibody but 
is yet to be functionally studied (Protty et al., 2009). Interestingly Tspan9 appears 
most highly expressed on platelets when compared to other mouse tissues in 
western blotting approaches potentially suggesting a key role for this protein in this 
cell type (Protty et al., 2009). Whilst the function of these tetraspanins in platelets has 
begun to be studied, several more have been identified as expressed by platelets by 
proteomics (Senis et al., 2007, Lewandrowski et al., 2009a). Tspan33 was the 
predicted to be the third most highly expressed platelet tetraspanin in human 
platelets behind CD9 and Tspan9 by Lewandrowski et al. and like Tspan9 has yet to 






















Table 2. Platelet tetraspanin knockout phenotypes 
A table of the known platelet tetraspanins (demonstrated as expressed on platelets 
using antibodies) and the platelet phenotype from the associated knockout mouse. 
The exact mechanism of action of these tetraspanins in platelets is unknown 
however the conclusions of the papers that published the platelet phenotype in each 












Several surface transmembrane proteins found in platelets have been identified as 
associated with tetraspanin microdomains using tetraspanin immunoprecipitation in 
Brij97. This method isolates tetraspanin microdomains from platelets as cell lysis in 
Brij97 does not disrupt the interactions between tetraspanins which hold tetraspanin 
microdomains together. The major platelet proteins immunoprecipitated in 
tetraspanin microdomains and the known platelet tetraspanins are shown in Figure 4. 
These include GPVI (Protty et al. 2009), the laminin binding integrin α6β1 (Miao et al., 
2001), the metalloproteinase ADAM10, the choline transporter CD92 (Lewandrowski 
et al., 2009b) and CD36, the scavenger receptor notably binding oxidised low density 
lipoprotein (oxLDL) (Miao et al., 2001). The interactions of these platelet proteins with 
tetraspanins are yet to be studied in detail, with the exception of CD151 and α6β1 
integrin and ADAM10, and so their tetraspanin partners responsible for their inclusion 
in platelet tetraspanin microdomains remains unclear (Orlowski et al., 2009, Dornier 









































































































































































































































































































































































































































First described by Bizzozero in 1882, platelets are small anucleate blood cells that 
are only found in mammals. Generated by megakaryocyte cells in the bone marrow, 
platelets circulate in the blood at concentrations around 1.5 – 4 x 108 /ml, but due to 
their marginalisation by the flow of the much larger red blood cells are found at much 
higher concentrations near the blood vessel walls (Watts et al., 2013). Platelets are 
an important cell type in the body as they play a major role in haemostasis. 
Monitoring the integrity of the vasculature, their primary function is to bridge and plug 
any sites of damage in the vessel endothelium. The importance of this role is clearly 
seen in patients with thrombocytopenia where, without platelet transfusions, bleeding 
ranging from petechia in the skin to intracranial haemorrhage occurs (Hux and 
Martin, 2012). Unfortunately the response of platelets to vessel damage can also be 
activated by diseased endothelium or by atherosclerotic plaque rupture. This 
pathological activation of platelets often results in occlusive blood clots that cause 
myocardial infarction or stroke which, when taken together, are currently the biggest 
cause of death in the UK (Jennings, 2009, von Hundelshausen and Weber, 2007). 
More recently other roles have been uncovered for platelets including functions in the 
innate immune system (von Hundelshausen and Weber, 2007) and during 
development (Uhrin et al., 2010, Echtler et al., 2010). Additional to these new roles in 
normal mammalian biology, platelets also have emerging roles in several different 
human pathologies including atherosclerosis, cancer metastasis, and most recently 
in deep vein thrombosis and ischaemic stroke reperfusion injury (Nieswandt et al., 
2011a, Fuchs et al., 2012, Lowe et al., 2012, Fuentes Q et al., 2012).  
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1.2.2 Platelet biogenesis 
Platelets, like all other blood cells, are the product of haematopoiesis in the bone 
marrow. Platelets are generated by megakaryocyte cells that descend from 
committed myeloid progenitor cells (called colony forming unit granulocyte erythroid 
macrophage megakaryocyte cells [CFU-GEMM]) (Yu and Cantor, 2012) (Figure 5). 
As they mature, megakaryocytes migrate from the osteoblastic bone marrow niche to 
the vascular bone marrow niche where they become large (~50 m across) polyploid 
cells under the regulation of the hormone thrombopoietin (Pitchford et al., 2012). 
Once matured, megakaryocytes form long cytoplasmic extensions from their cell 
body, called proplatelets, that extend into the blood vessels that supply the vascular 
niche. Platelets are shed from these proplatelet extensions into the bloodstream and 
in this way each megakaryocyte can produce 2000 - 3000 platelets in its lifetime 
(Patel et al., 2005, Yu and Cantor, 2012). The continual production of platelets by 
megakaryocytes is required as platelets only survive ~ 10 days in the circulation, 
after which they are cleared by splenic macrophages and Kupffer cells in the liver 




























Figure 5. Megakaryocyte cells descend from myeloid progenitor cells in 
haematopoiesis. 
This diagram is a much simplified diagram of the major later stages of 
haematopoiesis in the bone marrow. Megakaryocytes descend from the 
megakaryocyte committed progenitors colony-forming unit megakaryocyte cells 
(CFU-Meg cells). These cells descend from the committed myeloid progenitor cells 
colony-forming unit granulocyte erythroid macrophage megakaryocyte (CFU-GEMM). 
The differentiation process from CFU-Meg to megakaryocyte is regulated largely by 
the hormone thrombopoietin. All other blood cells are produced by haematopoiesis, 
those other than megakaryocytes which descend from CFU-GEMM cells are also 









1.2.3 Platelet function 
The primary and best understood function of platelets is preventing blood loss from 
damaged blood vessels. On encountering a damaged vessel or ruptured atheroma 
platelets respond to the activatory signals embedded in the exposed subendothelial 
matrix that are usually shielded from the flowing blood by the intact endothelium. 
These platelet agonists include collagens and laminins and also others such as the 
glycoproteins von Willebrand factor (vWF) and fibrinogen which become adhered to 
the collagen in the exposed matrix or are converted to an active form at the damaged 
site.  The agonists induce several physical and biochemical changes in recruited 
platelets in a process understood to have clearly defined steps which culminate in 
stable thrombus formation (Nieswandt et al., 2011b). A diagram of this process which 
is further discussed below can be seen in Figure 6. 
Step 1 - platelet tethering to the damaged vessel wall 
The platelet leucine rich repeat receptors GPIb, GPIX and GPV form a complex in 
the platelet membrane that is responsible for the recognition and binding of von 
Willebrand factor by platelets, after it has become immobilised on exposed sub-
endothelial collagen. This step, known as platelet tethering, is responsible for the 
recruitment of platelets from the flowing blood (Li and Emsley, 2013). The importance 
of this step is highlighted by the rare autosomal recessive bleeding disorder Bernard-
Soulier syndrome. Sufferers of this disorder carry mutations in the GPIb or GPIX 
genes, that result in significantly reduced levels of the protein complex on the platelet 
surface. Consequently Bernard-Soulier platelets can no longer recognise immobilised 
von Willebrand factor and the subsequent inability of their platelets to adhere to 
damaged vessels results in, what can be, a severe bleeding diathesis (Li and 
Emsley, 2013). In addition to the interaction between platelets and vWF proteins 
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upregulated on activated endothelial cells can also aid in platelet tethering to 
damaged vessels. These proteins include P-selectin which, through homotypic 
interactions, can tether activated platelets (which also express P-selectin) to 
endothelial cells. 
Step 2 - Firm adhesion and activation 
The second stage in platelet mediated thrombus formation is platelet activation and 
firm platelet adhesion. Though the interaction between the GPIb complex and von 
Willebrand factor can recruit platelets to a site of endothelial damage, the fast off-rate 
of this interaction results, not in the adhesion of platelets, but their rolling across the 
exposed matrix (Li and Emsley, 2013). This rolling and slowing of platelets is enough, 
however, to allow the low affinity immunoglobulin superfamily receptor GPVI to bind 
its ligand collagen. Constitutively associated with an Fc receptor -chain, this receptor 
recognises the frequent GPO repeats in collagen as a dimer. Despite its weak affinity 
for collagen, GPVI transduces powerful activatory signals into the platelet upon 
ligand engagement via the immunoreceptor tyrosine-based activation motif (ITAM) in 
its associated -chain. These signals activate platelets which leads to the activation 
of integrins such as the collagen binding α2β1 integrin and so the firm adhesion of 
the platelets to the damaged vessel wall (Nieswandt et al., 2011b).  
Step 3 - Platelet spreading 
Following firm adhesion the activated platelets change shape through cytoskeletal 
rearrangements that result in their spreading across the vessel wall. This spreading 
phase increases the amount of adhesion between the platelets and the vessel wall 
and also leads to the formation of actin stress fibres within the spread platelets, both 
of which are required for stable thrombus formation (Aslan and McCarty, 2013).  
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Step 4 - Platelet secretion 
In addition to spreading, platelets also release the contents of specialised organelles 
called  granules and dense granules.  granules contain large proteins such as 
fibrinogen, vWF and P-selectin, proteins which provide a framework around which a 
thrombus can develop (Jackson et al., 2003). Dense granules contain smaller, often 
signalling, molecules many of which act as secondary mediators that act to positively 
reinforce platelet activation in both paracrine and autocrine fashions. One of the most 
important of these secondary mediators is ADP which binds to its receptors on 
platelets and synergises with other activatory signals.  As well as the secreted ADP 
another important second secondary mediator of platelet activation, thromboxane A2 
is released by platelets. Not stored in the dense granules but generated in activated 
platelets from arachidonic acid in the cell membrane thromboxane A2 also has a 
receptor on platelets and also synergises with other activatory signals including ADP. 
Step 5 - Platelet aggregation and thrombus formation 
More platelets are recruited to the damaged site via the vWF secreted by endothelial 
cells and bound platelets and are activated by the secreted agonists ADP and 
thromboxane A2. This growing accumulation of activated platelets become linked 
together (or aggregated) by the binding of fibrinogen and vWF by the activated αIIbβ3 
integrins (Stegner and Nieswandt, 2011). This function of αIIbβ3 is essential to 
haemostasis, as loss of this protein results in the rare disorder Glanzmann’s 
thrombasthenia. Unable to bind fibrinogen or tightly bind vWF upon activation, the 
platelets of patients with Glanzmann’s thrombasthenia are unable to aggregate and 
maintain a stable thrombus resulting in severe bleeding (Stegner and Nieswandt, 
2011). The mass of aggregated platelets provides a pro-coagulant surface for the 
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coagulation cascade for thrombin generation. This procoagulent surface is generated 
by the flipping of negatively charged lipids from the inner leaflet of the platelet plasma 
membrane to the outer leaflet. Once flipped these lipids support the formation of the 
enzyme complex factor Xa and its subsequent cleavage of pro-thrombin to form 
activated thrombin. This step crucial to haemostasis as thrombin cleaves fibrinogen 
to form the fibrin mesh which stabilises the thrombus. Thrombin is also a powerful 
platelet agonist (Furie and Furie, 2006), as will be discussed later.  
Step 6 - Clot retraction 
The thrombus created by platelet aggregation and coagulation cascade activation is 
further stabilised by a processes called clot retraction. During this process actin 
stress fibres in the activated platelets contract, and as the αIIbβ3 integrins are 
attached to the actin cytoskeleton this puts tension through the fibrin mesh and 
causes the thrombus to shrink substantially (Stegner and Nieswandt, 2011). This 
process prevents the thrombus from being degraded or damaged by blood flow 
before the endothelium has had chance to repair the damaged vessel. In addition, 
secreted factors in the platelet releasate promote the repair of damaged vessels and 




































Figure 6. Platelets play a crucial role in thrombus formation.  
The primary role of platelets is in haemostasis. The diagram depicts the main phases 
of thrombus formation mediated by platelets. 
 
1. Due to the size difference between platelets and red blood cells the platelets are 
marginalised and are concentrated at the vessel walls. Here they are continuously 
exposed to nitric oxide released from the intact endothelium. This keeps the platelets 
in a quiescent state. 
 
2. In a phase of thrombus formation called platelet tethering platelets bind vWF factor 
immobilised on exposed collagen via GPIb. This interaction has a fast off rate 
resulting in the rolling of platelets across the damaged area of the vessel. This slows 
the recruited platelets down and allows an interaction between the low affinity 
collagen receptor GPVI and collagen. GPVI signalling causes platelet activation and 
the platelets become stably adhered to the matrix. 
 
3. The activated platelets spread across the matrix and release the contents of their 
dense and alpha granules. Further platelets are recruited to the growing thrombus 
and are activated by the secreted ADP (and Thromboxane A2).  
 
4. The platelets become bridged or aggregated together via their activated αIIbβ3 
integrin and the secreted fibrinogen. This growing thrombus provides a pro-coagulant 
surface for thrombin generation by the coagulation cascade. Thrombin both activates 
platelets and cleaves fibrinogen to form fibrin. The created fibrin mesh is bound by 
platelet αIIbβ3 integrin and aids thrombus stability.    
 
5. To prevent the thrombus from breaking down before the endothelium has healed 











1.2.4 Platelet activatory signalling 
The signalling events that take place during thrombus formation are generally well 
understood, with many of the major signalling receptors and their effector molecules 
already studied using knockout mouse models and tailored inhibitors. The major 
platelet activatory signalling pathways are discussed below.  
1.2.4.1 GPVI 
The immunoglobulin superfamily receptor GPVI is expressed on the platelet cell 
surface, at around 4000 - 6000 copies per platelet, constitutively associated with the 
FcR -chain. This receptor binds collagen (its physiological ligand) at its recurring 
GPO motifs as a dimer and, though a point for debate, is thought to exist on the 
platelet surface as a mixture of monomers and dimers (Clemetson, 2012). GPVI also 
binds the synthetic ligand collagen-related peptide (which is a series of GPO repeats) 
and the snake venom toxin convulxin. The ITAM motif YXXL/I6-12YXXL/I, in the tail of 
the GPVI associated -chain, becomes phosphorylated by the Src-family kinases Lyn 
and Fyn upon ligand binding. This phosphorylation leads to the binding of spleen 
tyrosine kinase (Syk) to the ITAM via its SH2 domains. The recruitment of Syk to the 
receptor leads to the phosphorylation of a protein called LAT (as well as others) 
around which a number of adapter and effector proteins form a signalosome (Dutting 
et al., 2012). The formation of this signalosome ultimately leads to the activation of 
phospholipase C 2 (PLC2) and the subsequent release of Ca2+ from the 
intracellular stores and the activation of protein kinase C (PKC). Both Ca2+ signalling 
and PKC lead to the inside-out activation of integrins, cytoskeletal rearrangements 
and granule secretion seen in platelet activation. This signalling cascade allows GPVI 
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to powerfully activate platelets despite being regarded as having low affinity for its 
ligand (Dutting et al., 2012).          
Despite this clearly important role in platelet function, patients with a loss of GPVI 
due to autoantibodies or gene mutation only present with mild bleeding disorders 
(Arthur et al., 2007, Dumont et al., 2009, Hermans et al., 2009). This was also the 
case for GPVI knockout mouse models which only had moderate bleeding in tail 
bleeding assays (Kato et al., 2003, Lockyer et al., 2006, Bender et al., 2011, 
Nieswandt et al., 2000, Nieswandt et al., 2001). A more essential role emerged for 
GPVI when thrombus formation in arteries was assessed, using intravital microscopy 
in the various GPVI knockout mouse models, and in infarct size after reperfusion 
injury in the brain (Massberg et al., 2003, Kleinschnitz et al., 2007). As the loss of 
GPVI does not cause severe bleeding there is the potential that GPVI may be a good 































Figure 7. Simplified diagram of GPVI signalling and signalosome formation.  
GPVI signalling is initiated by the binding of collagen by GPVI dimers at GPO motifs. 
This causes the phosphorylation of the associated -chain at its ITAM motif by the 
Src family kinases Fyn and Lyn. Syk binds the phosphorylated tyrosines in the ITAM 
motif via its tandem SH2 domains. The recruitment of Syk to GPVI leads to the 
formation of a downstream signalosome which contains a large number of adapter 
proteins and kinases centred around phosphorylated LAT. One outcome of 
signalosome formation is the activation of PLCand the subsequent increase in 
intracellular Ca2+ and PKC activation. This leads to integrin activation, cytoskeletal 
rearrangements and platelet granule release. This diagram shows a much simplified 










The major platelet integrin αIIbβ3 is the most highly expressed platelet membrane 
protein; with ~ 80000 copies per platelet this protein is thought to make up 15 % of 
the molecules on the platelet cell surface. Once activated by inside-out signalling this 
integrin plays a major role in the physical aggregation of platelets and contributes to 
platelet activation and thrombus formation through outside-in signalling. Once bound 
to its ligands, fibrinogen or vWF forming the bridges that hold the platelets and the 
thrombus together, changes in the intracellular tail of the  subunit leads to the 
activation of the Src family kinases with which it is associated (Stegner and 
Nieswandt, 2011). This conformational change in the integrin and the activation of 
Src family kinases was thought to lead to the recruitment of Syk to the integrin tail. 
Recent work from the Newman group has also suggested that II3 activates Syk 
indirectly, though Syk binding to an ITAM within another platelet receptor FcRIIA, 
which is proposed to interact with the integrin (Zhi et al., 2013). In either case similar 
to ITAM signalling this recruitment of Syk initiates a signalling cascade that finally 
converges on the activation of PKC isoforms and Ca2+ oscillations. Downstream of 
II3 this signalling pathway results in the activation of myosin light chain which is key 
in platelet shape change and actin stress fibre formation (Versteeg et al., 2013).  
1.2.4.3 ADP and Thromboxane A2 
ADP and thromboxane A2 released during platelet activation bind to their G protein-
coupled receptors in an autocrine (and paracrine) fashion. A diagram of a simplified 
signalling pathway downstream of these receptors can be seen in Figure 8. ADP 
binds to both P2Y1 and P2Y12 which synergise and produce a powerful activatory 
signal in platelets (Nieswandt et al., 2011b). These receptors couple to Gq and Gi, 
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G proteins which activate PLC and inhibit cAMP formation, respectively. PLC leads 
to the formation of the secondary messengers diacylglycerol and IP3  which lead to 
PKC activation and increases in intracellular Ca2+ respectively and subsequent 
decreases in inhibitory cAMP levels (Cunningham et al., 2013). The thromboxane 
receptor, TP, also couples to Gq and additionally Gwhich activates Rho/Rho 
kinase signalling. Together these signalling pathways stimulate cytoskeletal 
rearrangements, actin stress fibre formation and feed into the other platelet signalling 
pathways that also converge on intracellular Ca2+ increases and PKC activation, thus 
creating a positive activatory feedback system (Smolenski, 2012). The importance of 
these two secondary mediators is evidenced by the efficacy of the antiplatelet drugs 
aspirin and clopidogrel in preventing thrombosis after stent placement in 
atherosclerosis patients. Aspirin prevents thromboxane A2 production by platelets by 
irreversibly inhibiting cycloxygenase enzymes. Clopidogrel is also an irreversible 













Thrombin (or Factor IIa) is generated by the coagulation cascade from prothrombin 
(or Factor II) and activates human platelets by the protease activated receptors 
(PAR) PAR1 and PAR4 (Versteeg et al., 2013). These receptors are activated by the 
cleavage of their extracellular N-terminal tail by thrombin, which exposes a tethered 
ligand in this domain.  These G-protein coupled receptors also couple to the Gq and 
Gproteins, like the TP receptor, and so signalling after receptor activation also 
feeds into the PKC activatory pathways (Figure 8). Thrombin is viewed as a highly 
potent platelet agonist which plays a key role in thrombus formation (Stegner and 
Nieswandt, 2011). 
1.2.4.5 CLEC-2 
CLEC-2 is a recently discovered single transmembrane activatory receptor in 
platelets and its role in thrombus formation currently remains unclear (Stegner and 
Nieswandt, 2011). It is the only so-called hemITAM receptor on platelets, with a 
YXXL motif in its intracellular tail, and intriguingly its only know endogenous ligand, 
podoplanin, is expressed on lymphatic endothelium, and not in the vasculature 
(Suzuki-Inoue et al., 2011). Knockout mouse models for this receptor display 
impairment in thrombus formation in arterial environments suggesting however that it 
does have some unknown role to play in haemostasis (Nieswandt et al., 2011b). 
Despite its unknown role on platelets in haemostasis the signalling downstream of 
this receptor has been revealed using clustering antibodies and the snake venom 
toxin rhodocytin which binds CLEC-2. Similar to GPVI, clustering of CLEC-2 causes 
phosphorylation of its hemITAM by Src family kinases and subsequent recruitment of 
Syk and signalosome formation (Stegner and Nieswandt, 2011). Knockout mice for 
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CLEC-2, and indeed Syk or podoplanin, result in a defect in the separation of the 
lymphatic and blood vessels. This defect has been shown to critically involve 
platelets in a previously unknown role in development (Suzuki-Inoue et al., 2011). 
Recent work using the GPVI and CLEC-2 double knockout platelets and mice has 
highlighted a previously unappreciated functional redundancy between these two 
ITAM/hemITAM bearing receptors. Platelets deficient in both GPVI and CLEC-2 
displayed much more profound defects in haemostasis than seen in the single 
knockouts for either of these proteins. The mechanism by which this redundancy 
occurs is currently unknown and represents a new emerging role of platelet ITAM 







































Figure 8. Simplified diagram of GPCR signalling in platelets. 
This diagram shows the much simplified signalling cascades downstream of the 
platelet agonists ADP, thromboxane A2 and thrombin. Signalling through their 
respective G protein-coupled receptors, these platelet agonists cause cytoskeletal 
rearrangements downstream of myosin light chain phosphorylation and the decrease 
of cAMP levels and PKC activation which leads to integrin activation and 
degranulation. In this way ADP and thromboxane A2 positively feedback on platelet 
activation and thrombin powerfully activates platelets. This diagram was modified 






1.2.5 Platelet inhibitory signalling 
As demonstrated by the severe results of pathological platelet activation, it is 
essential that platelets are kept quiescent in healthy and undamaged vessels. The 
two best understood mechanisms for this are the release of nitric oxide and 
prostacyclin from the intact vessel endothelium. Nitric oxide, a membrane-permeable 
gas, is generated in endothelial cells by nitric oxide synthase (Busse and Mulsch, 
1990). This gas activates guanylyl cyclase in platelets leading to the accumulation of 
cyclic guanosine monophosphate (cGMP). This accumulation of cGMP leads to the 
activation of cGMP-dependent protein kinase (cGK) type I which phosphorylates 
many targets that prevent the release of Ca2+ from intracellular stores, and inhibits 
integrin activation and cytoskeletal rearrangements. Additionally a rise in cGMP 
inhibits phosphdiesterase 3A which results in a rise in cAMP levels (Gresele et al., 
2011). Prostacyclin is produced in endothelial cells by prostacyclin synthase and is 
bound by the IP receptor on platelets. This GPCR is coupled to G5 which activates 
adenylate cyclase and leads to an accumulation of cyclic adenosine monophosphate 
(cAMP) inside platelets.    Similar to the inhibitory mechanism of nitric oxide, this rise 
in cAMP levels activates a kinase (protein kinase A [PKA]), the targets of which 
inhibit integrin activation, cytoskeletal rearrangements, granule release and increase 









1.3 Project background and aims 
 
Both Tspan9 and Tspan33 have recently been identified on platelets but little is 
known about their function. Tspan9 was discovered by our group in a SAGE library of 
mouse megakaryocyte mRNA and a platelet proteomic study (Senis et al., 2007) and 
subsequently found to be relatively platelet specific in comparison to other mouse 
tissues (Protty et al., 2009). Tspan9 was also identified as the second most 
abundantly expressed tetraspanin after the highly expressed CD9 in another 
proteomic study of the platelet cell surface (Lewandrowski et al., 2009b). Since the 
publication of Tspan9 as a human and mouse platelet tetraspanin, our lab has 
generated a Tspan9 knockout mouse. Tspan33 was also identified as a probable 
platelet tetraspanin through its presence in the mouse megakaryocyte mRNA SAGE 
library and in human platelets by proteomics (Lewandrowski et al., 2009b, Senis et 
al., 2007). Tspan33 has already been identified as an important regulatory factor in 
erythropoiesis in a knockout mouse study and this mouse is available to us to study 
their platelets. 
The aim of this project is to functionally characterise both Tspan9- and Tspan33-
deficient platelets using their knockout mice and to identify their protein partners on 
the platelet cell surface. By analysing their knockout platelet phenotypes and 
identifying their partner proteins it is hoped that we may discover how these 
tetraspanins function on platelets and identify new regulatory mechanisms for 
important platelet proteins. This could lead to the identification of new anti-platelet 










PAR4 peptide (AYPGKF) Dr. Richard Farndale  
(Cambridge University, UK) 
Arachadonic acid Cayman Chemical 
(Cambridge Bioscience Ltd., UK) 
Collagen (HORM) Nycomed Austria 
(Linz, Austria) 
Collagen related peptide Dr. Richard Farndale  
(Cambridge University, UK) 
CLEC-2 antibody Dr. Steve Watson 







Lotrafiban Dr. Steve Watson 
CHAPTER II: MATERIALS AND METHODS 
2.1 Antibodies and reagents 
Agonists, antagonists and antibodies used are listed in Tables 3, 4 and 5, 
respectively. Antibodies were used at 1 g per immunoprecipitation, 1 g/ml for 
western blotting and 10 g/ml for flow cytometry and microscopy unless otherwise 
indicated by the manufacturer's protocol. Cell culture reagents were from PAA 
laboratories (Somerset, UK) unless otherwise stated.  






















Antibody Host species Source 
mouse IIb FITC Rat Emfret Analytics 
(Wurzburg, Germany) 
mouse 2 FITC Rat Emfret Analytics 
mouse 6 FITC Rat Emfret Analytics 
mouse GPVI FITC Rat Emfret Analytics 
mouse GPIb FITC Rat Emfret Analytics 
mouse CD9 FITC Rat Emfret Analytics 
mouse ADAM10 FITC Rat R&D Systems 
(Minnesota, USA) 
mouse CLEC-2 FITC Rat Dr. Steve Watson 
rat IgG2a FITC Rat AbD Serotec 
(Oxford, UK) 
mouse Gr-1 FITC Rat eBioscience 
(Hatfield, UK) 
mouse B220 FITC Rat eBioscience 
mouse Ter119 FITC Rat eBioscience 
mouse c-kit FITC Rat eBioscience 
mouse CD71 FITC Rat Becton Dickinson 
(California, USA) 

















human GPVI FITC 
(3J24) 
Mouse Dr. Jandrot-Perrus  
(Inserm U698, Paris, France) 
human GPVI dimer FITC 
(9E18) 
Mouse Dr. Jandrot-Perrus 







mouse CD9 Rat Emfret Analytics 
human GPVI 
(HY101) 
Mouse Dr. Pete Smethurst 
(Cambridge, UK) 
mouse GPVI F(ab)1 Rat Emfret Analytics 
mouse CD9 F(ab)1 Rat Emfret Analytics 
Table 3 



























Tspan9 knockout mice were generated from C57BL/6 mouse embryonic stem cells 
containing a genetrap vector (clone IST11668F5) between the first two exons of the 
Tspan9 gene at the Texas Institute for Genomic Medicine, Houston, Texas, USA. 
Rederivation of original mice onto clean BL/6 mice was performed at the Biomedical 
Services Unit at the University of Birmingham, UK and subsequent animals were 
produced through heterozygous x heterozygous mating to allow the use of litter 
matched control mice. The Tspan33 knockout mice were kindly provided by Dr. 
Schickwann Tsai (Salt Lake City, Utah) and are fully described in Heikens et al. 
(2007). These mice were also rederived onto clean BL/6 mice at the Biomedical 
Services Unit. GPVI knockout mice were kindly provided by Dr. Steve Watson 
(University of Birmingham, UK) and were originally described in Cheli et al. (2008a). 
GPVI heterozygote Tspan9 knockout (GPVI+/- Tspan9-/-) mice were generated by 
crossing Tspan9-/- mice with GPVI-/- mice followed by a cross between the F1 
generation of this cross with either Tspan9+/+ or Tspan9-/- mice. Litter matched 
controls were not available for this strain. Mice were aged at least 8 weeks before 
use in experiments. All mice were bred and used in the Biomedical Services Unit, a 
designated site for animal use at the University of Birmingham, UK. All animal work 








2.3 Platelet preparation 
2.3.1 Human platelet preparation 
Blood was drawn from the veins in the antecubital fossa using a 23 gauge butterfly 
needle and syringe. Blood was drawn into 10 % sodium citrate as anti-coagulant on 
the day of experiment. After collection, another anti-coagulant, 10 % acid citrate 
dextrose (ACD 120 mM sodium citrate, 110 mM glucose, 80 mM citric acid), was 
added to the blood. Platelet rich plasma (PRP) was collected after spinning anti-
coagulated blood at 200 x g in a swing out centrifuge for 20 min. Platelets were 
sedimented by spinning platelet rich plasma at 1000 x g for 10 min in a swing out 
centrifuge after the addition of prostacyclin (10 g/ml) to prevent platelet activation. 
Pelleted platelets were resuspended in modified Tyrode's buffer (134 mM NaCl, 0.34 
mM Na2HPO4, 2.9 mM KCl, 12 mM NaHCO3, 20mM HEPES, 5 mM glucose, 1 mM 
MgCl2, pH 7.3) to a final concentration of 5 x 108 - 1 x 109 for biochemistry 
experiments. Platelets were allowed to rest for 30 min after resuspension before use. 
This method was previously described in McCarty et al. (2006). 
2.3.2 Mouse platelet preparation 
Blood was drawn from the exposed descending aorta of mice, terminally 
anaesthetised with isoflurane, using a 23 gauge needle and syringe. Blood was 
drawn into 10 % ACD for washed platelets (Séverin et al., 2012), 10 % sodium citrate 
for PRP or 40 M D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK)  
and 5 U/ml Heparin for in vitro flow studies (Auger et al., 2005) and then immediately 
mixed with 200 µl of modified Tyrode's buffer. Anti-coagulated blood was first spun 
for 5 min at 425 x g in a bench top microfuge and the plasma and top third of partially 
separated red blood cells collected. Collected pre-spun blood was then spun at 200 x 
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g for 6 min in a swing out centrifuge to better sediment red blood cells. Plasma 
collected after the second spin was set aside and the remaining sample spun again 
at 200 x g for 6 min. Remaining plasma and platelet layer were collected from the 
sedimented red blood cells and pooled forming the PRP. For washed platelets 10 
g/ml of prostacyclin was added to the PRP which was then spun for 6 min at 1000 x 
g. Extracted platelets were resuspend in modified Tyrode's buffer and concentration 
adjusted to 2 x 108/ml for aggregation,  2 x 107/ml for spreading assays, 5 x 108/ml 
for biotinylation and 5 x 108 - 1 x 109 for other biochemistry experiments. Washed 





























2.4 Primary cell isolation 
 
2.4.1 Megakaryocyte isolation from adult mouse bone marrow 
 
Bone marrow was flushed from both femora and tibiae (previously stripped of all 
other tissue and sterilised with 70 % ethanol) of adult mice using approximately 10 ml 
of ice cold Dulbecco's modified eagle medium (DMEM) complete with 10 % foetal 
bovine serum (FBS), glutamine (20 mM) and the antibiotics penicillin (100 U/ml) and 
streptomycin (100 g/ml) and a 25 gauge needle. Collected bone marrow was spun 
for 5 min at 300 x g in a swing out centrifuge and the pellet resuspended in 6 ml of 
ammonium-chloride-potassium (ACK) buffer (0.15 M NH4Cl, 1 mM KHCO3, 0.1 mM 
Na2EDTA, pH 7.3) and left to incubate at room temperature for 5 min to allow red 
blood cell lysis. The ACK cell suspension was filtered through a sterile 70 m nylon 
mesh filter and spun at 300 x g for 5 min at 4 C in a swing out centrifuge. The cell 
pellet was resuspended in 1 ml complete DMEM media and incubated with the 
following antibodies for 30 min on ice: anti-Gr1, anti-B220 and anti-CD16/32. After 
incubation 1 ml of complete DMEM was added to the cells which were then spun 
down at 300 x g for 5 min at 4 C. The cell pellet was resuspended in 1 ml complete 
DMEM containing 2 x 107 anti-rat magnetic Dynal beads (Dynabeads, Invitrogen, 
UK), which had been previously washed 3 times in complete DMEM. Antibody 
stained cells containing the anti-rat magnetic beads were spun down at 300 x g for 5 
min at 4 C and then resuspended without a change in media. This step was 
repeated and then a magnet used to pull down the Dynal beads. After the bead pull 
down step the supernatant was removed into a fresh tube. The pulled-down beads 
were then resuspended in 500 l of complete DMEM then again pulled down using 
the magnet. Remaining supernatant was pooled with previous and the beads 
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discarded. The supernatants were spun down at 300 x g for 5 min at 22 C. The cell 
pellet was resuspended in 1.5 ml complete StemPro media (StemPro-34 serum free 
media plus provided nutrient supplement (Invitrogen), 20 mM glutamine and the 
antibiotics penicillin (100 U/ml) and streptomycin (100 g/ml)) containing 20 ng/ml of 
mouse stem cell factor (PeproTech, London, UK). Cells were incubated for 48 hr at 
37 C with 5 % CO2. After this time cells remaining in suspension were collected and 
spun at 300 x g for 5 min at 22 C and cell pellets were resuspended in 1.5 ml 
complete StemPro media containing 20 ng/ml stem cell factor and 50 ng/ml mouse 
thrombopoietin (PeproTech). After a further 3 - 4 days incubation at 37 C with 5 % 
CO2 cells were separated over a BSA gradient (4 ml of 3 % BSA with 4 ml 1.5 % BSA 
on top) for 45 min. Cells still in the top 8 - 10 ml after 45 min were spun down at 300 
x g for 5 min at 22 C and resuspended in 1.5 ml complete StemPro media 
containing 20 ng/ml stem cell factor and 50 ng/ml mouse thrombopoietin to continue 
differentiation. Cells collected in the bottom 2 ml were an enriched population of 
mature megakaryocytes and ready for further experiments. This method was taken 
from the method previously published in Dumon et al. (2006). 
2.4.2 Erythroblast isolation from adult mouse bone marrow and spleen 
This method was taken from Vegiopoulos et al. (2006). Bone marrow wash flushed 
from the hind legs of adult wildtype and Tspan33 knockout mice in the same way as 
for megakaryocyte isolation and then collected bone marrow was spun for 5 min at 
300 x g in a swing out centrifuge. Cells were resuspended in 100 l of complete 
DMEM media and were then ready to undergo antibody staining for flow cytometry 
and cell sorting. Spleens from adult wildtype and Tspan33 knockout mice were 
cleaned of any contaminating soft or connective tissue and then placed in 1 ml of 
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complete DMEM in dishes on ice. Cells were released from the whole spleens by 
pecking at the tissue using fine tipped curved tweezers. Media around the 'pecked' 
spleen was collected and spun for 5 min at 300 x g in a swing out centrifuge. Cells 
were resuspended in 100 l of complete media and were then ready to undergo 
antibody staining for flow cytometry. 
2.4.3 Erythroblast in vitro differentiation and maturation from foetal liver cells 
This method was taken from Dolznig et al. (2001). Tspan33 heterozygous mice were 
timed mated and resulting pregnant females schedule 1 culled by cervical dislocation 
at estimated day 14.5 gestation. The womb was dissected from the females and 
placed in a sterile tissue culture hood. Embryos were dissected out of the womb and 
tail tips taken for genotyping. Livers were dissected from the embryos into 1 ml of 
sterile PBS. Single cell suspensions were created by pipetting up and down. Cells 
were spun down at 200 x g for 5 min in a swing out centrifuge and cell pellets 
resuspended in ACK buffer to lyse red blood cells. After red cell lysis 1 ml of PBS 
was added to the cells which were then spun down at 200 x g for 5 min. Cells were 
resuspended in 1 ml complete erythro-StemPro-34 media (StemPro-34 serum free 
media plus provided nutrient supplement, 2 mM L-glutamine, 50 U/ml penicillin, 50 
ng/ml streptomycin, 100 ng/ml murine stem cell factor, 1 M dexamethasone (Sigma) 
and 2 U/ml human recombinant erythropoietin (Roche, West Sussex, UK)) in 12 well 
tissue culture plates. After 1 day incubation at 37 C with 5 % CO2 an additional 1 ml 
of StemPro-34 media was added to each well. On Day 2 of culture, without disturbing 
the cell layer in the bottom of the well, the top 1 ml of media was removed from each 
well, the cells were then resuspended in the remaining 1 ml of media and transferred 
into a 6-well tissue culture plate and an additional 2 ml of media added to each well. 
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Cells were fed with 1.5 ml complete erythro-StemPro-34 media (after removal of top 
1.5 ml media in each well) for 8 days. On day 9 cells were resuspended in the 3 ml of 
media in the well and spun down at 200 x g for 5 min in a swing out centrifuge, 
resuspended in 3 ml sterile PBS then spun down again. The washed cell pellet was 
resuspended in 2 ml of sterile PBS and layered on top of 2 ml of Ficoll-Paque PLUS 
(GE Healthcare, Buckinghamshire, UK). Layered cells were spun at 1100 x g for 5 
min at room temperature in a swing out centrifuge. The PBS cell layer and the Ficoll 
layer were collected from on top of the cell pellet and re-layered, Ficoll then cells. 
The re-layered cells were then spun at 200 x g for 5 min at 4 C . The pelleted cells 
were resuspended in 1 ml PBS then spun down at 200 x g for 5 min. The cells were 
resuspended to a final concentration of 2 - 3 x 106/ml in complete erythro-StemPro-























2.5 Platelet function testing 
 
2.5.1 Whole blood counting 
 
60 µl of anti-coagulated mouse whole blood was run through a Pentra 60 whole 
blood counting machine from ABX Diagnostics (London, UK), which had been 
previously calibrated for mouse blood. All cell count readings were normalised for the 
added volume of ACD and modified Tyrode's buffer to the blood.  
2.5.2 Tail bleeding 
Mice aged between 8 and 12 weeks were anaesthetised with isoflurane and 
administered 0.05 mg/kg of the analgesic buprenorphine by subcutaneous injection. 
Whilst under continued isoflurane anaesthesia 2 mm or 3 mm of tail tip was removed 
using a razor blade. Resulting blood drops were collected into pre-weighed 
Eppendorf tubes. Each drop of blood was estimated to be 30 l. The mice were 
allowed to bleed for either 20 min, until maximum blood loss (15 %, as estimated by 
weight) was reached or until bleeding ceased (judged as no blood fall for 5 min). 
Cauterisation of the wound ended the procedure. Collected blood was weighed to 
assess blood loss in mg and was normalised for animal weight variations. This 
method was taken from the method previously published in Mazharian et al. (2012).  
2.5.3 Light transmission lumi-aggregometry 
Aggregation of mouse platelets was measured in a Born lumi-aggregometer (model 
460VS; Chronolog, Labmedics, Manchester, UK). Samples were warmed to 37 C for 
1 min with no stirring, then stirred at 37 C for a further min before agonist addition. 
Light transmission through the platelet sample was measured against a sample of 
modified Tyrode's buffer and concomitantly recorded on a chart recorder (Chronolog, 
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Labmedics, Manchester, UK). Platelet responses were measured for at least 4 min 
after agonist addition (Suzuki-Inoue et al., 2003, Dawood et al., 2007).   
2.5.4 ATP secretion measurement  
Adenosine triphosphate (ATP) secretion was assessed at the same time as platelet 
aggregation in the aggregometer and recorded using the same chart recorder as for 
the aggregation responses. During the 1 min 37 C incubation with no stirring a 
premix of luciferin and luciferase was added to the platelet sample (Chronolog, 
Labmedics, Manchester, UK). This allowed ATP secreted from activated platelets to 
be measured indirectly by the release of light from the reaction catalysed by the 
luciferase enzyme. Each test was calibrated by the addition of 2 nmol of ATP at the 
end of each aggregation. Maximal ATP released from the platelets was measured 
(Dawood et al., 2007, Suzuki-Inoue et al., 2003) 
2.5.5 P-selectin exposure and fibrinogen binding 
Whole blood samples that had been collected into ACD were diluted 1:10 with 
modified Tyrode's buffer. Diluted blood was incubated at 37 C in a water bath for 5 
min and were then stimulated for 5 min with either 10 g/ml of collagen-related 
peptide or 500 M PAR4 peptide. Stimulated samples were incubated with either 
anti-mouse P-selectin antibody or fibrinogen, both conjugated to FITC, for 30 min. 
After staining samples were diluted 1:10 with modified Tyrode's buffer and then 
analysed using a FACScalibur flow cytometer (BD Biosciences, Oxford, UK), with 
platelet specific staining being isolated by gating on size. Geometric mean 
fluorescent intensities were used to measure P-selectin surface expression or the 




2.5.6 Platelet stimulations to generate samples for biochemical analyses 
For stimulation experiments mouse platelets at 5 x 108/ml were incubated for 5 min at 
37 C with 10 M lotrafiban, to prevent platelet aggregation, and indomethacin (10 
M) and apyrase (2 U/ml) to block signalling caused by Thromboxane A2 and ADP. 
After inhibitor incubation platelets were stimulated with 10 g/ml of CRP and samples 
taken at 10, 20, 30, 60 and 300 s after stimulation. Time course samples were 
directly lysed in an equal volume of 2x reducing Laemmli buffer (20 % glycerol, 10 % 
-mercaptoethanol, 4 % SDS, 50 mM Tris, 0.004 % Brilliant Blue R). Method 
described previously in Hughes et al. (2008).   
2.5.7 In vitro flow adhesion 
The Bioflux 200 microfluidic flow system (Labtech, Sussex, UK) was used to perfuse 
whole blood through collagen coated microcapillaries. Microcappillaries in 0 – 200 
dyne glass bottomed 24 well plates were coated with collagen (30 g/ml) (5 dyne for 
~ 30 s followed by gravity flow) overnight at 4 C. After washing with Tyrode’s buffer 
the coated capillaries were blocked with 5 mg/ml of denatured and filtered fatty acid 
free bovine serum albumin (10 dyne for 5 min followed by gravity flow) for 1 hr at 
room temperature. After blocking, capillaries were again washed with Tyrode’s buffer 
and kept in Tyrode’s until use. Whole blood was incubated with 0.2 M DiOC6 
membrane dye (Molecular Probes, Oregen, US) for 5 min at 37 C then flowed over 
the prepared capillaries at 300 or 1000 s-1 for 4 and 8 min respectively. The flow 
experiment was imaged using fluorescence video microscopy using a 40X Plan APO 
1.4 NA oil immersion DIC objective with a TE2000 (Nikon) microscope with Digital 
Sight DS-Qi1MC camera (Nikon) using NIS elements AR software (Nikon). Images 
were taken every 2 s. Images were analysed using the thresholding function of 
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ImageJ software to allow automated detection of the surface area covered by platelet 
aggregates in each field of view. This method was developed with support from 

























2.6 Protein biochemistry 
2.6.1 Biotinylation and immunoprecipitation of blood cells  
Washed platelets at 5 x 108 – 1 x 109/ml and red blood cells at 5 x 108/ml washed in 
Tyrode's buffer were incubated with 1 mg/ml of EZ link Sulpho NHS LC Biotin 
(Thermo Fisher Scientific, IL, USA) for 30 min at room temperature with gentle 
rocking to ensure good mixing. The reaction was quenched with 100 mM glycine. 
Biotinylated cells were then spun down at 1000 x g for 6 min in a swing out centrifuge 
(10 g/ml prostacyclin was added to platelets) and then resuspended in either 1 % 
Brij97 lysis buffer (1 % Brij97, 10 mM Tris pH 7.5, 150 mM NaCl, 1 mM CaCl2, 1 mM 
MgCl2, 0.01 % NaN3), 1 % Triton X-100 lysis buffer (1 % Triton X-100, 10 mM Tris pH 
7.5, 150 mM NaCl, 1 mM EDTA, 0.01 % NaN3) or 1 % Digitonin lysis buffer (1 % 
Digitonin (dissolved in methanol 10 % w/v), 10 mM Tris pH 7.4, 150 mM NaCl, 0.01 
% NaN3). Depending on the experiment some cells were resuspended in PBS before 
lysis and then lysed in an equal volume of 2x lysis buffer. Cells were lysed on ice for 
30 min then spun down for 10 min at 4 C at 20 817 x g in a bench top microfuge. 
The supernatant was rotated with protein G sepharose beads for 1 hr at 4 C after a 
sample was taken for whole cell lysate controls. The precleared lysates were spun 
down at 2655 x g in a bench top microfuge for 20 s at 4 C and the supernatant 
transferred onto protein G sepharaose beads that had been pre-coupled with the 
relevant antibody (1 g per IP). After rotation at 4 C for either 90 min or overnight 
beads were spun down at 2655 x g for 20 sec in a bench top microfuge and lysate 
aspirated. Beads were then washed four times with 1 ml of the lysis buffer that the 
cells were lysed in. Beads were then stored in Laemmli's buffer, reducing or non-
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reducing as appropriate. This method was previously published in Ellison et al. 
(2010), Serru et al. (1999) and Senis et al. (2009). 
2.6.2 Western blotting 
Protein samples denatured by incubating at 100 C for 5 min were separated on 
varying % polyacrylamide gels. Gels with a single polyacrylamide concentration were 
prepared and set in house, gradient gels (4 - 12 %) were from Invitrogen, Paisley, 
UK. Samples were run through the gels with 125 V for 2 hr or until the dye front 
reached the end of the gel. Separated proteins were then transferred onto methanol 
activated Immobilon FL transfer membrane (Merck Millipore, Billerica, MA) by wet 
transfer for 90 min with 30 V. The membrane was blocked for 1 hr or overnight with 
either 5 % Milk in TBS or 3 % BSA in TBS (Tris-buffered saline 20 mM Tris, 137 mM 
NaCl, pH 7.6) then incubated with primary antibody in 3 % BSA/TBST (Tris-buffered 
saline with 0.1 % Tween-100) overnight. After washing 3 x 10 min with TBST-high 
salt (TBST with 500 mM NaCl) the membrane was incubated with secondary 
antibodies conjugated to infra red dye (IR dye) 800 CW or 680 (LI-COR biosciences, 
Cambridge, UK) for 2 hr. The stained membrane was then washed 5 x 5 min with 
TBST high salt followed by a final wash in TBS to remove any Tween, then imaged 









2.7 Real time PCR 
2.7.1 RNA extraction from primary cells 
RNA was extracted from cultured megakaryocytes and sorted erythroblast cells using 
an extraction kit from Norgen BioTek (Ontario, Canada). Cell pellets that had been 
frozen at - 80 C were directly lysed with 350 l lysis solution and vortexed for 15 s. 
The amount of starting material varied for each experiment due to the nature in which 
the cells were obtained. Once lysed 200 l of 100 % ethanol was added to the cells 
which were then vortexed for 10 s. This lysate was added to an equilibrated resin 
column and spun at 20 817 x g for 1 min in a bench top microfuge to bring the lysate 
into the resin bed. The resin was washed with wash solution three times and then 
eluted with 50 l elution solution by spinning at 425 x g for 2 min then 20 817 x g for 
1 min. RNA quality was assessed by running 1 g of RNA  on a 1 % agarose gel 
(100 V for ~ 15 min). RNA yield was assessed using a Nanodrop spectrophotometer 
(Nanodrop, Delaware, USA).  
2.7.2 cDNA reverse transcription 
To generate the template required for real time PCR experiments cDNA was 
generated from the purified RNA using an Invitrogen High Capacity cDNA Reverse 
Transcriptase kit. For each reaction the following was required : 2 l of 10 x reverse 
transcription buffer, 0.8 l of 25 x deoxyribonucleotide triphosphates (dNTPs), 2 l 10 
x random decamer primers, 1 l reverse transcriptase enzyme and 14.2 l of RNA 
(neat from the extraction prep). For all erythroblast samples the reaction volume was 
increased to 60 l due to some of the low concentrations of RNA recovered. cDNA 
was generated with the following PCR cycle program: 10 min at 25 C, 120 min 37 
C, 5 min 85 C with a final hold at 4 C. cDNA was stored at - 20 C until use.      
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2.7.3 Real time PCR 
The real time PCR approach used FAM-TAMRA TaqMan hydrolysis probes (Applied 
Biosystems) with one internal control gene (GAPDH) for megakaryocyte analysis and 
two internal control genes for erythroblast samples (GAPDH and 18 S). The 
additional control gene for the erythroblast samples was to provide a control for initial 
cDNA loading. For each gene of interest, and a water only control, 10 l of master 
mix buffer and enzyme was mixed with 1 l of TaqMan primer and aliquoted into a 
half skirted 96 well real time PCR reaction plate. Each gene was assessed in 
duplicate. 9 l of cDNA (megakaryocyte samples diluted 1:30 and erythroblast 
samples diluted 1:3 in water) was added to each well and mixed by pipetting up and 
down. The plate was covered with an optical quality plastic cover and the samples 
analysed on an ABI Prism 7000 Sequence Detection system (Applied Biosystems) 
using the following PCR cycle program: 2 min at 50 C, 10 min at 95 C followed by 
44 cycles of 15 s at 95 C then 1 min at 60 C. Standard curves were generated with 
serial 2 fold dilutions of cDNA and PCR efficiencies calculated. Efficiencies were 
required to be within 10 % of the house keeping gene for valid experiments. Primers 
were tested on an equal mix of cDNAs previously generated from each of the 
following mouse whole organs, brain, heart, kidney, liver, lung, muscle and thymus. 
2.7.4 Analysis 
To generate relative values for the different TspanC8 tetraspanins the cycle threshold 
(ct) values for the house keeping gene GAPDH were subtracted from the ct values of 
each TspanC8 gene. This, now delta ct, value was used to compare the expression 
of the genes with the data being presented as percentage expression of the most 
highly expressed gene. For the analysis of the erythroblast cells an additional step 
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was used of normalising the initial ct values for each gene for differences in the ct 
values of the 18 S gene between the different erythroblast populations tested on the 
same plate. This allowed for any differences in cDNA concentrations between 
























2.8 Single particle tracking 
2.8.1 Antibody labelling 
50 g of each Fab fragment (JAQ1, CD9 or IgG) was mixed with 0.5 g Attofluor 
647N or 565 in PBS pH 7.4 (no calcium or magnesium) and incubated with rotation 
for 2 hr at room temperature. The reaction was quenched with Tris pH 7.5 at a final 
concentration of 10 mM. The antibody and fluor mix was added to an equilibrated 
desalting column (PD-10, Amersham, UK) and allowed to soak into the resin bed. 10 
l of PBS was added on top of the antibody soaked resin which was then spun at 106 
x g for 2 min at room temperature. The eluate from the spin was retained and the 
column then spun again after the addition of another 10 l of PBS. This fraction was 
also collected. The eluate fractions containing the antibodies were coloured slightly 
and these were aliquoted and stored at - 20 C until use. When higher concentrations 
of antibodies are labelled, the labelling efficiency can be measured using a 
spectrophotometer and the Beer-Lambert Law A =  b c where A is absorbance at 
280,  is the extinction coefficient (Lmol-1cm-1), b is path length (cm) and c is the 
concentration of species (M, molL-1). The final concentration of labelled antibody was 
0.5 g/ml.       
2.8.2 Coverslip preparation 
25 mm round glass coverslips were rinsed in acetone, then methanol, then ultrapure 
water. These rinsed coverslips were then submerged in 1 M potassium hydroxide 
and sonicated for 20 min. After sonication the coverslips were washed 10 times in 
ultrapure water. After washing, the coverslips were submerged in fresh ultrapure 
water and sonicated again for 5 min. The twice sonicated coverslips were then 
washed 15 times in ultrapure water. The prepared coverslips were completely dried 
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by passing quickly through a flame before being stored individually in 6 well plates. 
Extra caution was taken to prevent dust from gaining access to the prepared 
coverslips.  
2.8.3 Microscope and imaging set up 
500 l of washed mouse platelets at 2 x 107/ml were allowed to spread on a prepared 
glass coverslip held in a coverslip holder (Attofluor cell chamber, Invitrogen, UK) for 
35 min at 37 C. After spreading non-adhered platelets were removed from the 
coverslip by gentle washing, twice with Tyrode's. The relevant antibodies were 
incubated for 10 min at 37 C with the platelets in a volume of 500 l of Tyrode's at a 
final concentration of 10 ng/ml for JAQ1, 5 ng/ml for CD9 and 50 ng/ml for IgG 
controls. After incubation unbound antibody was removed by gentle washing with 
Tyrode's buffer three times. At this point the platelets were ready for imaging for a 
window of 1 hr. The platelets were imaged using an Olympus IX81-ZDC dual TIRF 
microscope with a Hamamatsu EM-CCD digital camera using an Olympus 150x 
UAPO N 1.45 NA immersion oil TIRF objective with Violet Diode 400-405nm, Argon-
Ion 457-514nm, Green Diode 561nm lasers. Videos were a sequence of 500 images 
captured every 100 ms. Laser power was kept to a minimum to avoid untimely 
bleaching of the fluors and camera gain was set to maximum. At least 15 different 
fields of view were imaged in ensemble labelled conditions and at least 30 for single 
particle labelled conditions.  
2.8.4 Analysis 
Single particle tracking videos were analysed using the purpose made software 
PaTrack (Espenel et al., 2008). Briefly the software was used to identify individual 
particles and track their movements based on preset parameters that defined 
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allowable individual point spread function limits. The tracked particles were then 
manually checked for software errors. Once the true tracks had been identified 
different aspects of the trajectories of each particle were extracted from the software, 
including motion type and diffusion speeds. Bootstrap Monte Carlo sampling was 
used to determine the sample sizes required for a true reflection of all types of 
trajectories displayed by a population. This was found to be 100 trajectories for both 
GPVI and CD9. The software, experimental and analysis approach was previously 




















2.9 Cell culture 
2.9.1 Cells 
Human embryonic kidney (HEK) 293T cells were cultured in DMEM medium 
containing 10 % FBS, 20 mM glutamine and the antibiotics penicillin (100 U/ml) and 
streptomycin (100 g/ml). 
2.9.2 HEK 293T cell transfection 
24 hr before transfection cells were plated out such that on the day of transfection ~ 
80 % confluencey was achieved (See Table 6) in DMEM media that did not contain 
antibiotics. On the day of transfection the appropriate amount of DNA and 
polyethylenimine (PEI, Sigma) (see table below) was added to Opti-MEM 
(Invitrogen), gently vortexed and allowed to incubate for 10 min. This mixture was 
added drop wise onto the cells which were used 48 hr later (Ehrhardt et al., 2006).    
Table 6. PEI transfection of HEK 293T cells guide 
Plate size Cells plated DNA PEI 
6-well 5 x 105 1 g 4 l 
6 cm 1 x 106 2 g 8 l 







2.10 Flow cytometry 
2.10.1 Measuring megakaryocyte ploidy 
Megakaryocyte cells matured in culture were spun down at 300 x g for 10 min then 
resuspended in 0.5 ml PBS and fixed with an equal volume of 1 % paraformaldehyde 
for 30 min on ice. Cells were washed free of fixative with 5 ml of PBS and spun down 
at 300 x g for 10 min. Washed cells were resuspended in 1 ml of DNA staining 
solution (PBS containing 2 mM MgCl2, 0.05 % saponin, 0.01 mg/ml of propidium 
iodide and 10 U/ml of RNAse) and stained overnight at 4 C. Stained cells were 
diluted with 1 ml of FACS buffer (0.2 % BSA, 0.02 % NaN3 in PBS) and analysed with 
a FACScalibur flow cytometer (BD Biosciences). Megakaryocytes were identified and 
gated on by size. The percentage of cells in each peak in a ploidy profile, generated 
by a histogram of propidium iodide (Sigma) intensity against cell count, was 
measured.   
2.10.2 Erythropoiesis analysis and erythroblast cell sorting 
Erythroblast cells isolated from adult bone marrow, adult spleen or cultured from 
foetal liver cells were spun down at 300 x g for 5 min at 4 C in a swing out centrifuge 
and resuspended in 100 l of 5 % ice cold FBS in PBS and transferred into a V-
bottomed 96 well plate. Cells were incubated with anti-CD16 antibody for 5 min to 
block the Fc receptors and then stained with fluorescein isothiocyanate-conjugated 
anti-Ter119, phycoerythrin-conjugated anti-CD71 and allophycocyanin-conjugated 
anti-CD45 in the dark for 1 hr. In addition to the multi stained cell samples single 
colour and unstained controls were included in the experiment to allow compensation 
adjustments. After staining 100 l of 5 % ice cold FBS in PBS was added to the cells 
which were then spun down at 300 x g for 5 min at 4 C and resuspended in 500 l of 
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5 % ice cold FBS/PBS. Cells going forward into real time PCR assays were passed 
through a 70 m mesh filter before being sorted using a Beckman Coulter MoFlo high 
speed cell sorter. Proerythroblasts were isolated by their double positive staining with 
anti-Ter119 and anti-CD71 and CFU-E cells isolated by their anti-CD71 low and anti-
Ter119 negative staining. Cells used to investigate erythropoiesis in the Tsapn33 
knockout mice were analysed using a Cyan flow cytometer and cell populations 
analysed by their Ter119/CD71 expression or their CD45/CD71 expression. 
Fluorescence crosstalk and bleed through was addressed with post acquisition 
compensation using the single colour control cells. Analysis and compensation was 
done using DAKO summit flow cytometry software. This method was previously 
published in Vegiopoulos et al. (2006). 
2.10.3 Analysis of blood cell surface proteins 
5 l of whole blood per condition was diluted with 45 l modified Tyrode's buffer. The 
diluted blood was stained for 30 min at room temperature with 10 g/ml of relevant 
anti-mouse antibody (including negative control antibodies). 1 ml of modified Tyrode's 
buffer was added and a FACScalibur flow cytometer was used to analyse stained 
samples. Platelet and red blood cells were gated by size. Fluorescence in the gate 
was measured and geometric mean fluorescence intensity used to assess the 















Tspan33 (or Penumbra) is a 283 aa tetraspanin that was first identified as a 
candidate mouse platelet tetraspanin in 2007 by its presence in a mouse 
megakaryocyte serial analysis of gene expression (SAGE) library (Senis et al., 2007). 
This study also identified Tspan33 in human platelets, a result which was replicated 
in another proteomic study of human platelet cell surface proteins in 2009 
(Lewandrowski et al., 2009a). Prior to these two findings Tspan33 had been identified 
as an important regulatory factor in erythropoiesis in a study that generated the 
Tspan33 knockout mouse (Heikens et al., 2007). At the time of this project this was 
the only published study of Tspan33 and it observed defects in erythropoiesis in 
Tspan33 knockout mice. Abnormal red blood cells termed basophilic and macrocytic, 
occurred in blood smears of 30 % of knockout animals. These abnormal red blood 
cells increased as the animals aged and developed a subsequent anaemia. In vitro 
work with an erythroblast cell line generated from the knockout mice indicated that 
Tspan33 was required for the survival of erythropoietin responsive erythroid 
progenitors in vitro however the mechanism for this remained unknown. No other 
tissues in the Tspan33 knockout mouse have been studied though it is clear that 
Tspan33 is expressed in other cell types (Heikens et al., 2007). As such the 
indication that Tspan33 may be a yet unstudied platelet tetraspanin was the 
foundation of a project that aimed to use the Tspan33 knockout mouse to discover 







3.2.1 The platelet count and other blood parameters of Tspan33 knockout mice 
were normal in comparison to wildtype. 
Before beginning detailed analysis of the platelet function in the Tspan33 knockout 
mouse whole blood counts were used assess the levels and normality of all the major 
blood cell types. The platelet count and other blood cell counts in the Tspan33 
knockout mouse appeared normal when compared to wildtype and other blood cell 
parameters also fell within the normal ranges (Table 7). The only statistically different 
parameter was the mean platelet volume which was significantly larger in the 
Tspan33 knockout mice by 0.2 m3, though still within the accepted normal range for 
platelet size (4 - 7 m3). Whilst a minor change, this small increase in platelet size 
appeared valid as it was accompanied by the trend for reduced platelet counts 
following the known inverse correlation between platelet size and platelet count 
(Levin and Bessman, 1983). As the increase in Tspan33-deficient platelet size was 
only small, the lack of significance in the decrease of the more variable parameter, 









































































































































































































































































































3.2.2 Tspan33 deficient megakaryocytes mature normally ex vivo. 
 
The significant increase in mean platelet volume in the Tspan33 knockout mouse 
indicated that there may have been a defect in platelet production. To assess this 
megakaryocytes were harvested and purified from adult mouse bone marrow and 
allowed to mature ex vivo. This well defined approach (Shivdasani and Schulze, 
2005) assesses megakaryocyte maturity as an increase in cell ploidy using flow 
cytometry analysis after staining with the DNA intercalating agent propidium iodide. 
In this controlled ex vivo environment Tspan33-deficient megakaryocytes developed 
normally and there were no significant differences between wildtype and knockout 
ploidy profiles (Figure 9). This suggested that Tspan33 was dispensable for 
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Figure 9. Tspan33-deficient megakaryocytes develop normally ex vivo. 
Megakaryocytes from wildtype and knockout mouse adult bone marrow were 
matured ex vivo. Megakaryocyte specific propidium iodide (PI) staining was isolated 
by gating on megakaryocytes by size. A. Representative ploidy profiles for wildtype 
and Tspan33-deficient megakaryocytes. B. % of total megakarocyte population in 
each peak of the PI histogram was measured. No clear differences were observed 

















3.2.3 Tspan33-deficent platelets had normal levels of major surface proteins. 
 
After the general assessment of haematopoiesis in the Tspan33 knockout mouse the 
platelets themselves became the focus of the investigation. Some tetraspanins have 
been found to influence partner protein trafficking to the cell surface (Shoham et al., 
2003, Haining et al., 2012, Berditchevski and Odintsova, 2007), therefore it was 
important to check the surface levels of the major platelet proteins in the Tspan33-
deficient platelets. Whole blood was stained with FITC conjugated antibodies against 
the following major platelet surface proteins IIb3, 21, 61, GPVI, GPIb, CD9, 
ADAM10 and CLEC-2. Flow cytometry allowed platelet specific staining to be 
isolated by gating on platelets by size and geometric mean fluorescence intensity 
was used to assess the protein surface levels (Figure 10A). All of the proteins 
measured were present in Tspan33-deficient platelets at levels that were not 
significantly different from those measured in wildtype platelets (Figure 10B). This 
data indicated that Tspan33 was not required for the surface expression of any of the 
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Figure 10. Tspan33-deficient platelets express normal levels of the major 
platelet surface glycoproteins.  
Whole blood drawn into acid citrate dextrose was incubated with the relevant anti-
mouse antibody conjugated to FITC. Platelet specific staining was isolated by gating 
on platelets by size. A. Representative FACS plots for each indicated protein. 
Wildtype in black and Tspan33-deficient in red. For simplicity only the control trace 
from wildtype staining is shown as it overlays the Tpsan33-deficient trace. B. 
Geometric mean intensity used to assess surface receptor levels. n = 3 - 6 +/- 
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3.2.4 Tspan33 knockout mice do not have a bleeding phenotype. 
 
The initial assessment of haemostasis in the Tspan33 knockout mice was the tail 
bleeding assay, a test analogous to the human bleeding time test used in the clinic 
(Marshall et al., 1997, Hughes et al., 2008). In this assay the tail tip is cut from the 
mice and subsequent blood loss in a set time-frame is recorded. Tail bleeding is well 
documented to detect gross defects in haemostasis. However, due to its inherent 
inclusion of several haemostatic responses and its variability, it is viewed as 
unreliable in identifying more subtle bleeding tendencies in which only one aspect of 
haemostasis, such as platelet function, may be only mildly affected (Greene et al., 
2010). In this initial screen of haemostasis blood loss from the Tspan33 knockout 
mice was not significantly different from wildtype and thus these mice were not 




























Figure 11. Tspan33 knockout mice do not have a bleeding defect as measured 
by the tail bleeding assay.  
Blood loss after tail tip excision is presented as a factor of mouse weight so as to 
normalise blood loss from mice of different sizes. No significant difference was found 
between the blood loss (mg/g) of wildtype and Tspan33 knockout mice using an 
unpaired Students t-test (p = 0.2861). All mice were aged between 8 - 12 weeks and 
between 2 - 3 mm of tail tip removed. n = 20 and error bars represent standard error 
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3.2.5 Tspan33-deficient platelets display normal responses to collagen-related 
peptide and thrombin in light transmission aggregometry. 
As previously stated the tail bleeding assay only allows an assessment of the 
functioning of haemostasis as a whole. To begin to focus more specifically on platelet 
function, light transmission lumi-aggregometry (LTA) was used assess platelet 
aggregation responses to different agonists. LTA is the gold standard in platelet 
function testing (Lordkipanidze et al., 2009), it captures platelet aggregation 
responses over time, including the very initial shape change and subsequent granule 
release allowing detailed analysis of specific platelet signalling pathways. Two 
agonists that stimulate two major platelet activatory pathways were used to 
investigate the functionality of Tspan33-deficient platelets; collagen-related peptide, 
which binds and activates the collagen receptor GPVI and thrombin which cleaves 
and activates the PAR G protein-coupled receptors. Aggregation experiments used 
washed platelet samples without added fibrinogen. Responses to both these agonists 
were normal and not significantly different to wildtype responses (Figure 12A, B, C 
and D). ATP secretion, which is a measurement of dense granule release, was also 
normal in the Tspan33-deficient platelets and not significantly different from wildtype 
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Figure 12. Tspan33-deficient platelets display normal responses to the 
agonists collagen-related peptide and thrombin.   
Tspan33 wildtype and deficient washed platelets were stimulated with collagen-
related peptide (0.3 g/ml) or thrombin (0.06 U/ml) and responses measured with 
lumi-aggregometry. No significant differences were seen in the aggregation traces 
(A, collagen-related peptide and B, Thrombin), percentage aggregation over time (C, 
collagen-related peptide, p = 0.84 and D, thrombin p = 0.69) or in the amount of ATP 
secretion (E, collagen-related peptide p = 0.91 and F, thrombin p = 0.17). n = 3 and 
error bars represent standard error. Statistical test used in C/D was a two-way 








3.2.6 Tetraspanin microdomains immunoprecipitated from Tspan33-deficient 
platelets have the normal complement of tetraspanin associated proteins. 
As all investigations had found that Tspan33-deficient platelets were no different in 
their functional responses from wildtype platelets a different approach that assessed 
the platelet tetraspanin microdomains themselves was the next step. An 
immunoprecipitation and western blotting approach that had been previously 
validated was used as a method of isolating and probing tetraspanin microdomains 
(Protty et al., 2009). The aim of this experiment was to compare the tetraspanin 
microdomains from wildtype and Tspan33-deficient platelets. To immunoprecipitate 
the highest amount of material possible CD9, the most highly expressed platelet 
tetraspanin, was immunoprecipitated from washed mouse platelets that had been 
surface biotinylated. These precipitates were separated on 4 - 12 % polyacrylamide 
gradient gels and the co-immunoprecipitated biotinylated surface proteins detected 
by western blotting with neutravidin.  
As it is thought that each tetraspanin is responsible for the inclusion of its partner 
protein in tetraspanin microdomains any proteins missing from the western blot of 
Tspan33-deficient samples could be potential partner proteins for Tspan33 (Charrin 
et al., 2003b). Thus informing a more directed approach to the further analysis of the 
Tspan33-deficient platelets. However, there was no significant differences between 
wildtype and Tspan33 deficient western blots (Figure 13). All the major bands in the 
microdomain pattern caused by neutravidin blotting in wildtype immunoprecipitates 
were also found at the same intensity in the Tspan33-deficient samples. Interestingly 
there appeared to be no clear band for Tspan33 which we would expect to see in the 
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wildtype but not in the knockout, however there were also no clear bands for any 












































Figure 13. Tspan33-deficient tetraspanin microdomains have a similar 
complement of membrane proteins as wildtype. 
5 x 108 washed platelets per condition were surface biotinylated using EZ-link sulpho 
NHS LC Biotin (1 mg/ml) for 30 min. After biotinylation the platelets were lysed in 1 % 
Brij97 lysis buffer for 1 hour whilst rotating with unconjugated protein G sepharose 
beads. After this preclear step lysates were incubated with beads that been pre-
coupled to either IgG control or anti-CD9 antibody for an additional hour. Samples 
were washed and separated on 4 - 12 % polyacrylamide gradient gels. Separated 
proteins were western blotted with neutravidin to detect biotinylated proteins from the 
platelet cell surface. No difference was found between wildtype and Tspan33-





















3.2.7 Tspan33 mRNA is highly expressed in human platelets but minimal in 
mouse platelets. 
Following the analyses of Tspan33-deficient platelets a new platelet transcriptomics 
study was published (Rowley et al., 2011). This study used paired-end next 
generation RNA sequencing to detect the levels of all the polyadenylated RNA 
transcripts in human and mouse platelets. It was the first study of its kind that 
focussed on solely platelets. The published lists of detected RNAs and their 
respective levels were mined for all the known mammalian tetraspanins (Figure 14). 
Tspan33 was the most highly expressed tetraspanin in human platelets at the mRNA 
level. In mouse platelets however the level of Tspan33 transcript detected was 1000 
times less than that detected in human platelets. Interestingly Tspan33 was not only 
differentially expressed tetraspanin between human and mouse platelets. It is 
possible that such a low level of mRNA would indicate that mouse platelets express 
no Tspan33 protein, or at best minimal levels in comparison to other tetraspanins. A 
lack of expression on mouse platelets would be consistent with the lack of platelet 





















































































































































































































































Presented here is a short investigation into the function of Tspan33 on platelets. The 
initial hypothesis for the project was that Tspan33 is a novel platelet tetraspanin and 
that it contributes to platelet function by regulating another platelet transmembrane 
protein. The aim of the project was to use the Tspan33 knockout mouse and 
Tspan33-deficient megakaryocytes and platelets to investigate the initial hypothesis. 
The final conclusion of this project was that Tspan33 does not play an important part 
in platelet generation, haemostasis or platelet activation downstream of the PAR 
receptors or GPVI. Additionally whilst highly expressed on human platelets Tspan33 
is minimally or not expressed on mouse platelets. This latter finding may potentially 
explain the results of the experiments using platelets from the Tspan33 knockout 
mouse and suggests that this knockout mouse is no longer a useful tool for further 
study of the function of this protein on platelets.  
The only significant difference found between wildtype and Tspan33-deficient 
platelets in this study was the larger mean platelet volume (by 0.2 m3) of Tspan33-
deficient platelets. The cause of this small change in platelet size was not discovered 
in this investigation and taken into context with the rest of the study such a small 
change may be insignificant in terms of understanding Tspan33 function in platelets. 
Further experiments including assessment of proplatelet generation and, taking into 
account the erythropoiesis defect, details of associated other bone marrow cell 
populations are required before this difference in the Tspan33 knockout mouse can 
be fully understood and its significance appreciated.  
Additional to the lack of a platelet function defect in the Tspan33 knockout mice the 
main evidence for concluding that Tspan33 is a human platelet tetraspanin but likely  
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not expressed on mouse platelets came from data mined from a transcriptomics 
paper that was published during the study. After extracting expression levels for all 
known mammalian tetraspanins from this study a striking difference in the RNA levels 
for Tspan33 became clear between human and mouse platelets. This 1000 fold 
difference mirrored albeit to a greater extent the differences in detection of Tspan33 
in the two original papers that were used as the premise for this study, with the 
human proteomics (Lewandrowski et al., 2009a, Senis et al., 2007) ranking Tspan33 
as a much more highly expressed tetraspanin than the mouse megakaryocyte SAGE 
library (Senis et al., 2007) (Table 4). One caveat to this data is however that one can 
never assume that RNA levels directly correlate with final protein levels (Greenbaum 
et al., 2003). Interestingly whilst the top ten expressed tetraspanins identified by 
Rowley et al. correlate well with the human platelet proteomics published by 
Lewandrowski et al. 2009, there is less agreement between the mouse 
megakaryocyte SAGE library and the Rowley transcriptomics study in terms of 
tetraspanins detected and their relative amounts (Table 8). As all three studies 
identified the known platelet tetraspanins - CD9, CD63, CD151, Tspan9 and Tspan32 
(demonstrating the validity of each approach) the differences between the 
megakaryocyte SAGE library and the platelet transcriptomics may be a reflection of 
true differences between the two cell types. 
As well as discovering that Tspan33 is most likely not expressed on mouse platelets 
this investigation has highlighted some interesting questions in terms of the study of 
platelet tetraspanins. In particular the big difference in expression of Tspan33 
between human and mouse. Human and mouse Tspan33 protein have 97 % identity 
(Heikens et al., 2007); why would two virtually identical proteins have such different 
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expression levels? This would not be the first example of differentially expressed 
proteins between human and mouse platelets (Kahn et al., 1998, Maruoka et al., 
2004) and interestingly it does not appear to be the only differentially expressed 
tetraspanin as CD82, CD81 and Tspan17 also appear to have differential expression 
according to the mined data from Rowley et al. Finally the question remains of what 
the function of Tspan33 is and understanding this became the focus of the work 
























































































































































































































































































































































































































































CHAPTER IV: TSPAN33 IS A MEMBER OF THE TSPANC8 
TETRASPANIN SUBFAMILY WHICH REGULATES THE PROTEASE 
ADAM10 
4.1 Introduction 
Whilst assessing the levels of the major platelet surface proteins on Tspan33-
deficient platelets by flow cytometry it was noticed that the levels of the 
transmembrane metalloprotease ADAM10 on red blood cells appeared reduced. The 
aim of the work in this chapter was to characterise and understand this loss of 
ADAM10 from Tspan33-deficient red blood cells. ADAM10 is one of the best known 
tetraspanin associated proteins in the field (Charrin et al., 2009). However its 
tetraspanin partner is unknown. A report identifying Tspan12 as a direct ADAM10-
interacting tetraspanin was not definitive because other tetraspanins could have been 
bridging the Tspan12-ADAM10 interaction under the immunoprecipitation conditions 
used (Xu et al., 2009). Moreover, Tspan12 has a relatively restricted expression 
profile (Junge et al., 2009), unlike the ubiquitous ADAM10. ADAM10 cleaves other 
transmembrane proteins in a process termed ectodomain shedding. This 'sheddase' 
action of ADAM10 results in the loss of the extracellular domains of its 
transmembrane target proteins from the cell surface. This can result in the release of 
transmembrane chemokines and growth factors such as heparin-bound epidermal 
growth factor (HB-EGF), the initiation of trans-cellular signal transduction such as that 
through the Notch receptors, the reduction in cell-cell adhesion through shedding of 
cadherins (Lichtenthaler, 2011, Saftig and Reiss, 2011, Vincent and Govitrapong, 
2011, Endres and Fahrenholz, 2010), and the down regulation of ligand binding 
signalling receptors such as GPVI (Gardiner et al., 2007, Bender et al., 2010). The 
importance of the function of ADAM10 is demonstrated by the embryonic lethality of 
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the ADAM10 knockout mouse which dies around E9.5 due to dysregulation of Notch 
signalling (Hartmann et al., 2002). ADAM10 is responsible for the initial cleavage of 
Notch, following ligand binding, that leads to intracellular cleavage by γ-secretase 
and translocation of the intracellular domain of Notch to the nucleus, where it 
functions as a transcription factor to drive cell fate decisions (Greenwald and Kovall, 
2013). ADAM10 is known to have over 40 targets and as such is involved in the 
activation, regulation and termination of a diverse array of cellular signalling (Deuss 
et al., 2008, Vincent and Checler, 2012). Much research has focussed on ADAM10 
as several of its targets play central roles in the development and progression of 
human diseases. An important example of this is the amyloid precursor protein, 
which gives rise to the beta amyloid peptide that forms amyloid plaques in 
Alzheimer’s disease. ADAM10 cleavage of amyloid precursor protein prevents beta 
amyloid production and so is protective against development and progression of the 
disease (Postina et al., 2004). ADAM10 is also upregulated on some cancers where 
its cleavage of epidermal growth factor can promote tumour invasiveness and the 
epithelial to mesenchymal transition necessary for metastasis.(Crawford et al., 2009). 
However, attempts to target ADAM10 in human diseases such as Alzheimer's 
disease are hampered by the ubiquitous nature of the protein, which would likely 
result in severe side-effects, and a lack of clear understanding of its regulation 
(Lichtenthaler, 2011, Saftig and Reiss, 2011, Vincent and Govitrapong, 2011, Endres 
and Fahrenholz, 2010). As such, determining which tetraspanin(s) interact with 
ADAM10, and how they regulate this metalloprotease, could have important 





4.2.1 ADAM10 surface levels are reduced on Tspan33-deficient red blood cells. 
The initial observation for this project came from a flow cytometry experiment that 
used whole blood samples to test for surface expression levels of several different 
proteins on Tspan33-deficient platelets (Figure 10). By gating on the red blood cell 
population instead of the platelet population (which are clearly separated by forward 
scatter and side scatter) the surface levels of the chosen proteins could also be 
detected on red blood cells (Figure 15A). Of the chosen panel of platelet proteins 
only ADAM10 and CD36 were shared between platelets and red blood cells. The 
surface levels of ADAM10 were significantly reduced in Tspan33-deficient cells by ~ 
90 % (Figure 15 B). This reduction may be specific to ADAM10 as the CD36 levels 
on Tspan33-deficient red blood cells were normal.    






































Figure 15. ADAM10 surface levels are reduced on Tspan33-deficient red blood 
cells. 
Whole blood drawn into acid citrate dextrose was incubated with the relevant anti-
mouse antibody conjugated to FITC. Red blood cell specific staining was isolated by 
gating on red blood cells by size. A. Representative FACS plots for each indicated 
protein, with wildtype in black and Tspan33-deficient in red. For simplicity only the 
negative control trace from the wildtype staining is shown as it superimposes with the 
Tspan33-deficient control. B. Geometric mean fluorescence intensity was used to 
assess receptor levels. n = 4, error bars represent standard error of the mean. 


















4.2.2 ADAM10 total cell levels are reduced on Tspan33-deficient red blood 
cells.  
To follow up the observed difference between surface levels of ADAM10 on 
Tspan33-deficient and wildtype red blood cells, an experiment was designed to 
specifically isolate and detect both the surface and total red blood cell ADAM10 
levels. An immunoprecipitation approach after biotinylation was selected. This 
allowed the detection of surface ADAM10 levels after immunoprecipitation by western 
blotting with neutravidin and total cell levels of ADAM10 by western blotting with an 
anti-ADAM10 antibody. There was a clear decrease in the both the surface level of 
biotinylated ADAM10 detected and the total levels of ADAM10 in Tspan33-deficient 
samples (Figure 16). This correlated with the significant decrease seen in the 
analysis of ADAM10 surface levels by FACS analysis. In addition this result indicated 
that the reduction in ADAM10 at the cell surface is not due to defective transport of 
the protein to the cell surface and actually reflects a loss of protein from the cell.  
In addition to this experiment assessing the levels of ADAM10, it also allowed an 
initial assessment of the tetraspanin microdomains on mouse red blood cells. Three 
major proteins appeared to co-immunoprecipitate with ADAM10 using this Brij97 lysis 
buffer approach, and their sizes were ~44, 48 and approximately 100 kDa. The 
identity of these is unknown, but they are likely to be tetraspanin microdomain-

















Figure 16. Total ADAM10 protein levels are reduced on Tspan33-deficient red 
blood cells.  
Washed red blood cells at 5 x 108/ml (per ip) were surface biotinylated using EZ-link 
sulpho NHS LC Biotin (1 mg/ml) for 30 min. After biotinylation the red blood cells 
were lysed for 30 min on ice in 1 % Brij97 lysis buffer, pre-cleared for 1 hour using 
protein G sepharose beads, then rotated with protein G sepharose beads that had 
been pre-coupled to IgG control or anti-ADAM10 antibody. Samples were washed 
and separated on a 4 - 12 % polyacrylamide gradient gel. Separated proteins were 
western blotted with neutravidin to detect biotinylated proteins from the cell surface 







4.2.3 ADAM10 mRNA levels are not reduced in Tspan33-deficient 
proerythroblasts. 
One explanation for the lower levels of ADAM10 protein seen in Tspan33-deficient 
red blood cells was that ADAM10 mRNA was expressed at lower levels in Tspan33-
deficient proerythroblasts, the precursors to red blood cells, which themselves, have 
minimal mRNA. To investigate this hypothesis, ADAM10 mRNA levels were 
measured by real time PCR in proerythroblasts sorted from ex vivo differentiated 
Tspan33 wildtype and knockout foetal liver. Red blood cells are the anucleate result 
of the final step in erythropoiesis, their complement of proteins determined by the 
biosynthesis of proteins in the preceding stages (Testa, 2004). Therefore to 
investigate protein expression levels, ADAM10 mRNA needed to be assessed in the 
proerythroblasts. Using this approach no difference was found in the ADAM10 mRNA 
levels between wildtype and Tspan33-deficient proerythroblasts (Figure 17). This 
result suggested that ADAM10 protein is likely to be produced in Tspan33-deficient 
proerythroblasts but that it was unable to be packaged into subsequent reticulocytes 


































Figure 17. ADAM10 mRNA levels in Tspan33-deficient proerythroblasts are not 
significantly different from wildtype. 
Foetal livers from E14.5 Tspan33 wildtype or knockout embryos were cultured ex 
vivo in medium that promoted erythroid differentiation. (A) Proerythroblast cells were 
sorted by their high Ter119 antigen and CD71 expression. The red boxes show the 
sorted population. (B) ADAM10 mRNA relative expression was assessed by real time 
PCR using Taqman fluorogenic probes. GAPDH was used to normalise results for 
loading and 18S used as a housekeeping reference gene. Real time PCR results 
were analysed using the delta CT method and shown as relative expression as a 







4.2.4 Characterisation of ADAM10 levels during erythropoiesis. 
As ADAM10 mRNA was expressed in Tspan33-deficient proerythroblast cells at 
similar levels to wildtype, it was important to check the cell surface levels of ADAM10 
before and after this stage to ascertain at which point ADAM10 was lost from the 
Tspan33-deficient erythrocytes. To do this, bone marrow was flushed from wildtype 
and Tspan33 knockout mice and erythroblasts resolved by their expression of the 
transferrin receptor (CD71) and Ter-119 antigen (Figure 18 A). Three stages of 
erythropoiesis were gated, CFU-E cells (early), proerythroblasts (mid) and 
reticulocytes/red blood cells (late) and surface ADAM10 levels were analysed in each 
gate (Figure 18 B). There was no significant difference in ADAM10 surface levels 
between wildtype and Tspan33-deficient CFU-E cells but a significant decrease in 
Tspan33-deficient proerythroblasts and red blood cells (Figure 18 C). Interestingly 
ADAM10 surface levels in wildtype cells decreased dramatically between CFU-E and 
proerythroblasts suggesting that ADAM10 is naturally lost from cells during the 
progression of erythropoiesis. There is currently no known function of ADAM10 in 
erythropoiesis and so the cause and nature of this decrease in expression is 
unknown. This result, in combination with Figure 15 and Figure 16, suggests that 
ADAM10 may be a partner protein for Tspan33. Other tetraspanins, such as CD81 
(which partners CD19), are required for the surface expression of their partner 
proteins and so when they are no longer expressed their partner protein does not 



















Figure 18. Characterisation of ADAM10 levels during erythropoiesis. 
Bone marrow was flushed from the hind legs of adult mice and erythroblasts were 
visualised by flow cytometry. A. Staining specific to the different stages of 
erythropoiesis were isolated by the well characterised expression of Ter-119 antigen 
and CD71 (the transferrin receptor). B. Representative FACS plots of ADAM10 
expression for each identified erythroblast stage indicated show wildtype in black and 
knockout in red. For simplicity only the control trace from wildtype staining is shown 
as the knockout control superimposed on the wildtype trace. C. ADAM10 levels on 
the cells in each gate were determined by geometric mean fluorescence intensity. n = 
3 error bars represent standard error of the mean, significance determined by one 





Red blood cells 






























4.2.5 Tspan33 is a member of the TspanC8 subfamily of tetraspanins.  
A sequence alignment analysis comparing Tspan33 with all the other known 
mammalian tetraspanins highlighted that Tspan33 falls in a cluster with five other 
related tetraspanins (Figure 19). This cluster of tetraspanins, containing Tspan33, 
Tspan17, Tspan15, Tspan14, Tspan10 and Tspan5, are distinct from all the other 
mammalian tetraspanins in that they all contain 8 cysteines in their EC2 domain. 
Subsequently termed the TspanC8 tetraspanins, these tetraspanins were a relatively 
unstudied group. Apart from Tspan33 (Heikens et al., 2007), none of the other 




























Figure 19. Tspan33 is part of the TspanC8 subfamily of tetraspanins. 
The protein sequence of Tspan33 was compared to all the other mammalian 
tetraspanins by sequence alignment using Clustal Omega software. This program 
produced a dendrogram that places Tspan33 in a subfamily of tetraspanins that all 
contained 8 cysteines in their EC2 domains. Only the tetraspanins in this subfamily 






4.2.6 The TspanC8 subfamily of tetraspanins all associate with ADAM10. 
Alongside this investigation of Tspan33 and ADAM10 in red blood cells, a cell line 
based assay, set up and carried out by another Tomlinson lab member, Dr Jing 
Yang, demonstrated an interaction between all six TspanC8 tetraspanins and 
ADAM10 (Appendix Figures 1 A). Furthermore this interaction appeared to promote 
the maturation of ADAM10 as evidenced by the increased amount of ADAM10 
without its pro-domain in TspanC8 co-transfected cells (Appendix Figure 1 B). 
ADAM10 is produced in the cell as an immature pro-protease that requires a 
cleavage step, mediated by the furin proteases in the Golgi, to remove its inhibitory 
pro domain thus forming the mature protein. Immature ADAM10 has an apparent 
molecular weight of ~ 80kDa and mature ADAM10 has an apparent molecular weight 
of ~ 60 kDa. The other related tetraspanins that are known to share partner proteins 
are CD9 and CD81, which both associate with EWI-2 and EWI-F (Montpellier et al., 
2011, Stipp et al., 2001, He et al., 2009). These results, in conjunction with two 
complementary publications, lead to a model in which the TspanC8 tetraspanins 
associate with ADAM10 in the ER, and this association promotes the trafficking of 










4.2.7 The TspanC8 subfamily of tetraspanins have differential expression 
between red blood cells and platelets.  
The next step in the investigation was to understand why the surface expression of 
ADAM10 was normal on Tspan33-deficient platelets and substantially reduced on red 
blood cells. As with most tetraspanins there is a lack of antibodies available for the 
TspanC8 tetraspanins, so the expression profiles of these proteins were assessed by 
real time PCR. As both platelets and red blood cells are anucleate cells, with very low 
mRNA levels, the TspanC8 expression profile was assessed in the progenitor cells: 
megakaryocytes for platelets and CFU-E and proerythroblast cells for red blood cells. 
Megakaryocytes, differentiated from adult mouse bone marrow, and proerythroblasts 
and CFU-E cells, sorted from mouse bone marrow, were lysed and all RNA 
extracted. cDNA was generated from extracted RNA and real time PCR used to 
assess relative levels of mRNA for each of the TspanC8 tetraspanins.  
In proerythroblasts, Tspan33 was the most highly expressed TspanC8 tetraspanin 
with very little or no expression of the other tetraspanins (Figure 20 A). It is important 
to note that Tspan33 mRNA was detected in the knockout sample because the real 
time PCR probe does not distinguish between the mRNA products from wildtype and 
gene-targeted Tspan33 loci. Therefore in Tspan33-deficient proerythroblasts, that 
have minimal expression of any TspanC8 tetraspanins, ADAM10 cannot egress from 
the ER thus explaining the loss of ADAM10 from Tspan33-deficient red blood cells. In 
megakaryocytes, however, Tspan14 was the most highly expressed TspanC8 
tetraspanin and Tspan33 was comparably expressed at very low levels (Figure 20 B). 
This supports the conclusion from the first chapter of this thesis that proposes that 
Tspan33 is not expressed in mouse platelets. In addition it suggests that ADAM10 
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surface expression is normal in Tspan33-deficient platelets because the 
megakaryocytes have their normal complement of TspanC8 tetraspanins. Finally, in 
CFU-E cells, Tspan33 and Tspan14 were expressed with the additional expression of 
Tspan5 (Figure 20 C). This result likely explains the normal surface expression of 
ADAM10 in this cell type (as shown in Figure 18), assuming that the remaining 
Tspan14 and Tspan5 can compensate for the loss of Tspan33, and additionally is 



































































































































Figure 20. Tspan33 in not expressed in megakaryocytes but is highly 
expressed in proerythroblasts. 
Wildtype and Tspan33-deficient megakaryocytes were differentiated in vitro from 
progenitors collected from adult bone marrow. Wildtype and Tspan33-deficient CFU-
E and proerythroblast cells were sorted from adult bone marrow with cells from three 
mice pooled for each experiment. A. Megakaryocytes. B. Proerythroblasts. C. CFU-E 
cells. cDNA, generated from extracted RNA from each cell type, was used as the 
template for real time PCR studies that used TaqMan fluorogenic probes for each of 
the TspanC8 tetraspanins. GAPDH was used to normalise results for loading and 
18S used as a housekeeping reference gene. Real time PCR results were analysed 
using the delta CT method and shown as relative expression as a percentage of the 
most highly expressed tetraspanin in each cell type. n = 3 - 4, error bars represent 























4.2.8 Characterisation of erythropoiesis in Tspan33 knockout mice. 
As previously reported, the Tspan33 knockout mouse have a red blood cell 
phenotype of basophilic macrocytic anaemia in aged animals (Heikens et al., 2007). 
The cause of this phenotype appeared to be due to defective responses of erythroid 
progenitors to erythropoietin. Analysis of the progression of erythropoiesis in vivo in 
the Tspan33 knockout mouse was not published in the paper in which the anaemia 
was reported. Interestingly, despite the appearance of basophilic red blood cells only 
being reported in 30 % of 12 week old mice (Heikens et al., 2007), the decrease in 
ADAM10 detected by flow cytometry was found in 100 % of knockout animals 
screened. The next step in this investigation was to analyse in vivo erythropoiesis by 
flow cytometry with the aim of assessing the sizes of the different erythroid cell 
populations. Should a particular compartment be enriched or diminished, this would 
indicate a stage of erythropoiesis to focus on to discover a role, if any, for ADAM10. 
Mice aged 12 weeks and mice aged 24 were both assessed to ensure any 
progressive defect was detected. 
Erythropoiesis was assessed in directly extracted cells from the bone marrow (Figure 
21) and the spleen (Figure 22), and in neither tissue were abnormalities found. No 
significant changes in the proportions of the different erythroid cell types were found 
in cells from the bone marrow (Figure 21 B, C and E) or the spleen (Figure 22 B, C 
and E). Furthermore, no difference was found between the two age groups of mice, 
so their results were grouped and displayed together. This failure to detect a defect in 
erythropoiesis suggests that the reported phenotype, which was observed in only 30 
% of mice (Heikens et al., 2007), may have been largely lost during the re-derivation 
and colony expansion that was carried out before the mice were analysed in our lab. 
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This theory is also consistent with the loss of phenotype on some genetic 
























































































































































































































Figure 21. Erythroid cell populations appear normal in Tspan33-deficient bone 
marrow. 
Bone marrow cells were flushed from wildtype and Tspan33 knockout mice into 10 % 
FCS in PBS. Cells were blocked with anti-CD16 antibody for 5 min, then stained with 
an erythroid antibody cocktail (including single colour controls) for 30 min on ice in 
the dark. Erythroid cells were isolated by flow cytometry after colour compensation A. 
Representative flow cytometry plots of CD71 and Ter119 stained erythroid committed 
cells from either wildtype or Tspan33 knockout mice B. percentage of Ter119 positive 
cells present in the CD71 and Ter119 flow cytometry plots. C. Percentage of cells 
expressing Ter119 that have high or low CD71 expression D. Representative flow 
cytometry plots of CD45 and CD71 stained progenitor cell populations from either 
wildtype or Tspan33 knockout mice E. Progenitor cell populations in the bone marrow 
identified using CD71 and CD45 staining. n = 3, error bars represent standard error 
of the mean. Statistical significance in B and C judged by an unpaired Student's t-test 
and in E by two way ANOVA followed by Bonferroni post test. Erythroid cocktail: 


































































































































































































Figure 22. Erythroid cell populations appear normal in Tspan33-deficient 
spleen. 
Spleen cells were taken from wildtype and Tspan33 knockout mice into 10 % FCS in 
PBS. Cells were blocked with anti-CD16 antibody for 5 min, then stained with an 
erythroid antibody cocktail (including single colour controls) for 30 min on ice in the 
dark. Erythroid cells were isolated by flow cytometry after colour compensation A. 
Representative flow cytometry plots of CD71 and Ter119 stained erythroid committed 
cells from either wildtype or Tspan33 knockout mice B. percentage of Ter119 positive 
cells present in the CD71 and Ter119 flow cytometry plots. C. Percentage of cells 
expressing Ter119 that have high or low CD71 expression D. Representative flow 
cytometry plots of CD45 and CD71 stained progenitor cell populations from either 
wildtype or Tspan33 knockout mice E. Progenitor cell populations in the spleen 
identified using CD71 and CD45 staining. n = 3, error bars represent standard error 
of the mean. Statistical significance in B and C judged by an unpaired Student's t-test 
and in E by two way ANOVA followed by Bonferroni post test. Erythroid cocktail: 
















Presented here is an investigation into the loss of ADAM10 from Tspan33-deficient 
red blood cells. The initial observation of this project was that the surface levels of the 
sheddase ADAM10 were reduced on Tspan33-deficient red blood cells and the aim 
of this project was to further characterise and understand this loss of ADAM10. The 
final conclusion of this project was that the reduction in ADAM10 at the cells surface 
of red blood cells can be seen in the Tspan33-deficient proerythroblast precursor 
cells despite their normal production ADAM10 mRNA. In addition Tspan33 was found 
to be part of a novel subfamily of tetraspanins termed the TspanC8 tetraspanins. 
Work published by our lab and others demonstrated that all the members of this 
subfamily interact with and promote the trafficking and maturation of ADAM10 
(Haining et al., 2012, Prox et al., 2012, Dornier et al., 2012). Finally erythropoiesis 
was assessed in the Tspan33 knockout mouse but no clear defect could be seen in 
the approach used. 
The discovery that Tspan33 was part of a subfamily of related tetraspanins, all of 
which share the same partner protein, was not a new concept in tetraspanin biology 
as both CD9 and CD81 interact with the Ig superfamily proteins EWI-2 and EWI-F 
(Stipp et al., 2001). Additionally, CD9 and CD81 are able to compensate for each 
other, with CD81 partially rescuing the fusion defect in CD9 null oocytes (Kaji et al., 
2002), and lymphatic defects and defects in macrophage migration and protease 
production in the lung only being revealed upon knockout of both genes in mice 
(Iwasaki et al., 2013, Takeda et al., 2008). The existence of the structurally defined 
TspanC8 subfamily has implications for research into the function of other 
tetraspanins. Other subfamilies of related tetraspanins were evident from the 
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dendrogram of mammalian tetraspanins and therefore these tetraspanins may too 
share partner proteins. As such there may be significant compensation between 
these tetraspanins in model systems thus masking any phenotype in 
knockout/knockdown experiments.  
In terms of ADAM10 research, the TspanC8 subfamily represents a previously 
unknown aspect of ADAM10 regulation and opens exciting new avenues in ADAM10 
research. For example the development of therapeutics targeted to ADAM10 have 
been hindered by the ubiquitous nature of the protein and the likely toxic side effects 
of targeting ADAM10 on every cell in the body (Saftig and Reiss, 2011). The 
TspanC8 tetraspanins, however, appear to have differential expression, and so 
targeting of a specific TspanC8/ADAM10 complex could confer increased tissue 
specificity for any treatment. The question of why one protein has six tetraspanins 
with which it associates remains unanswered. The current hypothesis to explain this 
phenomenon is that the association of ADAM10 with the TspanC8 tetraspanins can 
influence the substrate specificity of ADAM10 by regulating its cellular localisation 
and potentially further localisation in the cell membrane. Evidence from Dornier at al. 
(2012) suggests that Tspan10 is largely expressed on intracellular compartments and 
so could target ADAM10 away from the cell surface. Additionally this paper also 
presents evidence that Tspan5 and Tspan14 can promote the cleavage of the 
ADAM10 target protein Notch more effectively than Tspan15. Further research is 
required before the purpose of the association between TspanC8 tetraspanins and 
ADAM10 can be fully understood and their full therapeutic impact appreciated.  
Another question raised by this project is what, if any, is the function of ADAM10 in 
erythropoiesis. There are currently no published studies of ADAM10 in erythropoiesis 
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and there is also no published data on an erythroid specific ADAM10 knockout 
mouse. ADAM10 expression appeared to sharply reduce during wildtype 
erythropoiesis which would suggest that it may have no function in mid to late 
erythropoiesis. It is interesting, however, that Tspan33 knockout mice were published 
to have a defect in erythropoiesis and that the red blood cells were found to have a 
defect in ADAM10 expression. As the Tspan33 knockout mouse is a full knockout 
and erythropoiesis is supported and regulated by the surrounding bone marrow 
microenvironment (Chasis and Mohandas, 2008), the Tspan33-deficient stromal cells 
and erythroid associated macrophages could be the cell type in which ADAM10 
function is critically defective for erythropoiesis. Further research would be required 
to understand the function of this protein in erythropoiesis and thus if its loss could be 


























CHAPTER V: FUNCTIONAL STUDIES OF THE TSPAN9 KNOCKOUT 
MOUSE AND TSPAN9-DEFICIENT PLATELETS 
5.1 Introduction 
Tspan9 is a 239 amino acid tetraspanin that was first identified as a platelet 
tetraspanin in 2007 by its presence in a mouse megakaryocyte SAGE library and in a 
proteomic analysis of human platelet transmembrane proteins (Senis et al., 2007, 
Lewandrowski et al., 2009a). Tspan9 was confirmed at the protein level as expressed 
in both mouse and human platelets using an antibody made by our group in 2009 
(Protty et al., 2009) that recognises the C-terminal tail. As well as confirming the 
expression of Tspan9 on megakaryocytes and platelets, this publication also 
quantified the relative amount of Tspan9 on human platelets. Tspan9 was found to 
be expressed at 6 % of the levels of the highly expressed platelet tetraspanin CD9 
giving it a copy number of around 2800 (Protty et al., 2009). Prior to this publication 
Tspan9 was an unstudied tetraspanin. It appeared to be an interesting tetraspanin in 
terms of platelet biology as it was relatively specific to platelets, in comparison to 
other mouse tissues. Additionally, the availability of an antibody against Tspan9 was 
an advantage as many tetraspanins do not have antibodies available for their study 
(Protty et al., 2009). 
The aim of this project was to extend the work of Protty et al. and functionally 
characterise Tspan9 on platelets using the Tspan9 knockout mouse. This 
unpublished knockout had been generated by Texas A and M Institute for Genomic 






5.2.1 Confirmation of the generation of Tspan9 knockout mice 
The Tspan9 knockout mouse was generated using gene trapping technology at the 
Texas A and M Institute for Genomic Medicine. The gene trapping method prevents 
full transcription of the targeted gene by forcing a splicing event early in transcription 
between endogenous exon mRNA and the mRNA of the gene trap cassette. Thus 
transcription of any downstream exons is prevented. In this case the commonly used 
-geo gene trap cassette was introduced into C57BL/6 ES cells by retroviral infection. 
Infection is the favoured method over electroporation of plasmid DNA as it 
significantly reduces the possibility of multiple insertions of the gene trap cassette 
and favours the incorporation of the cassette into the 5’ end of targeted genes (Wiles 
et al., 2000, Skarnes, 2000).  The -geo gene trap cassette consists of (from the 5’ 
end) a splice acceptor site followed by a -galactosidase and neomycin 
phosphotransferase gene fusion transcript and a polyadenylation sequence 
(Friedrich and Soriano, 1991).  
In the ES cells used to generate the Tspan9 knockout mouse, this cassette had 
inserted between the first two exons of the gene, upstream of the other eight Tspan9 
exons and in the 5' untranslated region of the gene (the translation start site is found 
in the third exon). The consequent fusion transcript generated from 'trapped' Tspan9 
genes contained just the mRNA of the first exon and the -geo gene trap cassette. A 
diagram of the insertion site and genotyping strategy can be seen in Figure 23.   
Whilst gene trapping is a highly successful knockout mouse generation method, it is 
possible that the transcription machinery could bypass the splice acceptor site 
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introduced by the gene trap cassette (Forrai and Robb, 2005). Therefore it was 
important to check the Tspan9 protein levels in knockout animals. Western blotting of 
platelet and lung (where Tspan9 is also expressed) lysates from the mice confirmed 
the lack of Tspan9 protein in knockout animals and showed reduced protein levels in 
































Figure 23. Gene trap technology was utilised to generate the Tspan9 knockout 
mouse.  
A. The common gene trap cassette -geo was randomly incorporated into the 
Tspan9 gene between the first two exons using retroviral infection of C57BL/6 ES 
cells. The splice acceptor site in the cassette and the subsequent poly A tail causes 
termination of transcription before any of the coding region of the Tspan9 gene is 
transcribed. B. PCR was the approach selected for genotyping Tspan9 knockout 
animals. Two primers (denoted a and b in Figure.1A) specific for the Tspan9 gene 
either side of the cassette insertion site were used to amplify WT transcripts. The 
Tspan9 forward primer (a) in conjunction with a reverse primer specific for the -geo 
cassette (c) were used to amplify gene trapped transcripts. Abbreviations: LTR – long 




























Figure 24. Confirmation that Tspan9 knockout mice do not express Tspan9 
protein. 
Lysates of 1 x 107 platelets or 1 mg of lung tissue per lane were separated on a 12 % 

















5.2.2 Tspan9 knockout mice are born at expected frequencies. 
The health and development of some knockout mice can be affected by the loss of 
their targeted protein, as is the case for the tetraspanin CD151, the knockout mouse 
for which develops spontaneous nephritis (Sachs et al., 2006). This however was not 
the case for the Tspan9 knockout mice. These mice were indistinguishable from their 
wildtype littermates in size (as measured by weight, Figure 25) and health. Tspan9 
knockout pups were born at Mendelian frequencies from heterozygote/heterozygote 
breeding pairs (Table 9). The average litter size for heterozygote crosses was 7 and 
this was also the case for knockout/knockout breeding pairs which had a litter size 
range of 4 - 10 across 5 litters (data not shown). The apparent normality of the 
Tspan9 knockout mice continued throughout the aging process with Tspan9 




































Figure 25. Tspan9 knockout mice have similar weights to their wildtype 
littermates. 
Adult mice between the ages of 8 - 16 weeks were weighed and knockout animals 
were compared to wildtype littermates of the same sex (males n = 10, females n = 9). 
No significant difference was seen between either group as judged by a paired 









Table 9. Tspan9 knockout mice are born at expected Mendelian frequencies. 
Total numbers of mice of each genotype produced from heterozygote/heterozygote 
breeding pairs were counted. These numbers represent 65 different litters from 20 
different breeding pairs. A Chi2 test found no significant difference between observed 
and expected numbers of each genotype. 
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5.2.3 Tspan9 knockout mice do not have any gross morphological defects in 
their kidneys, liver or lungs. 
Aside from a high expression in platelets, Tspan9 was also detected in the lungs, 
liver and kidney (and other organs but to a lesser extent) in mice by western blot 
(Protty et al., 2009). As the function of the protein was unknown, it was possible that 
it was required for the proper development and/or maintenance of the architecture of 
the organs in which it was found. To check this, paraffin embedded sections of 
formalin fixed kidney, lung and liver were stained with haematoxylin and eosin to 
allow an assessment of the gross and finer structures of each organ. The sections 
were prepared, stained and analysed by pathologist Hanna Romanska, and no 
differences were found between the organs of wildtype and knockout animals (Figure 



























Figure 26. The gross morphology of the kidney, liver and lung remains normal 
in Tspan9 knockout mice. 
Whole organs (A. Kidney, B. Liver, C. Lung) fixed in Formalin were paraffin 
embedded, sectioned and stained with Haematolyxin and Eosin stain. Scale bar 
represents 500 m, images are representative of n = 3. Sections prepared and 
imaged by Hanna Romanska. 
 




































Figure 27. The general structure of the kidney, liver and lung remains normal in 
Tspan9 knockout mice. 
This figure shows representative images of the tissue sections in Figure 26 imaged at 
higher magnification. A. Kidney cortex B. Liver around a lobule central vein C. Lung 
around the bronchus. The higher magnification allowed closer inspection of the finer 
structure of each organ. Scale bar represents 50 m. Images representative of n = 3. 
Sections prepared and imaged by Hanna Romanska. 





















5.2.4 Tspan9 knockout mice have a significant reduction in heart to body 
weight ratio. 
In addition to analysing the structure of the kidneys, liver and lung in the Tspan9 
knockout mice, tissue sections from wildtype mice were stained with Tspan9 antibody 
and the Tspan9 knockout tissues as a control. Staining of Tspan9 in wildtype heart 
demonstrated Tspan9 expression in the small vessels and capillaries in the tissue 
(Figure 28 A), despite Tspan9 not appearing highly expressed in the heart by western 
blot. To assess the maintenance of the heart tissue without Tspan9 the 'dry' weight 
(not containing any exogenous blood) of whole hearts from Tspan9 wildtype and 
Tspan9 knockout mice was measured. In this measure Tspan9 knockout mice had a 
small but significant decrease of 7 % in their heart to body weight ratio (Figure 28 B). 
The cause of this decrease or indeed its effect on heart function is unknown, 
although a potential hypothesis is that the small vessels in which Tspan9 is 
expressed are in some way defective in Tspan9 knockout mice. A more detailed 
analysis of Tspan9 knockout hearts are required to understand this defect further, but 
fall outside the remit of this project. Additional sections of brain, lung, spleen, liver, 
skin and bone marrow stained with Tspan9 antibody can be seen in Appendix Figure 


















































Figure 28. Tspan9 knockout mice have a significant reduction in heart to body 
weight ratio. 
A. Formalin fixed whole hearts were sectioned and stained with Tspan9 antibody by 
Hanna Romanska. Scale bar represents 100 m. B. Tspan9 knockout mice had a 
significant reduction in heart weight, shown as heart weight in mg per g of whole 
mouse weight. n = 9 and error bars represent the standard error of the mean. 























5.2.5 The platelet count and other whole blood parameters of Tspan9 knockout 
mice were normal in comparison to wildtype. 
Before beginning the focussed analysis of Tspan9-deficient platelets a gross 
assessment of the different blood cell groups was made using whole blood counts 
from wildtype and Tspan9 knockout mice. Tspan9 knockout mice had normal platelet 
counts and normal platelet size. In addition, other blood cells also appeared 
unaffected by Tspan9 deletion as all other assessed blood parameters from Tspan9 
knockout mice fell within the normal ranges and were not significantly different from 








































































































































































































































































5.2.6 Tspan9-deficient platelets had normal levels of several platelet surface 
proteins. 
The investigation into the function of Tspan9 on platelets began with an analysis of 
surface levels for several platelet proteins in Tspan9-deficient platelets. As previously 
discussed in the analysis of Tspan33-deficient platelets, some tetraspanins have 
been found to influence partner protein trafficking to the cell surface (Shoham et al., 
2003, Haining et al., 2012, Berditchevski and Odintsova, 2007), thus it was again 
important to check this aspect of Tspan9-deficient platelets. Using the same method 
as set out in Figure 10 (Chapter 3), the surface levels of IIb3, 21, 61, GPVI, 
GPIb, CD9, ADAM10 and CLEC-2 were assessed (Figure 29 A). All of the proteins 
measured were present on Tspan9-deficient platelets at levels that were not 































Figure 29. Tspan9 knockout platelets express normal levels of the major 
platelet surface glycoproteins. 
Whole blood drawn into acid citrate dextrose was incubated with the relevant anti-
mouse antibody conjugated to FITC. Platelet specific staining was isolated by gating 
on platelets by size A. Representative FACS plots for each indicated protein. 
Wildtype in black and Tspan9-deficient in red. For simplicity only the control trace 
from wildtype staining is shown. B. Geometric mean fluorescence intensity used to 
assess surface receptor levels. n = 5 - 8 +/- values represent standard deviation 
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5.2.7 Tspan9 knockout mice do not have a bleeding phenotype. 
To begin to focus on platelet function in the Tspan9 knockout the next step in the 
analysis was to challenge haemostasis using the tail bleeding assay. This procedure, 
done in the same manner as for the Tspan33 knockout mice (Figure 11, Chapter 3) 
records blood loss in a set time-frame after tail tip excision. The blood loss from 
Tspan9 knockout mice was not significantly different from wildtype, as such these 
































Figure 30. Tspan9 knockout mice do not have a bleeding defect. 
Blood loss after tail tip excision is presented as a factor of mouse weight so as to 
normalise for mice of different sizes. No significant difference was found between the 
blood loss (mg/g) of wildtype and Tspan9 knockout mice using an unpaired Student's 
t-test. All mice were aged between 8 - 12 weeks and between 2 - 3 mm of tip 


















5.2.8 Tspan9 knockout platelets display aggregation defects in response to 
collagen-related peptide in light transmission aggregometry assays. 
After assessment of the functioning of haemostasis as a whole using the tail bleeding 
assay, the next step in the investigation was to focus specifically on the functioning of 
Tspan9-deficient platelets. The approach taken assessed platelets that had been 
washed free of any other blood components (washed platelets) and platelets in 
plasma (platelet rich plasma). Washed platelets were tested with thrombin, collagen-
related peptide, collagen and CLEC-2 antibody, and the platelet rich plasma with 
PAR4 peptide, collagen-related peptide, collagen, ADP and arachidonic acid. 
Washed platelets are not in the presence of any fibrinogen and so any aggregation in 
response to agonist relies on functional platelet activation and secretion of fibrinogen 
from the platelet alpha granules. The platelet rich plasma aggregation assesses the 
platelet responses in the more physiological environment of the plasma. The four 
agonists chosen for the Washed platelets target four important platelet receptors 
(PAR3 and PAR4, GPVI and CLEC-2) and, as CLEC-2 and GPVI share similar 
signalling molecules, two signalling pathways that powerfully activate platelets. PAR4 
peptide replaces thrombin in the platelet rich plasma conditions to prevent a mesh of 
fibrin forming in the aggregation tube. In addition to measuring aggregation as a 
readout for platelet activation, platelet secretion was directly measured by the 
addition of a luciferin/luciferase mix to the platelets. 
In platelet rich plasma conditions the responses of Tspan9-deficient platelets to 
intermediate doses of collagen-related peptide were almost abolished (Figure 31 B). 
Interestingly this defect could be overcome by increasing the dose of this agonist 
(Figure 31 C). However, responses to collagen (which also initially binds the same 
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receptor, GPVI) were not significantly different from wildtype at doses of 3 g/ml 
(Figure 31 D) and 10 g/ml (Figure 31 E). The responses to PAR4 peptide (250 M), 
ADP (10 M) and arachidonic acid (0.15 mM) were normal, suggesting a defect 
specifically in response to collagen-related peptide (Figure 31 A, F and G 
respectively). This result indicated that Tspan9 may be important in the function of 
GPVI, a platelet receptor that was recently published to be tetraspanin associated 
(Protty et al., 2009). Figure 31 shows representative aggregation traces in response 
to all the agonists just discussed, and Figure 32 shows quantitation of these traces as 
percentage aggregation over time. The defect in Tspan9-deficient platelet responses 
to intermediate doses of collagen-related peptide was also reflected in the amount of 
secretion detected, where total ATP secreted was significantly less than wildtype 
platelets (Figure 33 B). Secretion in response to all other agonists was normal (not 
measured in response to ADP), apart from in response to PAR4 peptide which had a 
small but significantly reduced secretion response (Figure 33). This result was 
unexpected as no defect was seen in the aggregation responses to this agonist.   
In Washed platelets the defect seen in Tspan9-deficient platelets in response to 
intermediate doses of collagen-related peptide was diminished such that there was 
no longer a significant difference between wildtype and Tspan9-deficient responses, 
however, a reproducible extension in the shape change phase could be noted 
(Figure 34 B). The responses of Tspan9-deficient washed platelets to all the agonists 
tested were not significantly different from wildtype (Figure 34 A - E representative 


























Figure 31 - Platelet rich plasma 
 
A. PAR4 250 M 
B. Collagen-related peptide 
intermediate  
C. Collagen-related peptide High  
D. Collagen 3 g/ml  
E. Collagen 10 g/ml  
F. ADP 10 M  
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Figure 32 - Platelet rich plasma 
 
A. PAR4 250 M 
B. Collagen-related peptide 
intermediate  
C. Collagen-related peptide High  
D. Collagen 3 g/ml  
E. Collagen 10 g/ml  
F. ADP 10 M  












































































































Figure 33 - Platelet rich plasma 
 
A. PAR4 250 M  
B. Collagen-related peptide 
intermediate  
C. Collagen-related peptide High  
D. Collagen 3 g/ml  
E. Collagen 10 g/ml   









Figure 31. Tspan9-deficient platelets in plasma display aggregation defects in 
response to collagen-related peptide. 
Tspan9 wildtype and deficient platelets in plasma at 2 x 108/ml were stimulated with 
the following agonists A. PAR4 peptide 250 M B. Collagen-related peptide 
intermediate dose C. Collagen-related peptide high dose D. Collagen 3 g/ml E. 
Collagen 10 g/ml F. ADP 10 M G. Arachidonic acid 0.15 mM. Responses were 
measured by lumi-aggregometery. Only in response to collagen-related peptide at 
intermediate doses did Tspan9-deficient platelet traces appear different from 
wildtype.  Representative traces of each experiment shown. n = 3 - 9 
Figure 32. Tspan9-deficient platelets in plasma display a significant defect in 
response to intermediate doses of collagen-related peptide. 
Aggregation traces from the experiments listed in Figure 30 were analysed by 
measuring the percentage aggregation reached at minute intervals after agonist 
addition. A. PAR4 peptide 250 M B. Collagen-related peptide intermediate dose C. 
Collagen-related peptide high dose D. Collagen 3 g/ml E. Collagen 10 g/ml F. ADP 
10 M G. Arachidonic acid 0.15 mM. A significant reduction in response was seen in 
Tspan9-deficient platelets in response to collagen-related peptide at intermediate 
doses. The responses to all other agonists appeared normal and were not 
significantly different from wildtype. n = 3 - 9, error bars represent standard error of 
the mean. Significance assessed by two way ANOVA followed by a Bonferroni post 
test.  
Figure 33. Tspan9-deficient platelets in plasma display a significant defect in 
ATP secretion in response to intermediate doses of collagen-related peptide 
and PAR4 peptide. 
Tspan9 wildtype and deficient platelets in plasma at 2 x 108/ml were stimulated with 
the following  A. PAR4 peptide 250 M B. Collagen-related peptide intermediate dose 
C. Collagen-related peptide high dose D. Collagen 3 g/ml E. Collagen 10 g/ml F. 
Arachidonic acid 0.15 mM and responses were measured by lumi-aggregometery. A 
significant decrease in secretion was seen in response to intermediate doses of 
collagen-related peptide and, to a lesser extent, PAR4 peptide. n = 3 - 9, error bars 































Figure 34 - Washed platelets 
 
A. Thrombin 0.06 U/ml 
B. Collagen-related peptide 
intermediate  
C. Collagen-related peptide High  
D. Collagen 3 g/ml  
E. Collagen 10 g/ml  
F. CLEC-2 antibody 3 g/ml 



































































































































































































Figure 35 - Washed platelets 
 
A. Thrombin 0.06 U/ml 
B. Collagen-related peptide 
intermediate  
C. Collagen-related peptide High  
D. Collagen 3 g/ml  
E. Collagen 10 g/ml  
F. CLEC-2 antibody 3 g/ml 






























































































































Figure 36 - Washed platelets 
 
A. Thrombin 0.06 U/ml 
B. Collagen-related peptide 
intermediate  
C. Collagen-related peptide High  
D. Collagen 3 g/ml  
E. Collagen 10 g/ml  
F. CLEC-2 antibody 3 g/ml 






Figure 34. Aggregation traces of wildtype versus Tspan9-deficient washed 
platelets. 
Tspan9 wildtype and deficient washed platelets at 2 x 108/ml were stimulated with the 
following agonists A. Thrombin 0.06 U/ml B. Collagen-related peptide intermediate 
dose C. Collagen-related peptide high dose D. Collagen 3 g/ml E. Collagen 10 
g/ml F. CLEC-2 antibody 3 g/ml G. CLEC-2 antibody 10 g/ml. Responses were 
measured by lumi-aggregometery. Representative traces of each experiment shown. 
n = 4 - 13 
Figure 35. Tspan9-deficient washed platelets display no significant defect in 
aggregation responses. 
Aggregation traces from the aggregation experiments listed in Figure 35 were 
analysed by measuring the percentage aggregation reached at minute intervals after 
agonist addition. A. Thrombin 0.06 U/ml B. Collagen-related peptide intermediate 
dose C. Collagen-related peptide high dose D. Collagen 3 g/ml E. Collagen 10 
g/ml F. CLEC-2 antibody 3 g/ml G. CLEC-2 antibody 10 g/ml. n = 4 - 13, error 
bars represent standard error of the mean. Significance assessed by two way 
ANOVA followed by a Bonferroni post test. 
Figure 36. Tspan9-deficient platelets have normal secretion responses to a 
range of agonists. 
Tspan9 wildtype and deficient washed platelets at 2 x 108/ml were stimulated with the 
following agonists A. Thrombin 0.06 U/ml B. Collagen-related peptide intermediate 
dose C. Collagen-related peptide high dose D. Collagen 3 g/ml E. Collagen 10 
g/ml F. CLEC-2 antibody 3 g/ml G. CLEC-2 antibody 10 g/ml and responses were 
measured by lumi-aggregometery. No significant differences were seen between 
wildtype and Tspan9-deficient platelets in total amount of ATP released after 
stimulation by any agonist. n = 4 - 13, error bars represent standard error of the 












5.2.10 Signalling downstream of GPVI is reduced in response to collagen-
related peptide in Tspan9-deficient platelets. 
The defect seen in the aggregation responses of Tspan9-deficient platelets to 
collagen-related peptide was similar to the defects in aggregation seen in the 
responses of the GADS knockout mouse (Hughes et al., 2008). GADS is an adapter 
molecule that is part of the signalosome complex that forms downstream of GPVI 
after ligand binding. Correct formation of this complex is essential for functional and 
efficient signal transduction from GPVI (Watson et al., 2001). As such, the defect in 
Tspan9-deficent platelets could have been due to defects in the recruitment of GADS 
or another protein in the GPVI signalling pathway. To assess the signalling 
downstream of GPVI, tyrosine phosphorylation in Tspan9-deficient platelets after 
collagen-related peptide stimulation was visualised using western blotting. Washed 
Tspan9-deficient or wildtype platelets were stimulated with high dose collagen-related 
peptide in the presence of apyrase and indomethacin to prevent signalling from 
secondary mediators and lotrafiban to prevent platelet aggregation and αIIbβ3 
signalling. At 10 s, 30 s, 60 s and 5 min after activation, samples were taken and 
subsequently western blotted for tyrosine phosphorylation (Figure 37). Tspan9-
deficient platelets did respond to the stimulation over the time course, however the 
response was weaker than that of the wildtype, consistent with the responses seen in 
aggregation experiments. Interestingly, no individual protein appeared affected in the 
Tspan9-deficient platelets suggesting that the defect that caused the reduction in 



















Figure 37. Tspan9-deficient platelets have reduced signalling responses to 
collagen-related peptide. 
Washed platelets at 5 x 108/ml were incubated at 37 C with apyrase (500 U/ml), 
indomethacin (10 mM) and lotrafiban (1 mM) for 5 min. Platelets were then stimulated 
with 10 g/ml collagen-related peptide and samples taken at 10 s, 30 s, 60 s and 5 
min. Samples were lysed directly in 2 x reducing sample buffer and separated on 4 - 
12 % gradient polyacrylamide gels. Western blotting with the anti-phosphotyrosine 












5.2.11 Tspan9-deficient platelets adhere normally to collagen under flow. 
Analysis of the behaviour of Tspan9-deficient platelets by aggregation and spreading 
assays allows a clear dissection of individual signalling pathways within the platelets. 
However, these assays do not allow assessment of platelet behaviour under the 
conditions that occur in vivo. It is well documented that physiological conditions such 
as shear forces affect the behaviour of platelets by modulating the action of several 
surface proteins, including GPVI (Auger et al., 2005, Moroi et al., 1996, Best et al., 
2003b). An assay that recapitulates some of the conditions that platelets experience 
in the vascular system is whole blood flow adhesion. In this assay whole blood is 
flowed at controlled rates across a glass capillary that can be coated with several 
different platelet agonists such as collagen and fibrinogen. Responses of the 
platelets to the coated capillary are recorded by fluorescence video microscopy so 
that platelet aggregate formation can be assessed in real time. Tspan9-deficient 
platelets were exposed to collagen in this assay at two different flow rates 1000 s-1 
(high, equivalent to arterial shear) and 300 s-1 (low, equivalent to venous shear) 
(Figure 38).  There was no significant difference between the surface area coverage 





























































































































































































Figure 38. Representative images of Tspan9 wildtype and deficient whole blood 
flowing over collagen. 
Representative images of Tspan9 wildtype and deficient platelets flowing over 
collagen coated capillaries at speeds of 1000 or 300 ss-. Fluorescence microscopy 
images were taken every 2 s with a 40 x oil objective. These images are 
representative of n = 3. The arrows denote the direction of flow. 
Figure 39. Tspan9-deficient platelets adhere normally to collagen under flow.  
Stills from each video at the noted time points were assessed for surface area 
coverage of platelets in the field of using imageJ software. A. At 1000 s-1 surface area 
coverage of Tspan9-defcient platelets over time was not significantly different from 
wildtype. B. At 300 s-1 surface area coverage of Tspan9-deficient platelets over time 
was not significantly different from wildtype. Error bars represent standard error of the 























Presented here is an investigation into the function of Tspan9 on platelets. The initial 
hypothesis for the project was that the tetraspanin Tspan9 was important for the 
function of platelets through its regulation of another platelet surface protein. The aim 
of this investigation was to use the newly generated and unpublished Tspan9 
knockout mouse and Tspan9-deficient platelets to investigate the initial hypothesis. 
The final conclusion of this project was that Tspan9 is required for normal GPVI-
induced platelet activation, but the defect is subtle and only observed in certain 
assays, most notably platelet aggregation in plasma to collagen-related peptide. 
The Tspan9 knockout mouse had never previously been studied and so initial 
investigations assessed its normality. No obvious differences were found between 
Tspan9 wildtype and knockout mice that could have indicated the function of Tspan9 
or any potential Tspan9 partner proteins. The only difference found was that Tspan9 
knockout mice had a 7 % reduction in their heart to body weight ratio. This result was 
initially surprising as Tspan9 was much more highly expressed in the other organs 
assessed and found to be normal in structure. However tissue sections of heart 
stained with the Tspan9 antibody highlighted a specific staining for Tspan9 on the 
small vessels and capillaries that permeate through the heart tissue. It could be 
possible that a defect in this vessel network could lead to decrease in heart mass as 
the muscles in the heart could be less oxygenated than in wildtype. Further 
investigations directly focussed on the heart would be required to understand this 
phenotype and to test this hypothesis.  
The production of Tspan9-deficient platelets appeared normal as there was no 
difference between wildtype and Tspan9-deficient platelet counts, platelet size or 
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expression of platelet surface proteins. There was, however, a significant defect in 
the responses of Tspan9-deficient platelets to the GPVI agonist collagen-related 
peptide in aggregation studies. This defect was seen as an extension of the shape 
change phase of activation before aggregation, and was so marked in platelet rich 
plasma that Tspan9-deficient platelets rarely aggregated in the same time frame as 
wildtype platelets. The result indicated that the Tspan9-deficient platelets were less 
sensitive to collagen-related peptide, however this effect appeared mild as it could be 
overcome by increasing the dose of the agonist.  
The cause of this defect appeared to be at the level of the receptor as the signalling 
proteins downstream of ligand binding appeared to be phosphorylated in the same 
manner as wildtype, but to a lesser extent despite being stimulated with the same 
dose of collagen-related peptide. Additionally many of the proteins that are involved 
in the GPVI signalling cascade are shared by the signalling pathway downstream of 
the platelet podoplanin receptor CLEC-2, which appeared to be functioning normally 
in aggregation experiments using Tspan9-deficient platelets. As GPVI was expressed 
at normal levels on Tspan9-deficient platelets, the cause of the defect in response to 
collagen-related peptide may be in the regulation of receptor clustering. As discussed 
in the introduction, the minimal signalling unit for GPVI is a dimer and further 
clustering of GPVI dimers are proposed to cause more powerful signal transduction 
into the platelet (Nieswandt and Watson, 2003). Should this process be disrupted, 
the signal transduction would be predicted to be weaker as a result of either less 
higher order clustering or less initial dimer formation. This could result in a defect like 
that seen in the Tspan9-deficient platelets. Interestingly, this hypothesis of defective 
receptor clustering could also offer an explanation for the marked difference in 
162 
 
responses seen between Tspan9-deficient platelets in plasma and washed platelets. 
In a paper that characterised a GPVI dimer specific antibody in human platelets, 
Loyau et al. (2012) remarked on an increase of GPVI dimers that occurred on 
platelets as they progressed through the preparation process, with low levels of GPVI 
dimer being detected on platelets in whole blood and a 7-fold increase seen on 
platelets washed and resuspended in buffer. A partial activation of platelets during 
preparation, causing a pre-clustering of GPVI, could cause the partial rescue of the 
defect seen between Tspan9-deficient platelet rich plasma and Watson washed 
platelets. An effect would not necessarily be expected on wildtype platelets as in both 
conditions GPVI is most likely already clustering at levels at or above the threshold 
required for efficient responses to ligand. The hypothesis that Tspan9 may be 
clustering GPVI is not an unlikely scenario as other tetraspanins have been 
published to be involved in clustering other surface molecules (Doyle et al., 2011, 
Bailey et al., 2011, Yang et al., 2002). This ability is currently thought to be due to 
tetraspanins regulating the lateral mobility of their partner proteins in the plasma 
membrane, thus modulating the nano-scale distribution of individual proteins (Yang et 
al., 2012a, van Spriel et al., 2012). Additionally, the relatively low copy number of 
GPVI on the platelet, compared to proteins such as GPIb and αIIbβ3, suggests that 
regulation may be required to bring these potentially disperse molecules together in 
an efficient and timely manner.  
One question raised by the phenotype of Tspan9-deficient platelets is the normality 
of the response to collagen, the physiological ligand of GPVI, and the lack of a 
bleeding defect in these mice. However, it is actually unsurprising in the context of 
GPVI heterozygote and GPVI knockout mice. GPVI knockout mice only display a 
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minor bleeding defect and indeed people with a GPVI deficiency due to 
autoantibodies also only present with mild bleeding (Chu et al., 2006, Cheli et al., 
2008b). Furthermore, GPVI heterozygote mouse platelets, with half the number of 
GPVI molecules, only have a minor defect in response to collagen in aggregation 
assays and no detectable defect in flow adhesion assays (Snell et al., 2002). 
Additionally people with naturally occurring polymorphisms in GPVI that result in 
reduced GPVI surface levels also show normal responses in flow experiments over 
collagen (Best et al., 2003a). In these scenarios, the collagen-binding integrin α2β1, 
which does not bind collagen-related peptide, may enable largely normal collagen 








The work presented in the previous chapter on functional assessments of platelets 
from the Tspan9 knockout mouse revealed a specific defect in the functioning of 
GPVI in Tspan9-deficient platelets. This defect manifested in aggregometry 
experiments as an insensitivity of Tspan9-deficient platelets to the GPVI specific 
agonist collagen-related peptide. The conclusions of the previous chapter suggested 
that GPVI, a previously published tetraspanin associated protein (Protty et al., 2009), 
may be a partner protein for Tspan9 and that Tspan9 may regulate the clustering 
and/or lateral mobility of GPVI. The aim of the work presented in this chapter was to 













6.2.1 Tspan9 is expressed on mouse platelets at similar levels as on human 
platelets, relative to CD9.    
The level of Tspan9 relative to CD9 was known for human platelets and suggested 
that the copy number for Tspan9 in human platelets was around 2800 and that CD9 
was around 49000 (Protty et al., 2009). It was important to know the levels of Tspan9 
on mouse platelets to understand if it was expressed at high enough levels to be a 
candidate tetraspanin to partner GPVI (with its human copy number of around 4000) 
(Senis et al., 2007). Using the western blotting approach described in Protty et al. 
(2009), lysates of HEK 293T cells that had been transfected with FLAG-tagged 
Tspan9 and CD9 constructs were first western blotted with an anti-FLAG antibody. 
The amount of each tetraspanin detected was quantified using the LI-COR Odyssey 
software (Figure 40 A). These same lysates and three different mouse platelet 
lysates were then western blotted with an anti-Tspan9 (Figure 40 B) or anti-CD9 
antibody (Figure 40 C). The amount of protein detected by these antibodies was also 
quantified and compared to the FLAG western blot. Using these data, the relative 
amounts of each protein could be measured. This method revealed that Tspan9 is 
expressed in mouse platelets at a 1 : 75 ratio to CD9 (Figure 40 D). This level 
compares to a 1 : 17.5 ratio seen for Tspan9 to CD9 in human platelets (Protty et al., 
2009). Even given this difference between human and mouse Tspan9 could still 
theoretically partner with the majority of GPVI molecules as this conclusion is 
dependent on the levels of CD9 being similar between human and mouse platelets, 
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Figure 40. Tspan9 is expressed on mouse platelets at similar levels as on 
human platelets, relative to CD9.  
A western blotting approach was used to discover the relative expression levels of 
Tspan9 and CD9 on mouse platelets. (A). Lysates of HEK 293T cells transfected with 
CD9 and Tspan9 FLAG-tagged constructs were western blotted with an anti-FLAG 
antibody. The intensity of each protein detected was quantified using the LI-COR 
Odyssey scanning system. These lysates and three different platelet lysates were 
then western blotted with (B). Tspan9 specific or (C). CD9 specific antibody and the 
amount of protein detected by these antibodies was related back to the amount 
detected in the FLAG western blot, and their relative intensities calculated. Both 
panels in B and C are from the same western blot. The relative intensity of CD9 in 
platelet lysates was arbitrarily set to 100 (D). The mean relative intensities for Tspan9 
and CD9 in three platelet lysates were averaged and presented as relative 
expression level. Error bars represent standard error. Method originally described in 






6.2.2 GPVI remains associated with tetraspanins in Tspan9-deficient platelets.  
If GPVI is the partner protein for Tspan9, and no other platelet tetraspanin, then it 
would be predicted that GPVI would no longer be associated with tetraspanin 
microdomains in Tspan9-deficient platelets, as seen for 6 integrin in CD151 
deficient cells (Yang et al., 2008). To test this, GPVI was immunoprecipitated from 
surface biotinylated Tspan9 wildtype and deficient platelets that had been lysed in 
Brij97, with CD9 and ADAM10 immunoprecipitations for controls and comparison. As 
previously discussed in the introduction to this thesis, lysis of cells in Brij97 lysis 
buffer appears to maintain the interactions between tetraspanins thus allowing whole 
microdomains to be captured by precipitating a tetraspanin microdomain resident 
protein (Charrin et al., 2003b). The neutravidin western blot for all three conditions in 
wildtype platelets showed the expected barcode pattern of tetraspanin associatated 
proteins in addition to the targeted protein (Figure 41). Interestingly, this was also the 
case in Tspan9-deficient platelets where GPVI immunoprecipitation resulted in the 
same barcode pattern as seen in the wildtype platelets (Figure 41). This result 
suggests either that GPVI is not a partner protein for Tspan9 or that another 























Figure 41. GPVI remains associated with tetraspanins in Tspan9-deficient 
platelets. 
5 x 108 washed platelets per i.p. were surface biotinylated using EZ-link sulpho NHS 
LC Biotin (1 mg/ml) for 30 min. After biotinylation the platelets were lysed in 1 % 
Brij97 lysis buffer for 1 hour whilst rotating with unconjugated protein G sepharose 
beads. After this preclear step lysates were incubated with beads that been pre-
coupled to either IgG control, anti-CD9, anti-ADAM10 or anti-GPVI antibody for an 
additional hour. Samples were washed and separated on 4 - 12 % polyacrylamide 
gradient gels. Separated proteins were western blotted with neutravidin to detect 
biotinylated proteins from the platelet cell surface. Both panels were from the same 
blot, but a weaker exposure of the CD9 immunoprecipitations is shown because of 











6.2.3 GPVI co-precipitates Tspan9 in Brij97 but not Digitonin. 
To look specifically for an interaction between GPVI and Tspan9 (instead of 
tetraspanin microdomains in general), immunoprecipitations of GPVI from human 
platelets lysed in Brij97 or Digitonin were the next step in the investigation. Digitonin 
was used as a separate condition to Brij97 as it is a more stringent detergent that has 
been used to identify specific tetraspanin binding partners. Examples of this include 
ADAM10 and the TspanC8 tetraspanins (Haining et al., 2012), CD151 and laminin 
binding integrins (Serru et al., 1999) and CD9 and CD81 with EWI-2 (Charrin et al., 
2003a). To increase the chances of detecting an interaction the amount of starting 
material used for the immunoprecipitations was increased and as such human 
platelets were used instead of using several mice for each experiment. In Brij97 lysis 
conditions GPVI co-precipitated Tspan9 suggesting that there is potential for their 
interaction in tetraspanin microdomains. However this was not the case in Digitonin 
lysis conditions where the co-precipitation of Tspan9 was lost (Figure 42). This result 
suggested either that GPVI is not the partner protein for Tspan9 or that GPVI-Tspan9 

























Figure 42. Tspan9 and GPVI co-precipitate in Brij97 but not in Digitonin. 
1 x 109 washed human platelets per i.p were lysed in either 1 % Brij97 or 1 % 
Digitonin lysis buffer and pre-cleared with protein G separose beads for 1 hr. 
Precleared lysates were divided between protein G sepharose beads that had been 
pre-coupled to either a IgG control (MOPC) or anti-human GPVI polyantibody and 
rotated for 90 min. Samples were washed and separated on a 12 % acrylamide gel 













6.2.4 Tspan9 does not appear to promote GPVI dimerisation in a cell line assay.  
Despite being unable to provide evidence for a direct interaction between GPVI and 
Tspan9 by immunoprecipitation, the question remained as to the cause of the 
phenotype seen in Tspan9-deficient platelets. To begin to investigate the hypothesis 
that Tspan9 may promote GPVI clustering, GPVI dimer specific antibodies were used 
to assess the levels of GPVI dimers in conditions with and without Tspan9 by flow 
cytometry. The antibodies 9E18 (dimer specific) and 3J24 (pan GPVI) were made 
and characterised by Loyau et al. (2012). These antibodies were raised against 
human GPVI and as such do not recognise mouse. Therefore this experiment used 
human GPVI constructs expressed in the HEK 293T cell line, chosen because it 
expresses neither GPVI nor Tspan9 (Figure 43 A). Using this approach, 
coexpression of Tspan9 with GPVI was not found to significantly increase the number 
of GPVI dimers detected by the 9E18 antibody, when compared to GPVI expression 

























































































Figure 43. Tspan9 expression does not promote GPVI dimerisation in HEK 
293T cells. 
HEK 293T cells transfected with GPVI (including the -chain) plus either Tspan9 
or CD9 were stained with the 9E18 dimer specific antibody, 3J24 pan GPVI 
antibody or anti-Tspan9 or anti-CD9 as indicated according to the method 
described in Loyau et al. (2012). (A) Representative flow cytometry dot plots. 
(B) GPVI dimer levels were corrected for the expression level of GPVI in each 
condition (assessed by the geometric mean fluorescence intensity of the pan 
GPVI antibody 3J24) and compared between the different transfection 
























6.2.5 Tspan9 regulates the lateral diffusion of GPVI. 
Tetraspanins are emerging as important regulators of the lateral diffusion of 
other proteins, modulating their movement in the membrane to influence and 
optimise cell functions (Espenel et al., 2008, Charrin et al., 2009). To test the 
hypothesis that Tspan9 regulates the lateral diffusion of GPVI, single-particle 
fluorescence microscopy was employed to directly measure the dynamics of 
individual GPVI molecules on Tspan9-deficient and wildtype platelets. This 
technique is well established in many cell types and has been used to assess 
the dynamics of several different types of transmembrane proteins (Kusumi et 
al., 2005). However, to our knowledge, this techique has yet to be used in the 
study of platelets. As such we began by developing a method. To view single 
molecules in the plasma membrane, total internal reflection microscopy is used 
to illuminate an area 100 nm from the coverslip, therefore the platelets were 
required to be spread across the coverslip. No physiological substrate was 
chosen to promote platelet spreading, instead glass alone was used to activate 
the platelets. This ensured that there was no ligand for GPVI (as ligand binding 
could alter dynamics) and no single activatory pathway targeted in this initial 
assessment of GPVI membrane dynamics. The platelets were spread on the 
glass for 35 min at 37 C, then incubated with fluorescent antibody for 10 min, 
then imaged. The antibodies used were Fab fragments of the monoclonal 
antibodies JAQ1 (against mouse GPVI) or Nyn.H3 (against mouse CD9, as a 
control), which had been labelled with a single Atto647N or 565 fluorescent 
probe, respectively. The antibodies were added to the cells such that only a 
subpopulation of either protein was labelled in any cell; for these proteins in 
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platelets the final amount of Fab required fell in the nano-molar range. GPVI-
deficient platelets and Fab fragments from control IgG antibodies were used as 
controls to demonstrate the specificity of the JAQ1 and Nyn.H3 Fab fragments 
used. The membrane dye DiOC6 was used to visualise the platelet outline and 
the cells were imaged with 130 ms exposures for 65 s, according to the method 
set out in Espenel et al. (2008) in which CD9 membrane dynamics in the PC3 
prostate cancer cell line were characterised. Stills from the imaging of GPVI and 
CD9 in wildtype and Tspan9-deficient platelets can be seen in Figure 44 and 
stills from the imaging of control fab fragments in wildtype platelets and of JAQ1 
fab in GPVI deficient platelets can be seen in Figure 45. After imaging videos 
were analysed using the purpose made software PaTrack (Pierre-Emmanuel 
Milhiet, Inserm 554, France), which tracked the trajectories of each particle on 
the imaged platelets. An image of tracked CD9 and GPVI trjectories in wildtype 
platelets can be seen in Figure 46. After tracking, the PaTrack software also 
allowed extraction of trajectory motion types and diffusion coefficients for CD9 








































































































































































































































































Figure 45. Stills from single particle tracking control experiments in wildtype 
and GPVI-deficient platelets. 
GPVI knockout platelets were labelled with JAQ1 Fab to demonstate the specificity 
JAQ1 binding to GPVI. Additionally non specfic IgG Fab fragments were used to stain 




















Figure 46. Examples of PaTrack software tracking of CD9 and GPVI proteins 
The purpose made software PaTrack was used to analyse the trajectories of JAQ1 
labelled GPVI proteins and Nyn.H3 labelled CD9 proteins in wildtype and Tspan-
deficient platelets. The trajectories of individual proteins are marked in blue with 
green stretches in the trajectory representing movements that the software has 
guessed. These trajectories were used by the software to calculate the mean 
squared displacement of each individual protein and subsequently motion type and 







In wildtype platelets three different motion types were detected for GPVI trajectories: 
(1) Brownian diffusion (24 % of total trajectories), characterised by a median diffusion 
coefficient of 0.079 m2/s, (2) confined or restricted diffusion (59 % of total 
trajectories) and (3) mixed trajectories with elements of both Brownian and confined 
diffusion (17 % of total trajectories) (Figure 47 A). In Tspan9-deficient platelets these 
three motion types were also displayed by GPVI molecules, however the percentage 
of confined diffusion was significantly increased (69 % of total trajectories). Brownian 
diffusion accounted for 20 % of total trajectories with a median diffusion coefficient of 
0.060 m2/s and mixed trajectories 11 % of total trajectories, both not significantly 
different from wildtype. This increase in confined trajectories in Tspan9-deficient 
platelets resulted in a significantly decreased median diffusion coefficient for the total 
population from 0.0126 m2/s to 0.007 m2/s (Figure 47 B).   
To determine whether this GPVI phenotype was shared by another protein in 
Tspan9-deficient platelets, the diffusion of CD9 was analysed. CD9 was chosen as it 
is the only mouse platelet tetraspanin for which a good monoclonal antibody is 
available. CD9 in wildtype and Tspan9-deficient platelets also displayed the three 
motion types as detected for GPVI (and also as found for CD9 in other cell types 
(Espenel et al., 2008). In wildtype platelets, Brownian diffusion accounted for 45 % of 
CD9 trajectories, with a median diffusion coefficient of 0.080 m2/s, confined diffusion 
38 % of total trajectories and mixed trajectories 17 % of total trajectories. Interestingly 
the percentage frequency of CD9 mixed trajectories was significantly increased in 
Tspan9-deficient platelets to 22 % of total trajectories (Figure 48 A). This increase in 
mixed trajectories caused a significant increase in the mean diffusion coefficient for 
the total population and for pure brownian trajectories (Figure 48 B). As the diffusion 
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of CD9 was not affected in the same way as GPVI, this suggests that the defect seen 
in GPVI lateral diffusion is not a result of all the proteins in the platelet membrane 
becoming more confined or slowing down. For easier comparison GPVI and CD9 
trajectory data for wildtype and Tspan9-deficient platelets has been complied into 


















































































Figure 47. GPVI displays increased confinement in Tspan9-deficient platelets. 
A minimum of 100 trajectories from 10 - 15 fields of view per mouse were analysed 
by the PaTrack software for both wildtype and Tspan9-deficient platelets spread on 
glass coverslips. The motion type of each trajectory and the associated coefficient of 
diffusion was extracted from the trajectory mean squared displacement over time. (A) 
The percentage frequency of each motion type in the total population is shown for 
wildtype and Tspan9-deficient platelets. 1000 trajectories from n = 3, error bars 
represent the standard error. (B) Scatter plot of diffusion coefficient for each GPVI 
molecule in the total population analysed or pure Brownian trajectories only. The 
median of each group is shown in red.  
Figure 48. CD9 displays an increase in mixed motion type in Tspan9-deficient 
platelets. 
A minimum of 100 trajectories from 5 - 10 fields of view per mouse were analysed by 
the PaTrack software for both wildtype and Tspan9-deficient platelets spread on 
glass coverslips. The motion type of each trajectory and the associated coefficient of 
diffusion was extracted from the trajectory mean squared displacement over time. (A) 
The percentage frequency of each motion type in the total population is shown for 
wildtype and Tspan9-deficient platelets. 2000 trajectories from n = 3, error bars 
represent the standard error. (B) Scatter plot of diffusion coefficient for each CD9 
molecule in the total population analysed or pure Brownian trajectories. The median 

















Protein  Tspan9 




/s  m2/s  %  %  %  
GPVI  Wildtype  0.0126  0.079  24  59  17  
GPVI  Knockout  0.007a 0.060  20  69c  11  
CD9  Wildtype  0.03  0.080  45  38  17  
CD9  Knockout  0.045b 0.100a  44  32  22c  
 
Table 11. Diffusion coefficients and modes of motion for GPVI and CD9 in 
wildtype and Tspan9-deficient platelets. 
D is the median coefficient of diffusion for the total population of trajectories 
analysed. DBrownian is the median coefficient of diffusion for the trajectories that were 
classified as pure Brownian motion. Percentage frequency for the different types of 
motion detected are also shown. a represents p < 0.0001, b represents p < 0.001 
and c represents p < 0.05. Statistical significance was measured by Kruskal-Wallis 
followed by a Dunn's multiple comparison test for diffusion coefficients, and by one 
way ANOVA followed by Sidak's multiple comparison test for (transformed) mode of 














6.2.6 Tspan9 knockout mice heterozygote for GPVI display an aggregation 
defect in response to collagen 
The functional data in the previous chapter, and the single particle tracking in this 
chapter, suggest that Tspan9 might promote GPVI lateral mobility to facilitate rapid 
GPVI clustering and signalling upon platelet engagement with collagen. If this were 
true, it would be predicted that reducing the number of GPVI molecules on the 
platelet cell surface should result in a more severe aggregation defect in the absence 
of Tspan9. To test this, a new knockout mouse strain was generated that lacked 
Tspan9 and was heterozygote for GPVI. This new strain (termed GPVI+/- Tspan9-/-) 
was generated by crossing GPVI knockout mice (Cheli et al., 2008a) with Tspan9 
knockout mice to produce mice heterozygous for both proteins. These double 
heterozygous mice were then crossed with mice either wildtype or knockout for 
Tspan9 to produce mice heterozygous for GPVI with or without Tspan9, respectively, 
and controls.  
The GPVI+/- Tspan9-/- platelets in plasma were tested in their response to a low dose 
(1 g/ml) of collagen in aggregometry assays. These platelets displayed a significant 
defect in aggregation to 1 g/ml collagen that manifested as an extension of the 
shape change phase in aggregometry traces (Figure 49 A). However, GPVI+/- 
Tspan9+/+ platelets aggregated normally to collagen, and quantitation of the data 
showed this to be similar to GPVI+/+ Tspan9+/+ and GPVI+/+ Tspan9-/- platelets (Figure 
49 B). As a control, aggregation to PAR4 peptide by platelets from all four mouse 
strains tested were normal (Figure 49 A and data not shown). Importantly, GPVI 
surface levels were reduced by approximately 50% in the GPVI+/- platelets, but other 
surface antigens tested were normal (Figure 50). Together these data show that the 
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aggregation defect in the absence of Tspan9 was exacerbated when GPVI levels are 
halved, since a collagen phenotype was now revealed. This is consistent with the 
hypothesis that Tspan9 promotes GPVI lateral mobility to promote rapid GPVI 














































































Figure 49. Tspan9-deficient platelets with reduced GPVI levels have an 
aggregation defect in response to collagen 
Platelet rich plasma at 2 x 108 platelets/ml from GPVI+/+ Tspan9+/+, GPVI+/+ Tspan9-/-, 
GPVI+/- Tspan9+/+ and GPVI+/- Tspan9-/- mice were tested by light transmission 
aggregometry using 1 g/ml collagen or 250 M PAR4 peptide. (A) Representative 
traces for GPVI+/- Tspan9+/+ and GPVI+/- Tspan9-/- responses to 1 g/ml collagen or 
250 M PAR4 peptide. (B) Aggregation traces were analysed as percentage 
aggregation over time. n=3-5 error bars represent standard error. Significance was 


























Figure 50. GPVI+/- Tspan9+/+ and GPVI+/- Tspan9-/- platelets express normal levels 
of several surface proteins, except for GPVI. 
Whole blood drawn into acid citrate dextrose was incubated with the relevant anti-
mouse antibody conjugated to FITC. Platelet specific staining was isolated by gating 
on platelets by size. A. Representative flow cytometry histogram plots for each 
indicated protein. GPVI+/+ Tspan9+/+   in black and GPVI+/- Tspan9+/+ in red and 
GPVI+/- Tspan9+/+ in blue. For simplicity only the control trace from wildtype staining is 
shown. B. Geometric mean intensity used to assess surface receptor levels. n = 3, 
+/- represents standard deviation around the mean.  
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Presented here is an investigation into the mechanism by which Tspan9 may 
regulate GPVI function on platelets.  The initial hypothesis was that Tspan9 regulates 
the clustering and/or the lateral mobility of GPVI. This was based on the results of 
function testing Tspan9-deficient platelets which revealed a specific defect in 
responses to the GPVI specific agonist collagen-related peptide, but without any 
effect on GPVI expression levels. The aim of this investigation was to use an 
immunoprecipitation and western blotting approach to discover if GPVI was a partner 
protein for Tspan9, and to use dimer specific antibodies, single-molecule 
fluorescence microscopy and a Tspan9-deficient mouse on a GPVI heterozygote 
background to investigate if Tspan9 could regulate GPVI clustering or lateral mobility. 
The final conclusion of this project was that GPVI may not necessarily be a direct 
partner protein for Tspan9, however Tspan9 does appear to promote GPVI lateral 
mobility in the platelet plasma membrane, which could explain the impaired GPVI-
induced aggregation in the absence of the tetraspanin.    
As the classical approaches to capturing an interaction specifically between GPVI 
and Tspan9 failed, it could not be concluded that GPVI is a partner protein for 
Tspan9. A clear example of how a direct partner protein of a tetraspanin behaves in 
this type of experiment can be seen for 6 integrin, a partner protein of CD151. In 
CD151 wildtype conditions, immunoprecipitation of tetraspanin microdomains in 
Brij97 precipitates 6. However, microdomain precipitates from CD151 knockout 
cells no longer contain 6, as without its partner protein, 6 can no longer interact 
with tetraspanins (Hemler, 2005). Despite the lack of definitive evidence that GPVI 
and Tspan9 interact directly with each other, the defect seen in Tspan9-deficient 
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platelets was specific for GPVI. Furthermore, reducing the number of GPVI 
molecules on the platelet surface by generating GPVI+/- Tspan9-/- mice exacerbated 
the Tspan9 phenotype, seen by the development of an aggregation defect to low 
dose collagen.  
Results from single particle tracking experiments suggested that the absence of 
Tspan9 leads to inefficient diffusion of GPVI in the plasma membrane caused by an 
increased confinement of GPVI molecules. This change in membrane dynamics 
causes a decrease in the diffusion speed of the GPVI population in the plasma 
membrane. This change could cause a dysregulation in GPVI distribution in the 
membrane, and so potentially clustering on collagen. Whilst this could be the cause 
of the aggregation defect seen in the Tspan9-deficient platelets, the question remains 
as to the mechanism by which Tspan9 can influence the type of diffusion GPVI 
undergoes in the platelet membrane, and this issue will be addressed in the General 
Discussion.  
The membrane dynamics of two other tetraspanins and their partner proteins have 
been investigated: CD151 and CD37 and their integrin partners 6β1 and 4β1, 
respectively (van Spriel et al., 2012, Yang et al., 2012b). In both of these studies, 
knockout of the tetraspanin had an effect on the lateral diffusion of the integrin, as 
seen here for GPVI. The CD37 study in particular has some interesting similarities to 
the result found with GPVI. Without CD37, the lateral diffusion of α4β1 was slower 
than in wildtype conditions (as measured by FRAP), and perhaps more interestingly, 
the integrin distribution in the plasma membrane was altered resulting in smaller 
integrin clusters than found in wildtype conditions (as measured by scanning electron 
microscopy) (van Spriel et al., 2012). Despite not analysing the individual movements 
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of 4 molecules, as done here for GPVI, the gross effects on the total population 
offer an appealing precedent when a potential clustering defect in GPVI is 
considered. Whilst the single particle tracking experiments have clearly demonstrated 
a change in the behaviour of GPVI molecules, evidence from the study on CD37 and 
4β1 suggest that larger scale studies of GPVI membrane diffusion may be more 
informative as to the overall effect of these changes on GPVI. Such studies may 




CHAPTER VII: GENERAL DISCUSSION 
The initial aims of this thesis were to investigate the function of the tetraspanins 
Tspan33 and Tspan9 on platelets, using their respective knockout mice. Experiments 
with Tspan33-deficient platelets, and evidence from a platelet transcriptomics study 
by Rowley et al. (2011), led to the conclusion that Tspan33 was not expressed on 
mouse platelets. However, analyses of Tspan33-deficient red blood cells identified a 
role for Tspan33 in surface expression of the metalloprotease ADAM10. Further work 
identified a subgroup of five other tetraspanins that had substantial sequence identity 
to Tspan33, termed the TspanC8s, and each could interact with ADAM10. This is the 
first demonstration of redundant functions between three or more tetraspanins. 
Moreover, it is possible that different TspanC8s target ADAM10 to distinct substrates. 
Assessments of Tspan9-deficient platelets identified a subtle but specific defect in 
aggregation induced by the collagen receptor GPVI. Development of single particle 
tracking, for the first time in platelets, led to the conclusion that Tspan9 may regulate 
the clustering of the platelet collagen receptor GPVI, most likely by regulating its 
membrane dynamics.  
7.1 Tspan33, and related TspanC8 tetraspanins, regulate ADAM10 
Despite being unable to study the function of Tspan33 on platelets, results from this 
thesis, in combination with other work from the lab and collaborators, demonstrated 
that Tspan33 is a member of the TspanC8 subfamily of tetraspanins, all of which 
partner and regulate the metalloprotease ADAM10 (Haining et al., 2012, Dornier et 
al., 2012, Prox et al., 2012). In terms of ADAM10 biology, finally revealing the 
tetraspanins with which it associates was exciting as it had been recognised as a 
tetraspanin associated protein, without an identified tetraspanin partner, since 2006 
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(André et al., 2006). Additionally, now that its partner tetraspanins have been 
identified, research assessing the regulation of ADAM10 by tetraspanins can develop 
and may lead to new approaches in the drug targeting of ADAM10 in human 
diseases such as Alzheimer's disease and cancer (Saftig and Reiss, 2011). In 
particular, the existence of six different tetraspanins, with differential expression, that 
all interact with ADAM10, provides great potential for obtaining increased specificity 
in the targeting of ADAM10. Work in this thesis, in Dornier et al. (2012) and in 
Haining et al. (2012), demonstrate that the TspanC8 tetraspanins have differential 
expression between different cell types and are able, to some extent, to compensate 
for each other. This may provide a mechanism for overcoming the issues associated 
with drug targeting the ubiquitously expressed ADAM10 (Saftig and Reiss, 2011).  
Several different approaches could harness the therapeutic potential of 
TspanC8/ADAM10 complexes. Monoclonal antibodies that target a specific TspanC8-
ADAM10 complex could potentially disrupt the interaction. This could deregulate 
ADAM10 substrate targeting, potentially preventing or upregulating the cleavage of a 
substrate of interest. A different approach would be to design a small molecule 
inhibitor that would disrupt the interaction between ADAM10 and a TspanC8 
tetraspanin in the endoplasmic reticulum or the golgi. This would prevent the cell 
surface expression of the protein and so potentially prevent the cleavage of several 
targets on the cell. Finally, TspanC8 tetraspanin mRNA could be introduced into cells 
using a modified targeted virus. This introduction of a particular TspanC8 tetraspanin 
could potentially modulate the expression or targeting of ADAM10, although the new 
TspanC8 would have to compete for ADAM10 with the endogenous TspanC8 
expressed in the targeted cell type. Depending on the outcome for ADAM10 function, 
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all three of these approaches could be useful in diseases such as Alzheimer's, where 
it is already well established that promoting the cleavage of amyloid precursor protein 
by ADAM10 is beneficial for prevention of both disease initiation and progression 
(Vincent and Checler, 2012), or in cancers where ADAM10 is upregulated (Saftig and 
Reiss, 2011).  
The question of why so many tetraspanins associate with ADAM10 is, in itself, a point 
of interest. Dornier et al. (2012) published a role for TspanC8s Tspan5 and Tspan14, 
but not Tspan15, in promoting the cleavage of Notch by ADAM10, suggesting that 
different TspanC8 tetraspanins may facilitate the targeting of ADAM10 to different 
substrates in different cell types. As many ADAM10 targets do not share an obvious 
cleavage recognition site, regulation by tetraspanins may address this unclear area of 
ADAM10 biology. A summary diagram of the regulation of ADAM10 by the TspanC8 
tetraspanins can be seen in Figure 51. Some important targets of ADAM10 in the 
cardiovascular system and a potential TspanC8 tetraspanin that may be involved in 
their targeting by ADAM10 have also been highlighted in the diagram, although aside 
from Tspan5 promoting ADAM10 cleavage of Notch, this is speculation included only 






















Figure 51. Tetraspanin association regulates ADAM10 egress from the 
endoplasmic reticulum and may regulate ADAM10 substrate targeting. 
1. The TspanC8 tetraspanins associate with ADAM10 in the endoplasmic reticulum. 
This association is necessary for the egress of ADAM10 from this compartment 
through an unknown mechanism (Haining et al., 2012, Dornier et al., 2012, Prox et 
al., 2012). 2. TspanC8 association also promotes the progression of ADAM10 
through the golgi where its maturation is completed by furin proteases that remove its 
prodomain. 3. After leaving the golgi it is hypothesised that different TspanC8 




Several different experiments could be done to begin investigate the regulation of 
ADAM10 substrate targeting by tetraspanins. Cleavage of ADAM10 targets in cell 
lines could be assessed before and after TspanC8 tetraspanin knockdown. Cell types 
would have to be carefully selected for this experiment and their TspanC8 repertoires 
determine beforehand by real time PCR. This experiment would have the drawback 
that ADAM10 surface expression would be affected by TspanC8 knockdown. A 
different approach could make use of biomolecular fluorescence complementation 
(BiFC) technology. The two proteins of interest (i.e. ADAM10 and a TspanC8) are 
expressed with opposite halves of yellow fluorescent protein (YFP). Upon interaction, 
the two halves of YFP can fold together irreversibly to form a fluorescent YFP 
molecule. This would allow the ADAM10-TspanC8 dimer to be imaged by fluorescent 
microscopy, potentially in relation to specific ADAM10 substrates. A more simple and 
complementary approach would be to look at the sub-cellular location of different 
fluorescently tagged tetraspanins versus ADAM10 substrates. 
Aside from the implications for aiding the understanding of ADAM10 regulation and 
new insights into its potential as a drug target, the existence of the TspanC8 
tetraspanin subfamily makes an important contribution to the study of tetraspanins. It 
is now clear that when studying the function of one tetraspanin it is important to 
consider also assessing any closely related tetraspanins. There were already hints to 
this phenomenon in the tetraspanin literature. In particular, there are several 
examples of compensation between the two closely related tetraspanins CD9 and 
CD81, in sharing of the partner proteins EWI-2 and EWI-F (Stipp et al., 2001) and the 
rescue of CD9-deficient oocyte fusion by CD81 (Takeda et al., 2008, Kaji et al., 2002, 
Takeda et al., 2003). For investigations into this compensation between TspanC8 
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tetraspanins, there is a clear need for good antibodies against tetraspanins so that 
the expression levels of the different family members can be determined on different 
cell types. 
The data mined from Rowley et al. (2011) in the investigation into the function of 
Tspan33 on platelets highlighted a differential expression of tetraspanins between 
human and mouse. This is not surprising given that certain other platelet proteins are 
differentially expressed between these species (e.g. the PAR thrombin receptors). 
Furthermore, this is unlikely to be a phenomenon restricted to platelets and therefore, 
despite the difficulty presented by a lack of antibodies to most tetraspanins, their 
expression should always be assessed when moving studies between species.  
Finally, the defect reported in erythropoiesis in the Tspan33 knockout mouse 
(Heikens et al., 2007) suggests that ADAM10 may be important in an aspect of red 
blood cell differentiation not previously appreciated. Additionally, given that Tspan33 
was first identified by its position in a susceptibility locus for myeloid malignancy 
(Chen et al., 2005), ADAM10 may also be an as yet overlooked protein in the 









7.2 Tspan9 and the regulation of GPVI membrane dynamics 
Investigations into the functionality of Tspan9-deficient platelets suggested that this 
tetraspanin was involved in the regulation of the platelet collagen receptor GPVI. The 
type of defects seen in Tspan9-deficient platelets with GPVI wildtype or heterozygous 
backgrounds led to the conclusion that Tspan9 may regulate the clustering of the 
receptor. Single particle tracking experiments suggested that the defect was at the 
level of GPVI membrane dynamics. Several further experiments, detailed in the 
following, could develop a better understanding of the phenotype of Tspan9-deficient 
platelets and so improve upon the current conclusions. Extension of analyses of the 
Tspan9 knockout mouse by moving to in vivo studies of platelet function could lead to 
a better appreciation of the importance of the contribution of Tspan9 to GPVI 
regulation. The phenotype displayed in ex vivo function tests suggests that platelet 
function is only mildly affected by the loss of Tspan9 as it is overcome at increasing 
doses of agonist. However, it cannot be for certain this would follow in vivo. One 
experiment in particular, the transient middle cerebral artery occlusion (tMCAO) 
model for ischaemic stroke would be particularly informative of the contribution of 
Tspan9 to GPVI function in vivo. This reperfusion injury or thrombo-inflammatory 
model has (a somewhat unexpected) significant role for GPVI whereas some other 
models that directly assess thrombosis have a less clear requirement for GPVI 
expression (Dutting et al., 2012). In vivo experiments are currently underway in 
collaboration with Prof Bernhard Nieswandt, to whom the Tspan9 knockout mice 
have been sent. Until there is an understanding of the contribution of Tspan9 to GPVI 
regulation in vivo it will be difficult to assess if there is any potential in drug targeting 
GPVI through its interaction with Tspan9.  
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Generation of Tspan9-deficient mice on the humanised GPVI background, developed 
by Mangin et al. (2012), would allow direct assessment of GPVI dimer levels on 
resting and activated platelets using the human GPVI dimer specific antibodies 
developed by Loyau et al. (2012) and Jung et al. (2012). This method would be more 
definitive than the cell line approach used in this thesis which did not find a role for 
Tspan9 in promoting GPVI dimerisation, despite other experiments indicating that this 
aspect of GPVI function could be affected. Finally, after the initial assessments of 
GPVI membrane dynamics presented in this thesis, more detailed analyses of the 
platelet plasma membrane, with single molecule fluorescent microscopy and FRAP 
experiments, will further contribute to the understanding of the behaviour of this 
protein (and others). In particular, assessment of GPVI-GPVI co-diffusion events, the 
nature, size and components of confinement areas in the platelet membrane, and 
how behaviour changes upon ligand binding, will be useful in understanding in more 
detail why GPVI is more confined in Tspan9-deficient platelets.  
GPVI initially appeared to be a good candidate partner protein for Tspan9 as it 
appeared specifically affected by Tspan9 deficiency and was already a known 
tetraspanin associated protein (Protty et al., 2009). However, GPVI still appeared 
associated with tetraspanin microdomains in Tspan9-deficient platelets. Given the 
results from the study of Tspan33 and the TspanC8 tetraspanins, one possible 
explanation for this is that the loss of Tspan9 is compensated for by another 
tetraspanin. According to the dendrogram of mammalian tetraspanins (Haining et al., 
2012), the most closely related tetraspanin to Tspan9 is Tspan4, which shares 56% 
amino acid sequence identity; all other tetraspanins are less than 40% identical to 
Tspan9. Tspan4 is relatively uncharacterised and is yet to be studied on platelets and 
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was not studied in this thesis, and so is an important topic for further study in the 
continuation of this project. The various human and mouse platelet proteomic and 
transcriptomics studies suggest that Tspan4 may be expressed on both human and 
mouse platelets, albeit at low levels (Senis et al., 2007, Lewandrowski et al., 2009a, 
Rowley et al., 2011). Tspan4 is one of the few tetraspanins for which a good antibody 
exists and so confirmation of its expression in platelets would be the first experiment 
in investigations into its function and potential compensation for Tspan9 on platelets. 
Other possibilities that could explain the association of GPVI with Tspan9-deficient 
tetraspanin microdomains include that Tspan9 does not associate directly with GPVI. 
Another unidentified tetraspanin could be a bridge between Tspan9 and GPVI or 
indeed the -chain. Another receptor that associates with the -chain is the high 
affinity receptor for IgE, FcRI, which was found to be associated with CD9 and CD81 
on antigen presenting cells (Peng et al., 2011). This suggests that an association 
between the -chain and a tetraspanin on platelets is possible. To investigate the 
possibility of the -chain bridging between tetraspanins and GPVI, the -chain could 
be immunoprecipitated from GPVI deficient platelets in Brij97 to assess if it is 
tetraspanin associated without GPVI. An alternative method for discovering the 
partner protein for Tspan9, which is less directed toward GPVI, would be to 
immunoprecipitate tetraspanin microdomains in Brij97 from Tspan9-deficient 
platelets, and use mass spectrometry to look for a platelet protein that is missing 
when compared to tetraspanin microdomains from wildtype platelets.     
Despite the partner protein for Tspan9 remaining unknown it is clear that removing it 
from the platelet cell surface has an effect on GPVI membrane dynamics, as shown 
by the single particle tracking experiments. There are no published mechanisms, 
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even for well established tetraspanin-partner protein pairs (Yang et al., 2012a, van 
Spriel et al., 2012), for exactly how tetraspanins exert their effects on partner protein 
lateral diffusion. It is therefore not straightforward to determine how Tspan9, which 
may not directly associate with GPVI, contributes to GPVI membrane dynamics. 
Three possible mechanisms are discussed in the following, along with experiments 
that could be used to test each hypothesis.  
The first mechanism suggests that Tspan9 and GPVI do interact in the platelet 
membrane and that through an interaction between the cytoplasmic tails of GPVI, or 
-chains, and Tspan9, the tail of GPVI folds up toward the underside of the cell 
membrane. This would reduce the number of interactions the GPVI tail was available 
for and so potentially limit the dwell time of GPVI in confined areas of the membrane, 
where it has been shown that interactions with intracellular scaffold proteins are 
promoted (Triller and Choquet, 2003). A diagram of this mechanism can be seen in 
Figure 52. There is some potential for an interaction between the tails of GPVI and 
Tspan9 as this area of Tspan9 contains several charged residues that could facilitate 
such an interaction (Seigneuret, 2006). There is currently no published interaction of 
this kind between a transmembrane partner protein and a tetraspanin, however the 
intracellular tails of tetraspanins have been demonstrated as important for their 
function in several studies (Wang et al., 2011, Harris et al., 2013, Latysheva et al., 
2006). To investigate this hypothesis, first the dwell time of GPVI molecules in 
confined areas of the membrane could be measured using the single molecule 
fluorescence microscopy approach described in Chapter 6. This could be compared 
between wildtype and Tspan9-deficient platelets to investigate if this is the cause of 
the observed increased confinement of GPVI in Tspan9-deficient platelets. Should 
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this be the case, the membrane dynamics of GPVI mutants that lack intracellular tail 
segments, or Tspan9 chimera constructs that contain another tetraspanin's 
intracellular tails, could be assessed in transfected cells and compared to wildtype 































Figure 52. The intracellular tails of Tspan9 may associate with the intracellular 
tails of GPVI causing it to fold up to the membrane  
An interaction between the intracellular tails of GPVI and Tspan9 causes the tail of 
GPVI to fold toward the membrane. This folding masks potential binding sites for 
cytosolic proteins which are thought to be abundant underneath membrane 
confinement areas. This folding would reduce these cytosolic proteins from binding 
the tail and causing overly long GPVI dwell times in confinement. In Tspan9-deficient 
platelets this folding would not occur, leading to cytosolic proteins binding the tail of 




An alternative mechanism that could also explain the increased confinement of GPVI 
in Tspan9-deficient platelets is that Tspan9 associates not with GPVI but another 
platelet membrane protein. This protein, without its tetraspanin partner, could 
become immobile in confined areas in the membrane. This unknown protein could 
then act as a barrier to GPVI molecules leaving these confined areas, thus increasing 
GPVI dwell times. A diagram of this mechanism can be seen in Figure 53. The idea 
that immobile proteins form a barrier around areas of confinement in the membrane 
is described by Kusumi et al. (2005) and forms part of the picket fence model of 
plasma membrane compartmentalisation. To investigate this hypothesis, single 
molecule fluorescence microscopy could be used to assess the dwell times of GPVI 
molecules between Tspan9 wildtype and deficient platelets, as previously mentioned, 
and additionally the sizes of the regions of GPVI confinement can be measured. This 
would distinguish between GPVI molecules being more confined due to larger 
confinement areas, as opposed to increased confinement area fencing. Assessment 
of the dynamics of other known tetraspanin associated proteins, such as ADAM10 
(Haining et al., 2012), could also be informative as other proteins should also 
encounter the same barrier, should it exist, causing a similar increase in confined 



































Figure 53. Tspan9 may regulate the lateral diffusion of another partner protein, 
which without Tspan9 causes increased confinement of GPVI. 
Tspan9 may not associate with GPVI and instead partner another protein, depicted in 
this diagram as Protein X. The association of Tspan9 with Protein X regulates the 
lateral diffusion of this protein, promoting Brownian modes of motion. In Tspan9-
deficient platelets, Protein X becomes more confined without Tspan9, augmenting 
the picket fence barrier around confinement areas. This increase in confined domain 
barriers prevents GPVI from leaving confined domains as easily, causing its 

















The final hypothesis suggests that Tspan9 associates with GPVI and that this 
interaction promotes the association of specific lipids with the tetraspanin-receptor 
complex (Figure 54). The association of lipids such as cholesterol is thought to 
promote protein lateral diffusion (Mayor and Rao, 2004, Dietrich et al., 2002) and 
may aid GPVI in overcoming the expected decrease in diffusion speed when it 
dimerises. Overcoming this limiting step in higher order clustering would potentially 
allow the formation of GPVI dimer clusters at rates comparable to initial dimer 
formation itself. As receptor clustering is thought to increase signalling strength into 
the platelet (Nieswandt and Watson, 2003), a reduction in dimer diffusion speed 
could result in the collagen-related peptide insensitivity seen in Tspan9-deficient 
platelets. To investigate this hypothesis, the association of GPVI with lipid could be 
assessed using fractionation of wildtype and Tspan9-deficient platelet membranes 
over sucrose gradients, predicting that GPVI would appear in increased density 
fractions in Tspan9-deficient conditions. Alternatively, a lipidomics approach could be 
adopted, in which GPVI could be immunoprecipitated from wildtype or Tspan9-
deficient platelets and any associated lipid analysed and compared using mass 
spectrometry. A similar approach was taken to determine the composition of T-cell 
receptor activation domains (Zech et al., 2009). Additionally, single particle 
fluorescence microscopy could be used to capture instances of co-diffusion between 
GPVI molecules and measure the speed at which they diffuse before and after 
dimerisation. A similar analysis for CD9 molecules demonstrated a continuation of 
the same diffusion speed of CD9 molecules before and during co-diffusion, and a 
similar hypothesis regarding diffusion with a platform of associated lipid was 
proposed to explain this phenomenon (Espenel et al., 2008). Important to the 
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discussion, in the context of this hypothesis, is the potential association of GPVI with 
lipid rafts. Whilst it has been reported that GPVI is associated with lipid rafts, this 
subject remains a controversial area in GPVI biology, with two labs reporting GPVI 
association under basal conditions (Wonerow et al., 2002, Ezumi et al., 2002) and 
another suggesting the translocation of GPVI to rafts upon dimerisation (Locke et al., 
2002). In the light of this controversy it is difficult to assess the contribution of lipid 
rafts to the regulation of GPVI dimerisation and clustering. Should this hypothesis of 
tetraspanins bringing associated lipid to GPVI be correct, then the lipid rafts in which 
GPVI has been captured could be tetraspanin microdomains mistaken for lipid rafts. 
As discussed in the introduction to this thesis, tetraspanin microdomains can 
occasionally be found in the light fractions of sucrose gradients if the cells have been 
lysed in low stringency conditions. The difference in lipid raft preparation between 
labs could mean that in some cases tetraspanin microdomains are captured and in 
some cases not, perhaps explaining the difference seen between the two conflicting 






























Figure 54. Tspan9 association with GPVI brings tetraspanin associated lipids to 
GPVI which promotes efficient GPVI multimerisation.  
1. Tspan9 associates with GPVI, which in turn leads to association of tetraspanin 
associated membrane lipids with GPVI. As such, GPVI diffuses through the platelet 
membrane in its own tiny microdomain.  
2. GPVI association with Tspan9 leads to its association with the tetraspanin web. 
This series of interactions organises the GPVI population such that dimerisation 
occurs efficiently. 
3. GPVI dimers, associated with their mini microdomains, cluster as efficiently as 
GPVI monomers dimerise, due to their association with membrane lipid through 
Tspan9. This lipid association overcomes a limiting step in GPVI dimer diffusion that 
would be caused by the increase in size from GPVI monomer to dimer, thus allowing 















Taking a step back from speculation on the mechanism of how Tspan9 influences the 
membrane dynamics of GPVI, a more general mechanism of tetraspanin regulation 
of GPVI can be considered. Through its association with a tetraspanin, GPVI would 
be expected to undergo a series of interactions with tetraspanin microdomains during 
its diffusion through the platelet membrane. Interacting with the tetraspanin web in 
this way could modulate the distribution of GPVI in the membrane such that the 
population is optimised to ensure an appropriate pool of GPVI dimers is maintained, 
resulting in efficient responses to ligand. This organisation of partner protein 
distribution by interaction with the tetraspanin web is seen in the regulation of 4β1 
integrin by CD37 on B cells (van Spriel et al., 2012). Additionally, GPVI association 
with tetraspanins would, upon clustering, promote the interaction of other 
tetraspanins and their partners with GPVI clusters. Of particular interest in this 
scenario is the recruitment of ADAM10, a sheddase for GPVI, to GPVI clusters. 
Occuring through the interactions of Tspan14 and GPVI-associated tetraspanins this 
could be a mechanism to ensure efficient receptor shedding. To investigate this 
hypothesis, confocal microscopy or scanning electron microscopy could be used to 
assess and compare the distribution of GPVI in wildtype and Tspan9-deficient 
platelets. 
7.3 The role of Tspan9 on cell types other than platelets. 
As the aim of this thesis was to investigate the function of Tspan9 on platelets, no 
other cell types have been a focus of investigation. Despite being most highly 
expressed on platelets and, compared to other tetraspanins, relatively platelet 
specific, Tspan9 has been shown to be clearly expressed in mouse brain, heart, 
kidney, lung and liver by western blot (Protty et al., 2009). Closer inspection of tissue 
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sections from these organs, stained with Tspan9 antibody (Appendix Figure 2), 
revealed the expression of Tspan9 to be mainly on the endothelial and epithelial cells 
of these tissues. As GPVI expression is restricted to platelets, the work in this thesis 
cannot provide substantial insights into the function of Tspan9 in endothelial or 
epithelial cells. One approach to attempt to discover partner proteins for Tspan9 
could be the proteomics approach previously discussed, where tetraspanin 
microdomains are immunoprecipitated from a particular tissue, taken from Tspan9 
wildtype or knockout mice, and mass spectrometry used to analyse the resident 
proteins. Any protein missing in the knockout microdomains would be a likely 
candidate partner protein for Tspan9. As Tspan9 is most highly expressed in lung, 
compared to other organs (Protty et al., 2009), this would be a good tissue to use for 












7.4 Contribution and context of this thesis to wider research on tetraspanins, 
platelets and ADAM10 
Despite being unable to arrive at a firm conclusion as to the function of Tspan9 on 
platelets, the work in this thesis on the function of the tetraspanins Tspan9 and 
Tspan33 has contributed novel findings to the fields of platelet, red blood cell, 
tetraspanin and ADAM10 research. 
Aside from the previously discussed contribution to ADAM10 biology, investigations 
into Tspan33 and the TspanC8 tetraspanins has led to the identification of Tspan14 
as a promising avenue of research into the function of ADAM10 and tetraspanins on 
mouse platelets. Additionally ADAM10 has also been identified as having possible 
roles in erythropoiesis, and its dysregulation or mutation as having possible roles in 
the development of myeloid malignancies as previously discussed. Studies into the 
function of Tspan9 have added to the growing evidence that tetraspanins can 
regulate the membrane dynamics of their partner proteins and has highlighted 
potentially the first definitive mechanism of action for a tetraspanin on platelets. The 
single particle tracking studies are the first of their kind in platelets. Subsequent 
development of the technique could lead to a new avenue of research into platelets 
and megakaryocytes, presenting the opportunity to investigate and characterise the 
organisation of the platelet cell membrane and address long standing questions such 
as the mechanisms regulating receptor multimerisation. Additionally, prior to the 
results presented in this thesis, the function of Tspan9 was unknown in any cell type 
and as such lends a starting point for the study of this protein in other cell types in the 



































Figure 1. All TspanC8 tetraspanins associate with ADAM10 and promote its 
maturation. 
HEK 293T cells were co-transfected with HA tagged ADAM10 and a FLAG tagged 
tetraspanin from the TspanC8 subfamily or CD9, CD151 or Tspan9 as a control. 
Cells were lysed in 1 % Digitonin lysis buffer and FLAG immunoprecipitated. (A) 
FLAG immunoprecipitates were western blotted with an anti HA antibody to detect 
ADAM10 co-precipitation. (B) Whole cell lysates from each condition were western 
blotted for ADAM10 and revealed an increase in mature ADAM10 (lower band) in 
TspanC8 transfected cells. (C) The effect on ADAM10 maturation was quantified as 
% of total ADAM10 detected using the Odyssey LI-COR infra red imaging system. 
Only in TspanC8 transfected cells was the % of mature ADAM10 significantly 
increased over basal (ADAM10 transfection alone). n = 3 error bars represent 
standard error. Significance determined by one way ANOVA followed by Dunn's 
multiple comparison post test (D) Immunoprecipitates were western blotted with an 
anti FLAG antibody to detected the precipitated tetraspanin in each condition. This 
work was done by Dr. Jing Yang from our lab and quantitated by Elizabeth Haining. 

































































Figure 2. Tspan9 antibody stained tissue sections from Tspan9 wildtype and 
knockout mice. 
Paraformaldehyde fixed whole tissues from Tspan9 wildtype and knockout mice were 
sectioned and stained with the anti Tspan9 antibody. Sectioning, staining and 
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